<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "form10k.pdf">


<HTML>
<HEAD>
   <TITLE>Filed by sedaredgar.com - Anavex Life Sciences Corp. - Form 10-K</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR></B>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 10-K </FONT></B></P>
<P align=center>(Mark One) </P>
<P align=center>[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</P>
<P align=center>For the fiscal year ended: <B><U>September 30, 2008 </U></B></P>
<P align=center>or </P>
<P align=center>[&nbsp;&nbsp; ] TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>
<P align=center>For the transition period from&nbsp;__________________ to
__________________</P>
<P align=center>Commission file number: <B><U>000-51652 </U></B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES CORP.</FONT></U></B><B>
<BR></B>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="50%"><B><U>20-8365999 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>State or other jurisdiction of incorporation or
      organization </TD>
    <TD align=center width="50%">(I.R.S. Employer Identification No.)
  </TD></TR></TABLE>
<P align=center><B><U>27 Marathonos Ave., 15351 Athens, Greece</U></B><B>
<BR></B>(Address of principal executive offices and Zip Code) </P>
<P align=center>Registrant's telephone number, including area code <B><U>30 210
  603 4026</U></B></P>
<P align=center><B><U>14 Rue Kleberg, CH-1201 Geneva, Switzerland</U></B><B>
<BR></B>(Former name or former address, if changed since last report) </P>
<P align=center>Securities registered pursuant to Section 12(b) of the Act</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center>Title of Each Class </TD>
    <TD align=center width="50%">Name of each Exchange on which registered
  </TD></TR>
  <TR vAlign=top>
    <TD align=center><B><U>Nil </U></B></TD>
    <TD align=center width="50%"><B><U>N/A </U></B></TD></TR></TABLE>
<P align=center>Securities registered pursuant to Section 12(g) of the Act </P>
<P align=center><B><U>Common Stock, par value $0.001 per share<BR></U></B>(Title
of Class) </P>
<P align=center>Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. <BR><B>Yes
[&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp; No [X] </B></P>
<P align=center>Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the Act. <BR><B>Yes
[X]&nbsp;&nbsp; &nbsp;No [&nbsp;&nbsp; ] </B></P>
<P align=center>Note &#150; Checking the box above will not relieve any registrant
required to file reports pursuant to Section 13 or 15(d) of the <BR>Exchange Act
from their obligations under those Sections. </P>
<P align=center>Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the <BR>Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was <BR>required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.<BR><B>Yes
[X]&nbsp;&nbsp;&nbsp; No [&nbsp;&nbsp; ] </B></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>ii </P>
<P align=center>Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this <BR>chapter) is not
contained herein, and will not be contained, to the best of registrant&#146;s
knowledge, in definitive proxy <BR>or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K.
<BR><B>Yes [&nbsp; &nbsp;]&nbsp;&nbsp; &nbsp;No [X]</B> </P>
<P align=center>Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, <BR>or a
smaller reporting company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer&#148; and &#147;smaller reporting <BR>company&#148; in Rule 12b-2 of the
Exchange Act</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center>Large accelerated filer [&nbsp; &nbsp;] </TD>
    <TD align=center width="40%" >&nbsp; </TD>
    <TD align=center width="29%">Accelerated
      filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      [&nbsp;&nbsp; ] </TD></TR>
  <TR vAlign=top>
    <TD align=center>Non-accelerated filer&nbsp;&nbsp; [&nbsp; &nbsp;] </TD>
    <TD align=center width="40%" >(Do not check if a smaller
      reporting company) </TD>
    <TD align=center width="29%">Smaller reporting company <B>[X]</B>
  </TD></TR></TABLE></DIV>
<P align=center>Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act). <BR><B>Yes[&nbsp;&nbsp;
]&nbsp;&nbsp;&nbsp; No [X]</B> </P>
<P align=center>State the aggregate market value of the voting and non-voting
common equity held by non-affiliates computed by <BR>reference to the price at
which the common equity was last sold, or the average bid and asked price of
such common <BR>equity, as of the last business day of the registrant&#146;s most
recently completed second fiscal quarter. </P>
<P align=center>10,854,920 common shares at a price of $2.77 per share for an
aggregate market value of $30,068,128.40 <SUP>1</SUP></P>
<P align=center><SUP>1</SUP> The aggregate market value of the voting stock held
by non-affiliates is computed by reference to the <BR>price at which the common
equity was last sold as reported by the OTC Bulletin Board on January 8,
2009.</P>
<P align=center>Indicate the number of shares outstanding of each of the
registrant&#146;s classes of common stock, as of the latest <BR>practicable date:
<U>19,982,420 shares of common stock are issued and outstanding as of January 9,
2009.</U></P>
<P align=center>DOCUMENTS INCORPORATED BY REFERENCE </P>
<P align=center>Not Applicable </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center>iii </P>
<P align=center><B>TABLE OF CONTENTS </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_4">PART
      I </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_4">1
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_4">ITEM
      1. BUSINESS </A></TD>
    <TD align=right width="4%" ><A
      href="#page_4">1
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_12">ITEM
      1A. RISK FACTORS </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_12">9
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_20">ITEM
      1B. UNRESOLVED STAFF COMMENTS </A></TD>
    <TD align=right width="4%" ><A
      href="#page_20">17
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_21">ITEM
      2. PROPERTIES </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_21">18
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_21">ITEM
      3. LEGAL PROCEEDINGS </A></TD>
    <TD align=right width="4%" ><A
      href="#page_21">18
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_21">ITEM
      4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_21">18
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_21">PART
      II </A></TD>
    <TD align=right width="4%" ><A
      href="#page_21">18
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_21">ITEM
      5. MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
      ISSUER PURCHASES OF EQUITY SECURITIES </A></TD>
    <TD align=right width="4%"  bgColor=#eeeeee ><A
      href="#page_21">18
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_24">ITEM
      6 SELECTED FINANCIAL DATA </A></TD>
    <TD align=right width="4%" ><A
      href="#page_24">21
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_24">ITEM
      7 MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
      OF OPERATION </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_24">21
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_30">ITEM
      7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </A></TD>
    <TD align=right width="4%" ><A
      href="#page_30">27
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_30">ITEM
      8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_30">27
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_32">ITEM
      9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
      FINANCIAL MATTERS </A></TD>
    <TD align=right width="4%" ><A
      href="#page_32">29
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_32">ITEM
      9A. CONTROLS AND PROCEDURES </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_32">29
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_34">ITEM
      9B OTHER INFORMATION </A></TD>
    <TD align=right width="4%" ><A
      href="#page_34">31
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_35">PART
      III </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_35">32
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_35">ITEM
      10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </A></TD>
    <TD align=right width="4%" ><A
      href="#page_35">32
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_38">ITEM
      11. EXECUTIVE COMPENSATION </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_38">35
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_41">ITEM
      12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
      RELATED STOCKHOLDER MATTERS. </A></TD>
    <TD align=right width="4%" ><A
      href="#page_41">38
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_43">ITEM
      13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
      INDEPENDENCE </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_43">40
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_44">ITEM
      14. PRINCIPAL ACCOUNTING FEES AND SERVICES </A></TD>
    <TD align=right width="4%" ><A
      href="#page_44">41
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_45">PART
      IV </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_45">42
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_45">ITEM
      15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES. </A></TD>
    <TD align=right width="4%" ><A
      href="#page_45">42
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_47">SIGNATURES
      </A></TD>
    <TD align=right width="4%" bgColor=#eeeeee ><A
      href="#page_47">44
      </A></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_4></A>
<P align=center>- 1 - </P>
<P align=center><B>PART I</B></P>
<P align=justify><B>ITEM 1. BUSINESS </B></P>
<P align=justify><B><I>Forward-Looking Statements</I></B></P>
<P align=justify>This annual report contains forward-looking statements. These
statements relate to future events or our future financial performance. In some
cases, you can identify forward-looking statements by terminology such as &#147;may&#148;,
&#147;should&#148;, &#147;expects&#148;, &#147;plans&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;estimates&#148;,
&#147;predicts&#148;, &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other
comparable terminology. These statements are only predictions and involve known
and unknown risks, uncertainties and other factors, including the risks in the
section entitled &#147;Risk Factors&#148; that may cause our or our industry&#146;s actual
results, levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking statements. </P>
<P align=justify>Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. Except as required by
applicable law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform these
statements to actual results. </P>
<P align=justify>Our financial statements are stated in United States Dollars
(USD) and are prepared in accordance with United States Generally Accepted
Accounting Principles. </P>
<P align=justify>In this annual report, unless otherwise specified, all dollar
amounts are expressed in United States dollars and all references to &#147;common
shares&#148; refer to the common shares in our capital stock. </P>
<P align=justify>As used in this annual report, the terms &#147;we&#148;, &#147;us&#148;, &#147;our&#148;, and
&#147;Anavex&#148; mean Anavex Life Sciences Corp., unless the context clearly requires
otherwise. </P>
<P align=justify><B><I>Corporate Overview </I></B></P>
<P align=justify>Our principal business office is located at 27 Marathonos Ave.,
15351 Athens, Greece. Our registered office for service in the State of Nevada
is located at Business First Formations, Inc., 2470 Wrondel Way Ste 114, Reno NV
89502. </P>
<P align=justify><I>Corporate History </I></P>
<P align=justify>We were incorporated in the State of Nevada on January 24,
2004, originally under the name of Thrifty Printing, Inc. From inception to
January 25, 2007, we were in the business of providing on-line photofinishing
services through our website. </P>
<P align=justify>On January 25, 2007, we completed a merger with our
wholly-owned subsidiary, Anavex Life Sciences Corp. As a result, we have changed
our name from &#147;Thrifty Printing, Inc.&#148; to &#147;Anavex Life Sciences Corp.&#148; We
changed the name of our company to better reflect the new direction and business
of our company. </P>
<P align=justify>Our name change was effected with NASDAQ on January 25, 2007
and our common shares became quoted on the OTC Bulletin Board on January 25,
2007 under the new stock symbol of "AVXL". </P>
<P align=justify><B><I>Our Current Business </I></B></P>
<P align=justify>With the completion of the patent and patent application
acquisition on January 31, 2007, with Dr. Alexandre Vamvakides, we acquired all
rights to three patents and one patent application as well as all inventions
described in those patents as well as eight compounds that are in the
pre-clinical stage and which are derivatives of the patents and patent
application.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_5></A>
<P align=center>- 2 - </P>
<P align=justify>With this acquisition, we changed our business model to the
research and development. We will conduct the research and development on our
patents and patent application, and possibly new intellectual property that we
will acquire or develop, of novel drug targets for the treatment of cancer and
diseases of the central nervous system.</P>
<P align=justify>Under the direction of Dr. Alexandre Vamvakides, our Chief
Scientific Officer, we have contracted with researchers and laboratories for the
conduct of specific research and reports as well as to conduct in-house research
in our own facilities. Currently, we have several compounds at various
preclinical stages. We intend to begin clinical phase trials on our most
advanced compounds in 2009. We also intend to continue to work on other
compounds, which are currently at different stages of early development. </P>
<P align=justify><I>The Market </I></P>
<P align=justify>We believe that our compounds may most likely be useful, in
medication for the treatment of diseases of the central nervous system and
cancer. </P>
<P align=justify><U>Diseases of the Central Nervous System</U> </P>
<P align=justify>We expect that the market for treatments for diseases of the
central nervous system will grow over the next decade. We believe that this
expansion will be driven by the introduction of new technologies and products
which will be developed as a result of a clearer understanding of the underlying
biochemical mechanisms that cause neurological disorders. This enhanced
understanding has led, and will continue to lead to the development of
rationally designed drugs specifically targeted to the neuropharmacological
mechanisms responsible for central nervous system disorders. </P>
<P align=justify>The market for treatments for diseases of the central nervous
system is expected to be the fastest growing disease area over the next two
decades for two main reasons: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>Improved patient and physician awareness of central nervous system
  disorders;
  <LI>A better understanding of the neuropharmacological mechanisms underlying
  those disorders. </LI></UL>
<P align=justify>Central nervous system disorders are a broader group of
diseases than either cancer or Cardiovascular Disease. They include many of the
classic diseases of old age (Parkinson&#146;s and Alzheimer&#146;s are two examples.)
Central nervous system disorders also include psychiatric disorders such as
depression and schizophrenia. Diseases of the peripheral nervous system such as
multiple sclerosis (MS) are also central nervous system disorders. Central
nervous system disorders vary greatly in their severity, both from one patient
to another and from one disease to another. </P>
<P align=justify>In medicine, an &#147;indicator&#148; is a term used to describe a valid
reason to use a certain test, medication, procedure or surgery. We use the term
&#147;central nervous system indications&#148; to refer to instances of central nervous
system disease where treatment is indicated. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_6></A>
<P align=center>- 3 - </P>
<P align=center><IMG
src="chart1.jpg" width="613" height="374"
border=0></P>
<BR>
<P align=justify>Even though, the <B>Alzheimer&#146;s disease market</B> share,
estimated at 4% of the market for central nervous system treatments and valued
at approximately $2,719 million per year in 2004 may seem small compared to the
other central nervous system indications, it exhibits continuously rising levels
of sales growth, despite the lack of efficacy that currently available compounds
possess. The market features only two major classes of treatments, low number of
major brands and increasing patient population leading to an unprecedented
opportunity for market penetration. </P>
<P align=justify>The <B>depression market</B> is dominated by a large number of
blockbuster brands, with the leading nine brands accounting for approximately
75% of total sales. However, the dominance of the leading brands is waning,
largely due to the effects of patent expiration and generic competition. The
need for innovation is evident as demonstrated by the low sales growth rates,
creating at the same time opportunities that will dramatically change the
depression market. </P>
<P align=justify>The <B>epilepsy market</B> features two classes of drugs, older
traditional Anti Epileptic Drugs and second generation Anti Epileptic Drugs,
with the former marketed before 1980, and the latter class marketed in the early
1990s is developed through intelligent synthetic design techniques and are
currently the driving force of the market. However, second generation
anti-convulsants offer limited benefits in terms of efficacy over traditional
anticonvulsants but confer benefits in terms of side effects and dosing. Because
epilepsy afflicts sufferers in several different ways, there is considerable
need for an array of drugs that can be used in combination with both traditional
Anti Epileptic Drugs and other second generations Anti Epileptic Drugs that can
confer efficacious treatment to the widest range of epilepsy sufferers.
Furthermore, with additional benefits in supplementary indications such as
migraine prophylaxis, bipolar disorder and neuropathic pain, second-generation
Anti Epileptic Drugs have greatly expanded the potential of the market for
epilepsy treatments and are the driving force behind sales. </P>
<P align=justify><U>Cancer</U> </P>
<P align=justify>Cancer is the second leading cause of death by disease,
following heart disease, in our society. There are many treatment methods but
none of them are highly effective and about one third of patients die of cancer
within 5 years of diagnosis. The market for a patented compound with a novel
mechanism of action that could improve on the effectiveness of current
treatments would be substantial. IMS Global Learning Consortium, Inc. estimates
that the market for cancer drugs will reach $80 billion annually by 2012, almost
double the 2007 value of $41Bn (Ref: IMS Global Oncology Forecast, 2008) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_7></A>
<P align=center>- 4 - </P>
<P align=justify>The SIGMACEPTOR&#153;-C program leverages the unique properties of
sigma-1 and/or sigma-2 receptor ligands to create a potent class of promising
drug candidates designed to combat a number of cancers, including colon, breast,
prostate and melanoma. Sigma receptors are highly expressed in different tumor
cell types and binding by appropriate sigma-1 and/or sigma-2 ligands, can induce
selective apoptosis. In addition, through tumor cell membrane reorganization and
interactions with sodium and chloride channels, the company&#146;s drug candidates
are believed to play an important role in inhibiting the processes of metastasis
(spreading of cancer cells from the original site to other parts of the body),
angiogenesis (the formation of new blood vessels) and tumor cell proliferation.
The compounds in the Anavex oncology program are in pre-clinical testing, and
there is no guarantee that the activity demonstrated in pre-clinical models will
be shown in human testing. </P>
<P align=justify><I>The Market in General </I></P>
<P align=justify>Pharmaceutical companies provide remedies and treatments for
central nervous system diseases and cancer. We believe that as these
technologies are developed and to the extent they are approved, the central
nervous system diseases and cancer drug market will expand, as new therapeutics
become available for currently unmet needs. We hope to develop compounds to
market to Pharmaceutical companies for use in any of these treatment methods.
</P>
<P align=justify>Three approaches are primarily used to treat central nervous
system diseases and cancer: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>Neurosurgery or invasive techniques. </P>
  <LI>
  <P>Pharmacological techniques, including drugs. </P>
  <LI>
  <P>Physiologically based techniques, such as transcytosis. </P></LI></UL>
<P align=justify>Invasive procedures utilize catheter-based delivery of the drug
directly into the brain. This technique has proven useful in the treatment of
brain tumors, but is not successful in distributing drugs throughout the entire
brain. Amgen, Inc. recently had clinical trials for the treatment of Parkinson&#146;s
Disease using intrathecal delivery through the use of various catheter/pump
techniques. In the trials conducted by Amgen, Inc., improvements were found in
cells at various distances from the end of the catheter, but improvements were
not seen uniformly throughout the brain. </P>
<P align=justify>The physiological route is a popular approach to cross the
blood-brain barrier via lipid mediated free diffusion or by facilitated
transport. This is the most common strategy used for the development of new
neuropharmaceuticals, but has experienced limited success as it requires that
the drug have sufficient lipophilic or fat-soluble properties so that it can
pass through lipid membranes. Unfortunately, the current method of delivery by
this route is nonspecific to the brain and side effects are common since most
organs are exposed to the drug. Furthermore, many of the potential lipophilic
therapeutic molecules are substrates for the blood-brain barrier&#146;s multi-drug
resistant proteins, which actively transport the therapeutic agent back into the
blood. Consequently, large doses need to be used so that sufficient amounts of
the drug reach the brain. These high doses can result in significant side
effects as the drug is delivered to essentially all tissues of the body, which
is extremely inefficient as seen with most anticancer drugs and many of the new
central nervous system medications. </P>
<P align=justify>Companies and organizations that are developing treatments
based on various physiological approaches include Angiochem, Axonyx, AramaGen
Technology, Synt:em, to-BBB, Xenoport Inc., Oregon Health and Science University
Neuro-oncology, Xenova Group Ltd., d-Pharm, Neurochem Inc., and Vasogen Inc.
</P>
<P align=justify>We believe that as these technologies are developed and to the
extent they are approved, the central nervous system diseases and cancer drug
market will expand, as new therapeutics become available for currently unmet
needs. We hope to develop compounds that can be used in any of these treatment
methods. </P>
<P align=justify><I>Competition</I></P>
<P align=justify>Our competition is other biomedical development companies that
are also trying to discover compounds to be used in the treatment of central
nervous system diseases and cancer. Our research and development is highly
speculative </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_8></A>
<P align=center>- 5 - </P>
<P align=justify>and we may never discover or develop any compounds that we are
capable of selling to pharmaceutical companies for inclusion in their treatments
of central nervous system diseases and cancer. </P>
<P align=justify>We want to caution our investors that most of our competitors
have greater capital resources, larger overall research and development staffs
and facilities, and a longer history in drug discovery and development,
obtaining regulatory approval, and pharmaceutical product manufacturing and
marketing than we do. With these additional resources, our competitors will be
able to respond to the rapid and significant technological changes in the
biotechnology and pharmaceutical industries faster than we can. Our future
success will depend in large part on our ability to acquire funding to par for
our research and development. To continue to acquire funding for our research
and development, we will likely have to show progress toward our goals and will
eventually be expected to develop a compound that will be purchased by a
pharmaceutical company. </P>
<P align=justify>Rapid technological development, as well as new scientific
developments, may result in our compounds becoming obsolete before we can
recover any of the expenses incurred to develop them.</P>
<P align=justify><I>Patents, Trademarks and Intellectual Property </I></P>
<P align=justify>On January 31, 2007, we purchased from Dr. Vamvakides the
intellectual property owned by Dr. Vamvakides for the research and development
of new drug formulations or components, including three patents and one patent
application. Specifically, patent applications, trademarks and licenses acquired
from Dr. Vamvakides consist of: </P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=bottom bgcolor="#EEEEEE">
      <TD colspan="3"
      align=center style="BORDER-BOTTOM: #000000 1px solid">&nbsp;&nbsp;<B>PATENTS</B>
      </TD>
    </TR>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=center style="BORDER-BOTTOM: #000000 1px solid"><B>Title of Application/</B>
        <BR> <B>Patent No./Jurisdiction</B> </TD>
      <TD
      width="25%" align=center style="BORDER-BOTTOM: #000000 1px solid"><B>Filing/Issue/</B>
        <BR> <B>Expiration</B> </TD>
      <TD
      width="50%" align=center style="BORDER-BOTTOM: #000000 1px solid"><BR> <B>Claims</B>
      </TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Patent No. <BR>
        1002616/Greece </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      width="25%">February 21, 1996/ <BR>
        February 20, 1997/ <BR>
        February 20, 2017 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      width="50%">Invention related to the synthesis and the method of synthesis
        of molecules of a novel formula. This method is to be applied for the
        obtention of anticonvulsant, antidepressant and nootropic pharmaceuticals.
      </TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Patent No. <BR>
        1004208/Greece </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      width="25%">October 15, 2001/ <BR>
        April 4, 2003/ <BR>
        April 4, 2023 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      width="50%">Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium channel
        ligands, with synergic sigma/muscarinic (neuroactivating) and sigma/sodium
        channel (neuroprotective) components, as prototypical activating &#150;
        neuroprotectors and neuroregenerative drugs </TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Patent No. <BR>
        1004868/Greece </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="25%">April
        22, 2003/ <BR>
        April 26, 2005/ <BR>
        April 26, 2025 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      width="50%">Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium channel
        ligands, ortho-and allo-sterically operating, as prototypical neuromodulating
        and neuroregenerative drugs </TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Patent Application
        No. <BR>
        20070100020/ <BR>
        Greece </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      width="25%">January 17, 2007 <BR>
        April 7, 2008 <BR>
        January 18, 2027 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="50%">New
        sigma (&#156;) receptor ligands with anti-apoptotic and/or pro- apoptotic
        properties over cellular biochemical mechanisms, with neuroprotective,
        anti-cancer, anti-metastatic and anti-(chronic) inflammatory action </TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify>We regard patents and other proprietary technology rights a key
element in our goal of building a successful biomedical company. Accordingly, we
plan to protect all of our key technology, inventions and improvements to our
inventions by filing patent applications in a timely fashion. We plan to seek
patent protection in the United States, Canada, Japan, Western European
countries and additional countries on a selective basis for our compounds or
other inventions and improvements. However, we note that filing and prosecuting
patent applications are expensive processes and we have very limited financial
resources. </P>
<P align=justify>Our proprietary technology is protected by a group of four
patents that is owned exclusively by us and filed with Greek National Office of
Industrial Property. We also plan to acquire or register for other patents and
intellectual property for similar types of compounds.</P>
<P align=justify>We also rely on trade secrets and unpatentable know-how that we
seek to protect, in part, by confidentiality agreements. It is now our policy to
require our employees, consultants, contractors, manufacturers, outside
scientific collaborators and sponsored researchers, board of directors and other
advisors to execute confidentiality agreements upon the commencement of
employment, advisory, or consulting relationships with us. These agreements will
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_9></A>
<P align=center>- 6 - </P>
<P align=justify>provide that all confidential information developed or made
known to the individual during the course of the individual&#146;s relationship with
us is to be kept confidential and not disclosed to third parties except in
specific limited circumstances.</P>
<P align=justify>We also require signed confidentiality or material transfer
agreements from any company that is to receive our confidential information. In
the case of employees, consultants and contractors, the agreements will
generally provide that all inventions conceived by the individual while
rendering services to us shall be assigned to us as our exclusive property.
There can be no assurance, however, that all persons who we desire to sign such
agreements will sign, or if they do, that these agreements will not be breached,
that we would have adequate remedies for any breach, or that our trade secrets
or unpatentable know-how will not otherwise become known or be independently
developed by competitors. </P>
<P align=justify>Our patent position, like that of many biomedical companies, is
uncertain and involves complex legal and technical questions for which important
legal principles are unresolved. Much of our intellectual property is still only
filed with the Greek National Office of Industrial Property and we plan to file
additional patent applications in Canada and the U.S. for further inventions. We
may not be successful in obtaining critical claims or in protecting our
potential drug compounds or processes. Even if we do obtain patents, they may
not adequately protect the technology we own or have licensed. In addition,
others may challenge, seek to invalidate, infringe or circumvent any patents we
own or license, and rights we receive under those patents may not provide
competitive advantages to us. Further, the manufacture, use or sale of our
potential drug compounds may infringe the patent rights of others. </P>
<P align=justify>Our success will also depend in part on our ability to
commercialize our compounds without infringing the proprietary rights of others.
We have not conducted extensive freedom of use patent searches and no assurance
can be given that patents do not exist or could not be filed which would have an
adverse affect on our ability to market our technology or maintain our
competitive position with respect to our technology. If our compounds or other
subject matter are claimed under other existing United States or other patents
or are otherwise protected by third party proprietary rights, we may be subject
to infringement actions. In such event, we may challenge the validity of such
patents or other proprietary rights or we may be required to obtain licenses
from such companies in order to develop, manufacture or market our technology.
There can be no assurances that we would be able to obtain such licenses or that
such licenses, if available, could be obtained on commercially reasonable terms.
Furthermore, the failure to either develop a commercially viable alternative or
obtain such licenses could result in delays in marketing all of our potential
drug compounds based on our drug technology or the inability to proceed with the
development, manufacture or sale of potential drug compounds requiring such
licenses, which could have a material adverse affect on our business, financial
condition and results of operations. If we are required to defend ourselves
against charges of patent infringement or to protect our proprietary rights
against third parties, substantial costs will be incurred regardless of whether
we are successful. Such proceedings are typically protracted with no certainty
of success. An adverse outcome could subject us to significant liabilities to
third parties and force us to curtail or cease our research and development of
our technology. </P>
<P align=justify><I>Government Approval </I></P>
<P align=justify>Regulation by governmental authorities in the United States and
foreign countries is a significant factor in the development, manufacture, and
expected marketing of our potential drug compounds and in our ongoing research
and development activities. The nature and extent to which such regulation will
apply to us will vary depending on the nature of any potential drug compounds
developed. We anticipate that all of our potential drug compounds will require
regulatory approval by governmental agencies prior to commercialization.</P>
<P align=justify>In particular, human therapeutic products are subject to
rigorous non-clinical and clinical testing and other approval procedures of the
FDA and similar regulatory authorities in other countries. Various federal
statutes and regulations also govern or influence testing, manufacturing,
safety, labeling, storage, and record-keeping related to such products and their
marketing. The process of obtaining these approvals and the subsequent
compliance with the appropriate federal statutes and regulations requires
substantial time and financial resources. Any failure by us or our collaborators
to obtain, or any delay in obtaining, regulatory approval could adversely affect
the marketing of any potential drug compounds developed by us, our ability to
receive product revenues, and our liquidity and capital resources. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_10></A>
<P align=center>- 7 - </P>
<P align=justify>The steps ordinarily required before a new drug may be marketed
in the United States, which are similar to steps required in most other
countries, include: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>non-clinical laboratory tests, non-clinical studies in animals, formulation
  studies and the submission to the FDA of an investigational new drug
  application; </P>
  <LI>
  <P>adequate and well-controlled clinical trials to establish the safety and
  efficacy of the drug; </P>
  <LI>
  <P>the submission of a new drug application or biologic license application to
  the FDA; and </P>
  <LI>
  <P>FDA review and approval of the new drug application or biologics license
  application. </P></LI></UL>
<P align=justify>Non-clinical tests include laboratory evaluation of potential
drug compound chemistry, formulation and toxicity, as well as animal studies.
The results of non-clinical testing are submitted to the FDA as part of an
investigational new drug application. A 30-day waiting period after the filing
of each investigational new drug application is required prior to commencement
of clinical testing in humans. At any time during the 30-day period or at any
time thereafter, the FDA may halt proposed or ongoing clinical trials until the
FDA authorizes trials under specified terms. The investigational new drug
application process may be extremely costly and substantially delay the
development of our potential drug compounds. Moreover, positive results of
non-clinical tests will not necessarily indicate positive results in subsequent
clinical trials. The FDA may require additional animal testing after an initial
investigational new drug application is approved and prior to Phase III
trials.</P>
<P align=justify>Clinical trials to support new drug applications are typically
conducted in three sequential phases, although the phases may overlap. During
Phase I, clinical trials are conducted with a small number of subjects to assess
metabolism, pharmacokinetics, and pharmacological actions and safety, including
side effects associated with increasing doses. Phase II usually involves studies
in a limited patient population to assess the efficacy of the drug in specific,
targeted indications; assess dosage tolerance and optimal dosage; and identify
possible adverse effects and safety risks. </P>
<P align=justify>If a compound is found to be potentially effective and to have
an acceptable safety profile in Phase II evaluations, Phase III trials are
undertaken to further demonstrate clinical efficacy and to further test for
safety within an expanded patient population at geographically dispersed
clinical trial sites. </P>
<P align=justify>After successful completion of the required clinical trials, a
new drug application is generally submitted. The FDA may request additional
information before accepting the new drug application for filing, in which case
the new drug application must be resubmitted with the additional information.
Once the submission has been accepted for filing, the FDA reviews the new drug
application and responds to the applicant. The FDA&#146;s requests for additional
information or clarification often significantly extend the review process. The
FDA may refer the new drug application to an appropriate advisory committee for
review, evaluation, and recommendation as to whether the new drug application
should be approved, although the FDA is not bound by the recommendation of an
advisory committee. </P>
<P align=justify>If the FDA evaluations of the application and the manufacturing
facilities are favorable, the FDA may issue an approval letter or an
&#147;approvable&#148; letter. An approvable letter will usually contain a number of
conditions that must be met in order to secure final approval of the new drug
application and authorization of commercial marketing of the drug for certain
indications. The FDA may also refuse to approve the new drug application or
issue a &#147;not approvable&#148; letter outlining the deficiencies in the submission and
often requiring additional testing or information. </P>
<P align=justify><I>The Food and Drug Administration&#146;s Modernization Act</I>
codified the FDA&#146;s policy of granting &#147;fast track&#148; review of certain therapies
targeting &#147;orphan&#148; indications and other therapies intended to treat severe or
life threatening diseases and having potential to address unmet medical needs.
Orphan indications are defined by the FDA as having a prevalence of less than
200,000 patients in the United States. We anticipate that certain
neurodegenerative diseases which could potentially be treated using our
technology could qualify for fast track review under these revised guidelines.
</P>
<P align=justify>Previously, the FDA approved cancer therapies primarily based
on patient survival rates or data on improved quality of life. The FDA
considered evidence of partial tumor shrinkage, while often part of the data
relied on for approval </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_11></A>
<P align=center>- 8 - </P>
<P align=justify>was insufficient by itself to warrant approval of a cancer
therapy, except in limited situations. Under the FDA&#146;s revised policy, which
became effective in 1998, the FDA has broadened authority to consider evidence
of partial tumor shrinkage or other clinical outcomes for approval. This revised
policy is intended to facilitate the study of solid tumor therapies and shorten
the total time for marketing approvals. We intend to take advantage of this
policy; however, it is too early to tell what effect, if any, these provisions
may have on the approval of our potential drug compounds. </P>
<P align=justify>Sales outside the United States of potential drug compounds we
develop will also be subject to foreign regulatory requirements governing human
clinical trials and marketing for drugs. The requirements vary widely from
country to country, but typically the registration and approval process takes
several years and requires significant resources. In most cases, if the FDA has
not approved a potential drug compound for sale in the United States, the
potential drug compound may be exported for sale outside of the United States,
only if it has been approved in any one of the following: the European Union,
Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa.
There are specific FDA regulations that govern this process. </P>
<P align=justify>We are also subject to various federal, state and local laws,
regulations and recommendations relating to safe working conditions, laboratory
and manufacturing practices, and the use and disposal of hazardous or
potentially hazardous substances, including radioactive compounds and infectious
disease agents, used in connection with our research work. We cannot accurately
predict the extent of government regulation that might result from future
legislation or administrative action. </P>
<P align=justify><I>Research and Development </I></P>
<P align=justify>We are a research and development company and we plan to focus
our efforts in research and development, through our three patents and one
patent application, and possibly further intellectual property that we may
acquire or develop, of novel drug targets for the treatment of cancer and
diseases of the central nervous system. Please see the Plan of Operations
section beginning on page 21 for our planned research and development activities
in the next 12 months. </P>
<P align=justify>The majority of our research and development activities are
performed at Eurogenet Labs S.A., a private Greek company, in Athens, Greece.
Under the direction of our Chief Scientific Officer, Dr. Vamvakides, Eurogenet
Labs S.A. provides research facilities and personnel to carry out various
research and development functions required to further develop our acquired
patents. </P>
<P align=justify><I>Employees </I></P>
<P align=justify>We currently employ two executive officers including a
president, and a chief scientific officer. Additionally we have three employees
to assist in product research, strategic planning and business development. On
February 1, 2008 we hired 19 consulting laboratory staff to work in our research
facilities. We also intend to contract with scientists and research laboratories
in order to accomplish our research objectives. Currently we have 24 consultants
assisting us in our Research and Development activities. We anticipate we may
spend up to approximately $900,000 in compensation to our officers, employees
and consultants during the next 12 months. </P>
<P align=justify><B><I>Executive Offices and Resident Agent </I></B></P>
<P align=justify>Our principal business office is located at 27 Marathonos Ave.,
15351 Athens, Greece. Our resident agent for service is Business First
Formations, Inc., 2470 Wrondel Way Ste 114, Reno NV 89502. </P>
<P align=justify><B><I>Reports to Security Holders</I></B></P>
<P align=justify>We file reports and other information with the SEC. This annual
report on Form 10-K, historical information about our company and other
information can be inspected and copied at the Public Reference Room of the SEC
located at Room 1580, 100 F Street, N.E., Washington D.C. 20549. Copies of such
materials, including copies of any portion of this annual report on Form 10-K,
can be obtained from the Public Reference Room of the SEC at prescribed rates.
You can call the SEC at 1-800-SEC-0330 to obtain information on the operation of
the Public Reference Room. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_12></A>
<P align=center>- 9 - </P>
<P align=justify>Such materials may also be accessed electronically by means of
  the SEC&#146;s home page on the Internet (<U>http://www.sec.gov</U>). </P>
<P align=justify><B>ITEM 1A. RISK FACTORS</B></P>
<P align=justify>Much of the information included in this annual report includes
or is based upon estimates, projections or other &#147;forward looking statements&#148;.
Such forward looking statements include any projections or estimates made by us
and our management in connection with our business operations. While these
forward-looking statements, and any assumptions upon which they are based, are
made in good faith and reflect our current judgment regarding the direction of
our business, actual results will almost always vary, sometimes materially, from
any estimates, predictions, projections, assumptions or other future performance
suggested herein.</P>
<P align=justify>Such estimates, projections or other &#147;forward looking
statements&#148; involve various risks and uncertainties as outlined below. We
caution the reader that important factors in some cases have affected and, in
the future, could materially affect actual results and cause actual results to
differ materially from the results expressed in any such estimates, projections
or other &#147;forward looking statements&#148;. Prospective investors should consider
carefully the risk factors set out below.</P>
<P align=justify><B><I>Risks Related to our Company </I></B></P>
<P align=justify><I>We have had a history of losses and no revenue, which raise
substantial doubt about our ability to continue as a going concern.</I></P>
<P align=justify>Since inception (January 23, 2004), we have incurred aggregate
net losses of $7,062,814 from operations. We can offer no assurance that we will
ever operate profitably or that we will generate positive cash flow in the
future. To date, we have not generated any revenues from our operations. Our
history of losses and no revenues raise substantial doubt about our ability to
continue as a going concern. We will not be able to generate significant
revenues in the future and our management expects acquisitions and exploration
expenditures and operating expenses to increase substantially over the next 12
months. As a result, our management expects the business to continue to
experience negative cash flow for the foreseeable future and cannot predict
when, if ever, our business might become profitable. We will need to raise
additional funds, and such funds may not be available on commercially acceptable
terms, if at all. If we are unable to raise funds on acceptable terms, we may
not be able to execute our business plan, take advantage of future
opportunities, or respond to competitive pressures or unanticipated
requirements. This may seriously harm our business, financial condition and
results of operations.</P>
<P align=justify><I>We are an early development stage biotechnology research and
development company and may never be able to successfully develop marketable
products or generate any revenue. We have a very limited relevant operating
history upon which an evaluation of our performance and prospects can be made.
There is no assurance that our future operations will result in profits. If we
cannot generate sufficient revenues, we may suspend or cease operations.</I></P>
<P align=justify>We are an early development stage company and have not
generated any revenues to date and have no operating history. All of our
potential drug compounds are in the concept stage and have not undergone
significant testing in non-clinical studies or in clinical trials. Moreover, we
cannot be certain that our research and development efforts will be successful
or, if successful, that our potential drug compounds will ever be approved for
sales to pharmaceutical companies or generate commercial revenues. We have no
relevant operating history upon which an evaluation of our performance and
prospects can be made. We are subject to all of the business risks associated
with a new enterprise, including, but not limited to, risks of unforeseen
capital requirements, failure of potential drug compounds either in non-clinical
testing or in clinical trials, failure to establish business relationships and
competitive disadvantages as against larger and more established companies. If
we fail to become profitable, we may suspend or cease operations.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_13></A>
<P align=center>- 10 - </P>
<P align=justify><I>We may be unable to continue as a going concern in which
case our securities will have little or no value.</I></P>
<P align=justify>Our independent auditors have noted in their report concerning
our annual financial statements as of September 30, 2008 that we have incurred
substantial losses since inception, which raises substantial doubt abut our
ability to continue as a going concern. In the event we are not able to continue
operations you will likely suffer a complete loss of your investment in our
securities. See our auditors&#146; report on our consolidated financial statements
elsewhere in this Form 10-K.</P>
<P align=justify><B><I>Risks Related to our Business </I></B></P>
<P align=justify><I>Even if we are able to develop our potential drug compounds,
we may not be able to receive regulatory approval, or if approved, we may not be
able to generate significant revenues or successfully commercialize our
products, which will adversely affect our financial results and financial
condition and we will have to delay or terminate some or all of our research and
development plans and we may be forced to cease operations.</I></P>
<P align=justify>All of our potential drug compounds will require extensive
additional research and development, including non-clinical testing and clinical
trials, as well as regulatory approvals, before we can market them. We cannot
predict if or when any of the potential drug compounds we intend to develop will
be approved for marketing. There are many reasons that we may fail in our
efforts to develop our potential drug compounds. These include:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>the possibility that non-clinical testing or clinical trials may show that
  our potential drug compounds are ineffective and/or cause harmful side
  effects; </P>
  <LI>
  <P>our potential drug compounds may prove to be too expensive to manufacture
  or administer to patients; </P>
  <LI>
  <P>our potential drug compounds may fail to receive necessary regulatory
  approvals from the United States Food and Drug Administration or foreign
  regulatory authorities in a timely manner, or at all; </P>
  <LI>
  <P>even if our potential drug compounds are approved, we may not be able to
  produce them in commercial quantities or at reasonable costs; </P>
  <LI>
  <P>even if our potential drug compounds are approved, they may not achieve
  commercial acceptance; </P>
  <LI>
  <P>regulatory or governmental authorities may apply restrictions to any of our
  potential drug compounds, which could adversely affect their commercial
  success; and </P>
  <LI>
  <P>the proprietary rights of other parties may prevent us or our potential
  collaborative partners from marketing our potential drug compounds.
</P></LI></UL>
<P align=justify>If we fail to develop our potential drug compounds, our
financial results and financial condition will be adversely affected, we will
have to delay or terminate some or all of our research and development plans and
may be forced to cease operations.</P>
<P align=justify><I>Our research and development plans will require substantial
additional future funding which could impact our operational and financial
condition. Without the required additional funds, we will likely cease
operations.</I></P>
<P align=justify>It will take several years before we are able to develop
marketable potential drug compounds, if at all. Our research and development
plans will require substantial additional capital, arising from costs to: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>conduct research, non-clinical testing and human studies; </P>
  <LI>
  <P>establish pilot scale and commercial scale manufacturing processes and
  facilities; and </P>
  <LI>
  <P>establish and develop quality control, regulatory, marketing, sales,
  finance and administrative capabilities to support these programs.
</P></LI></UL>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_14></A>
<P align=center>- 11 - </P>
<P align=justify>Our future operating and capital needs will depend on many
factors, including: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>the pace of scientific progress in our research and development programs
  and the magnitude of these programs; </P>
  <LI>
  <P>the scope and results of preclinical testing and human studies; </P>
  <LI>
  <P>the time and costs involved in obtaining regulatory approvals; </P>
  <LI>
  <P>the time and costs involved in preparing, filing, prosecuting, maintaining
  and enforcing patent claims; </P>
  <LI>
  <P>competing technological and market developments; </P>
  <LI>
  <P>our ability to establish additional collaborations; </P>
  <LI>
  <P>changes in our existing collaborations; </P>
  <LI>
  <P>the cost of manufacturing scale-up; and </P>
  <LI>
  <P>the effectiveness of our commercialization activities. </P></LI></UL>
<P align=justify>We base our outlook regarding the need for funds on many
uncertain variables. Such uncertainties include the success of our research
initiatives, regulatory approvals, the timing of events outside our direct
control such as negotiations with potential strategic partners and other
factors. Any of these uncertain events can significantly change our cash
requirements as they determine such one-time events as the receipt or payment of
major milestones and other payments.</P>
<P align=justify>Additional funds will be required to support our operations and
if we are unable to obtain them on favorable terms, we may be required to cease
or reduce further research and development of our drug product programs, sell
some or all of our intellectual property, merge with another entity or cease
operations. </P>
<P align=justify><I>If we fail to demonstrate efficacy in our non-clinical
studies and clinical trials our future business prospects, financial condition
and operating results will be materially adversely affected.</I></P>
<P align=justify>The success of our research and development efforts will be
greatly dependent upon our ability to demonstrate potential drug compound
efficacy in non-clinical studies, as well as in clinical trials. Non-clinical
studies involve testing potential drug compounds in appropriate non-human
disease models to demonstrate efficacy and safety. Regulatory agencies evaluate
these data carefully before they will approve clinical testing in humans. If
certain non-clinical data reveals potential safety issues or the results are
inconsistent with an expectation of the potential drug compound&#146;s efficacy in
humans, the regulatory agencies may require additional more rigorous testing,
before allowing human clinical trials. This additional testing will increase
program expenses and extend timelines. We may decide to suspend further testing
on our potential drug compounds if, in the judgment of our management and
advisors, the non-clinical test results do not support further development.</P>
<P align=justify>Moreover, success in non-clinical testing and early clinical
trials does not ensure that later clinical trials will be successful, and we
cannot be sure that the results of later clinical trials will replicate the
results of prior clinical trials and non-clinical testing. The clinical trial
process may fail to demonstrate that our potential drug compounds are safe for
humans and effective for indicated uses. This failure would cause us to abandon
a drug candidate and may delay development of other potential drug compounds.
Any delay in, or termination of, our non-clinical testing or clinical trials
will delay the filing of an Investigational New Drug application and New Drug
Application with the FDA and, ultimately, our ability to commercialize our
potential drug compounds and generate product revenues. In addition, our
clinical trials will involve small patient populations. Because of the small
sample size, the results of these early clinical trials may not be indicative of
future results. </P>
<P align=justify>Following successful non-clinical testing, potential drug
compounds will need to be tested in a clinical development program to provide
data on safety and efficacy prior to becoming eligible for product approval and
licensure by </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_15></A>
<P align=center>- 12 - </P>
<P align=justify>regulatory agencies. From the first human trial through product
approval can take many years and 10-12 years is not unusual. </P>
<P align=justify>If any of our future clinical development potential drug
compounds become the subject of problems, our ability to sustain our development
programs will become critically compromised. For example, efficacy or safety
concerns may arise, whether or not justified, that could lead to the suspension
or termination of our clinical programs. Examples of problems that could arise
include, among others: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>efficacy or safety concerns with the potential drug compounds, even if not
  justified; </P>
  <LI>
  <P>unexpected side-effects; </P>
  <LI>
  <P>regulatory proceedings subjecting the potential drug compounds to potential
  recall; </P>
  <LI>
  <P>publicity affecting doctor prescription or patient use of the potential
  drug compounds; </P>
  <LI>
  <P>pressure from competitive products; or </P>
  <LI>
  <P>introduction of more effective treatments. </P></LI></UL>
<P align=justify>Each clinical phase is designed to test attributes of the drug
and problems that might result in the termination of the entire clinical plan
can be revealed at any time throughout the overall clinical program. The failure
to demonstrate efficacy in our clinical trials would have a material adverse
effect on our future business prospects, financial condition and operating
results. </P>
<P align=justify><I>If we do not obtain the support of qualified scientific
collaborators, our revenue, growth and profitability will likely be limited,
which would have a material adverse effect on our business.</I></P>
<P align=justify>We will need to establish relationships with leading scientists
and research institutions. We believe that such relationships are pivotal to
establishing products using our technologies as a standard of care for various
indications. Additionally, although in discussion, there is no assurance that
our current research partners will continue to work with us or that we will be
able to attract additional research partners. If we are not able to establish
scientific relationships to assist in our research and development, we may not
be able to successfully develop our potential drug compounds. If this happens,
our business will be adversely affected.</P>
<P align=justify><I>We may not be able to develop market or generate sales of
our products to the extent anticipated. Our business may fail and investors
could lose all of their investment in our company.</I></P>
<P align=justify>Assuming that we are successful in developing our potential
drug compounds and receiving regulatory clearances to market our products, our
ability to successfully penetrate the market and generate sales of those
products may be limited by a number of factors, including the following: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>If our competitors receive regulatory approvals for and begin marketing
  similar products in the United States, the European Union, Japan and other
  territories before we do, greater awareness of their products as compared to
  ours will cause our competitive position to suffer; </P>
  <LI>
  <P>Information from our competitors or the academic community indicating that
  current products or new products are more effective than our future products
  could be, if and when they are generated, impede our market penetration or
  decrease our future market share; and, </P>
  <LI>
  <P>The price for our future products, as well as pricing decisions by our
  competitors, may have an effect on our revenues. </P></LI></UL>
<P align=justify>If this happens, our business will be adversely affected.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_16></A>
<P align=center>- 13 - </P>
<P align=justify><I>None of our potential drug compounds may reach the
commercial market for a number of reasons and our business may fail.</I></P>
<P align=justify>Successful research and development of pharmaceutical products
is high risk. Most products and development candidates fail to reach the market.
Our success depends on the discovery of new drug compounds that we can
commercialize. It is possible that our potential drug compounds may never reach
the market for a number of reasons. They may be found ineffective or may cause
harmful side-effects during non-clinical testing or clinical trials or fail to
receive necessary regulatory approvals. We may find that certain potential drug
compounds cannot be manufactured at a commercial scale and, therefore, they may
not be economical to produce. Our potential drug compounds could also fail to
achieve market acceptance or be precluded from commercialization by proprietary
rights of third parties. Furthermore, we do not expect our potential drug
compounds to be commercially available for a number of years, if at all. If none
of our potential drug compounds reach the commercial market, our business will
likely fail and investors will lose all of their investment in our company. If
this happens, our business will be adversely affected.</P>
<P align=justify><I>If our competitors succeed in developing products and
technologies that are more effective than our own, or if scientific developments
change our understanding of the potential scope and utility of our potential
drug compounds, then our technologies and future potential drug compounds may be
rendered undesirable or obsolete.</I></P>
<P align=justify>We face significant competition from industry participants that
are pursuing technologies similar to those that we are pursuing and are
developing pharmaceutical products that are competitive with our potential drug
compounds. Nearly all of our industry competitors have greater capital
resources, larger overall research and development staffs and facilities, and a
longer history in drug discovery and development, obtaining regulatory approval
and pharmaceutical product manufacturing and marketing than we do. With these
additional resources, our competitors may be able to respond to the rapid and
significant technological changes in the biotechnology and pharmaceutical
industries faster than we can. Our future success will depend in large part on
our ability to maintain a competitive position with respect to these
technologies. Rapid technological development, as well as new scientific
developments, may result in our potential drug compounds becoming obsolete
before we can recover any of the expenses incurred to develop them. For example,
changes in our understanding of the appropriate population of patients who
should be treated with a targeted therapy like we are developing may limit the
drug&#146;s market potential if it is subsequently demonstrated that only certain
subsets of patients should be treated with the targeted therapy.</P>
<P align=justify><I>Our reliance on third parties, such as university
laboratories, contract manufacturing organizations and contract or clinical
research organizations, may result in delays in completing, or a failure to
complete, non-clinical testing or clinical trials if they fail to perform under
our agreements with them.</I></P>
<P align=justify>In the course of product development, we may engage university
laboratories, other biotechnology companies or contract or clinical
manufacturing organizations to manufacture drug material for us to be used in
non-clinical and clinical testing and contract research organizations to conduct
and manage non-clinical and clinical studies. If we engage these organizations
to help us with our non-clinical and clinical programs, many important aspects
of this process have been and will be out of our direct control. If any of these
organizations we may engage in the future fail to perform their obligations
under our agreements with them or fail to perform non-clinical testing and/or
clinical trials in a satisfactory manner, we may face delays in completing our
clinical trials, as well as commercialization of any of our potential drug
compounds. Furthermore, any loss or delay in obtaining contracts with such
entities may also delay the completion of our clinical trials, regulatory
filings and the potential market approval of our potential drug compounds. </P>
<P align=justify><I>If we fail to compete successfully with respect to
acquisitions, joint venture and other collaboration opportunities, we may be
limited in our ability to research and develop our potential drug compounds.
</I></P>
<P align=justify>Our competitors compete with us to attract established
biotechnology and pharmaceutical companies or organizations for acquisitions,
joint ventures, licensing arrangements or other collaborations. Collaborations
include contracting with academic research institutions for the performance of
specific scientific testing. If our competitors successfully enter into
partnering arrangements or license agreements with academic research
institutions, we will then be precluded from pursuing those specific
opportunities. Since each of these opportunities is unique, we may not be able
to find a substitute. Other companies have already begun many drug development
programs, which may </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_17></A>
<P align=center>- 14 - </P>
<P align=justify>target diseases that we are also targeting, and have already
entered into partnering and licensing arrangements with academic research
institutions, reducing the pool of available opportunities. </P>
<P align=justify>Universities and public and private research institutions also
compete with us. While these organizations primarily have educational or basic
research objectives, they may develop proprietary technology and acquire patents
that we may need for the development of our potential drug compounds. We will
attempt to license this proprietary technology, if available. These licenses may
not be available to us on acceptable terms, if at all. If we are unable to
compete successfully with respect to acquisitions, joint venture and other
collaboration opportunities, we may be limited in our ability to develop new
products. </P>
<P align=justify><I>The use of any of our potential drug compounds in clinical
trials may expose us to liability claims, which may cost us a significant
amounts of money to defend against or pay out, causing our business to
suffer.</I></P>
<P align=justify>The nature of our business exposes us to potential liability
risks inherent in the testing, manufacturing and marketing of our potential drug
compounds. We currently do not have any potential drug compounds in clinical
trials, however, when any of our potential drug compounds enter into clinical
trials or become marketed products they could potentially harm people or
allegedly harm people and we may be subject to costly and damaging product
liability claims. Some of the patients who participate in clinical trials are
already critically ill when they enter a trial. The waivers we obtain may not be
enforceable and may not protect us from liability or the costs of product
liability litigation. Although we intend to obtain product liability insurance
that we believe is adequate, we are subject to the risk that our insurance will
not be sufficient to cover claims. The insurance costs along with the defense or
payment of liabilities above the amount of coverage could cost us significant
amounts of money, causing our business to suffer.</P>
<P align=justify><I>The patent positions of biopharmaceutical products are
complex and uncertain and we may not be able to protect our patented or other
intellectual property. If we cannot protect this property, we may be prevented
from using it or our competitors may use it and our business could suffer
significant harm. Also, the time and money we spend on acquiring and enforcing
patents and other intellectual property will reduce the time and money we have
available for our research and development, possibly resulting in a slow down or
cessation of our research and development.</I></P>
<P align=justify>We own four patents related to certain of our potential drug
compounds. However, these patents do not ensure the protection of our
intellectual property for a number of reasons, including the following: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>Competitors may interfere with our patent process in a
      variety of ways. Competitors may claim that they invented the claimed
      invention prior to us. Competitors may also claim that we are infringing
      on their patents and therefore cannot practice our technology as claimed
      under our patents and patent applications. Competitors may also contest
      our patents and patent application, if issued, by showing the patent
      examiner that the invention was not original, was not novel or was
      obvious. In litigation, a competitor could claim that our patents and
      patent application are not valid for a number of reasons. If a court
      agrees, we would lose that patents or patent application. As a company, we
      have no meaningful experience with competitors interfering with our
      patents or patent applications.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>Because of the time, money and effort involved in
      obtaining and enforcing patents, our management may spend less time and
      resources on developing potential drug compounds than they otherwise
      would, which could increase our operating expenses and delay product
      programs.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>Receipt of a patent may not provide much practical
      protection. If we receive a patent with a narrow scope, then it will be
      easier for competitors to design products that do not infringe on our
      patent.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify>In addition, competitors also seek patent protection for
      their inventions. Due to the number of patents in our field, we cannot be
      certain that we do not infringe on existing patents or that we will not
      infringe on patents granted in the future. If a patent holder believes our
      potential drug compound infringes on their patent, the patent holder may
      sue us even if we have received patent protection for our technology. If
      someone else claims we infringe on their patent, we would face
  a</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_18></A>
<P align=center>- 15 - </P>
<P style="MARGIN-LEFT: 10%" align=justify>number of issues which could cause a
slow down or cessation of our research and development, including the following:
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="15%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Defending a lawsuit takes significant time and can be
      very expensive.</P></TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>If the court decides that our potential drug compound
      infringes on the competitor&#146;s patent, we may have to pay substantial
      damages for past infringement.</P></TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>The court may prohibit us from selling or licensing the
      potential drug compound unless the patent holder licenses the patent to
      us. The patent holder is not required to grant us a license. If a license
      is available, we may have to pay substantial royalties or grant cross
      licenses to our patents.</P></TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>Redesigning our potential drug compounds so that they do
      not infringe on other patents may not be possible or could require
      substantial funds and time.</P></TD></TR></TABLE>
<P align=justify>It is also unclear whether our trade secrets are adequately
protected. While we use reasonable efforts to protect our trade secrets, our
employees or consultants may unintentionally or willfully disclose our
information to competitors. Enforcing a claim that someone else illegally
obtained and is using our trade secrets, like patent litigation, is expensive
and time consuming, and the outcome is unpredictable. In addition, courts
outside the United States are sometimes less willing to protect trade secrets.
Our competitors may independently develop equivalent knowledge, methods and
know-how.</P>
<P align=justify>We may also support and collaborate in research conducted by
government organizations, hospitals, universities or other educational
institutions. These research partners may be unwilling to grant us any exclusive
rights to technology or products derived from these collaborations prior to
entering into the relationship.</P>
<P align=justify>If we do not obtain required licenses or rights, we could
encounter delays in our product development efforts while we attempt to design
around other patents or even be prohibited from developing, manufacturing or
selling potential drug compounds requiring these licenses. There is also a risk
that disputes may arise as to the rights to technology or potential drug
compounds developed in collaboration with other parties.</P>
<P align=justify><I>We will incur increased costs as a result of recently
enacted and proposed changes in laws and regulations and we cannot predict the
impact of any future changes in law. </I></P>
<P align=justify>We face burdens relating to the recent trend toward stricter
corporate governance and financial reporting standards. New legislation or
regulations such as Section 404 of the <I>Sarbanes-Oxley Act of 2002</I> follow
the trend of imposing stricter corporate governance and financial reporting
standards have led to an increase in our costs of compliance including increases
in consulting, auditing and legal fees. The new rules could make it more
difficult or more costly for us to obtain certain types of insurance, including
directors&#146; and officers&#146; liability insurance, and we may be forced to accept
reduced policy limits and coverage or incur substantially higher costs to obtain
the same or similar coverage. The impact of these events could also make it more
difficult for us to attract and retain qualified persons to serve on our board
of directors, our board committees or as executive officers. A failure to comply
with these new laws and regulations may impact market perception of our
financial condition and could materially harm our business. Additionally, it is
unclear what additional laws or regulations may develop, and we cannot predict
the ultimate impact of any future changes in law.</P>
<P align=justify><I>Trends, Risks and Uncertainties.</I></P>
<P align=justify>We have sought to identify what we believe to be the most
significant risks to our business, but we cannot predict whether, or to what
extent, any such risks may be realized nor can we guarantee that we have
identified all possible risks that might arise. Investors should carefully
consider all of the risk factors before making an investment decision with
respect to our common stock. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_19></A>
<P align=center>- 16 - </P>
<P align=justify><B><I>Risks Related to our Common Stock</I></B></P>
<P align=justify><I>A decline in the price of our common stock could affect our
ability to raise further working capital and adversely impact our operations.
</I></P>
<P align=justify>A prolonged decline in the price of our common stock could
result in a reduction in the liquidity of our common stock and a reduction in
our ability to raise capital. Because our operations have been financed through
the sale of equity securities, a decline in the price of our common stock could
be especially detrimental to our liquidity and our continued operations. Any
reduction in our ability to raise equity capital in the future would force us to
reallocate funds from other planned uses and would have a significant negative
effect on our business plans and operations, including our ability to develop
new products and continue our current operations. If the stock price declines,
there can be no assurance that we can raise additional capital or generate funds
from operations sufficient to meet our obligations. We believe the following
factors could cause the market price of our common stock to continue to
fluctuate widely and could cause our common stock to trade at a price below the
price at which you purchase your shares of common stock: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>actual or anticipated variations in our quarterly operating results; </P>
  <LI>
  <P>announcements of new services, products, acquisitions or strategic
  relationships by us or our competitors; </P>
  <LI>
  <P>changes in accounting treatments or principles; </P>
  <LI>
  <P>changes in earnings estimates by securities analysts and in analyst
  recommendations; and </P>
  <LI>
  <P>general political, economic, regulatory and market conditions. </P></LI></UL>
<P align=justify>The market price for our common stock may also be affected by
our ability to meet or exceed expectations of analysts or investors. Any failure
to meet these expectations, even if minor, could materially adversely affect the
market price of our common stock. </P>
<P align=justify><I>If we issue additional shares of common stock in the future,
it will result in the dilution of our existing shareholders. </I></P>
<P align=justify>Our certificate of incorporation authorizes the issuance of
150,000,000 shares of common stock. Our board of directors has the authority to
issue additional shares of common stock up to the authorized capital stated in
the certificate of incorporation. Our board of directors may choose to issue
some or all of such shares of common stock to acquire one or more businesses or
to provide additional financing in the future. The issuance of any such shares
of common stock will result in a reduction of the book value or market price of
the outstanding shares of our common stock. If we do issue any such additional
shares of common stock, such issuance also will cause a reduction in the
proportionate ownership and voting power of all other shareholders. Further, any
such issuance may result in a change of control of our corporation. </P>
<P align=justify><I>If a market for our shares of common stock does not develop,
shareholders may be unable to sell their shares of common stock. </I></P>
<P align=justify>There is currently a limited market for our common stock, which
trades through the Over-the-Counter Bulletin Board quotation system. Trading of
stock through the Over-the-Counter Bulletin Board is frequently thin and highly
volatile. There is no assurance that a sufficient market will develop in the
stock, in which case it could be difficult for shareholders to sell their stock.
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_20></A>
<P align=center>- 17 - </P>
<P align=justify><I>Trading on the OTC Bulletin Board may be volatile and
sporadic, which could depress the market price of our common stock and make it
difficult for our stockholders to resell their shares.</I></P>
<P align=justify>Our common stock is quoted on the OTC Bulletin Board service of
the Financial Industry Regulatory Authority (FINRA). Trading in stock quoted on
the OTC Bulletin Board is often thin and characterized by wide fluctuations in
trading prices, due to many factors that may have little to do with our
operations or business prospects. This volatility could depress the market price
of our common stock for reasons unrelated to operating performance. Moreover,
the OTC Bulletin Board is not a stock exchange, and trading of securities on the
OTC Bulletin Board is often more sporadic than the trading of securities listed
on a quotation system like Nasdaq or a stock exchange like Amex. Accordingly,
shareholders may have difficulty reselling any of the shares.</P>
<P align=justify><I>Our stock is a penny stock. Trading of our stock may be
restricted by the SEC&#146;s penny stock regulations and FINRA&#146;s sales practice
requirements, which may limit a stockholder&#146;s ability to buy and sell our
stock.</I></P>
<P align=justify>Our stock is a penny stock. The Securities and Exchange
Commission has adopted Rule 15g-9 which generally defines &#147;penny stock&#148; to be
any equity security that has a market price (as defined) less than $5.00 per
share or an exercise price of less than $5.00 per share, subject to certain
exceptions. Our securities are covered by the penny stock rules, which impose
additional sales practice requirements on broker-dealers who sell to persons
other than established customers and &#147;accredited investors&#148;. The term
&#147;accredited investor&#148; refers generally to institutions with assets in excess of
$5,000,000 or individuals with a net worth in excess of $1,000,000 or annual
income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock
rules require a broker-dealer, prior to a transaction in a penny stock not
otherwise exempt from the rules, to deliver a standardized risk disclosure
document in a form prepared by the SEC which provides information about penny
stocks and the nature and level of risks in the penny stock market. The
broker-dealer also must provide the customer with current bid and offer
quotations for the penny stock, the compensation of the broker-dealer and its
salesperson in the transaction and monthly account statements showing the market
value of each penny stock held in the customer&#146;s account. The bid and offer
quotations, and the broker-dealer and salesperson compensation information, must
be given to the customer orally or in writing prior to effecting the transaction
and must be given to the customer in writing before or with the customer&#146;s
confirmation. In addition, the penny stock rules require that prior to a
transaction in a penny stock not otherwise exempt from these rules; the
broker-dealer must make a special written determination that the penny stock is
a suitable investment for the purchaser and receive the purchaser&#146;s written
agreement to the transaction. These disclosure requirements may have the effect
of reducing the level of trading activity in the secondary market for the stock
that is subject to these penny stock rules. Consequently, these penny stock
rules may affect the ability of broker-dealers to trade our securities. We
believe that the penny stock rules discourage investor interest in and limit the
marketability of our common stock.<B> </B></P>
<P align=justify>In addition to the &#147;penny stock&#148; rules promulgated by the
Securities and Exchange Commission, FINRA has adopted rules that require that in
recommending an investment to a customer, a broker-dealer must have reasonable
grounds for believing that the investment is suitable for that customer. Prior
to recommending speculative low priced securities to their non-institutional
customers, broker-dealers must make reasonable efforts to obtain information
about the customer&#146;s financial status, tax status, investment objectives and
other information. Under interpretations of these rules, FINRA believes that
there is a high probability that speculative low priced securities will not be
suitable for at least some customers. FINRA requirements make it more difficult
for broker-dealers to recommend that their customers buy our common stock, which
may limit your ability to buy and sell our stock. </P>
<P align=justify><B>ITEM 1B. UNRESOLVED STAFF COMMENTS</B></P>
<P align=justify>Not Applicable.<FONT color=#808080> </FONT></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_21></A>
<P align=center>- 18 - </P>
<P align=justify><B>ITEM 2. PROPERTIES</B></P>
<P align=justify><B><I>Executive Offices and Registered Agent </I></B></P>
<P align=justify>Our principal business office is located at 27 Marathonos Ave.,
15351 Athens, Greece. This space is located within our rented laboratory for
which we pay $70,000 per month. The lease is for a year to year basis and may be
terminated with three months notice.</P>
<P align=justify>Our registered office for service in the State of Nevada is
located at 3990 Warren Way, Reno, NV 89509.</P>
<P align=justify><B>ITEM 3. LEGAL PROCEEDINGS</B></P>
<P align=justify>We know of no material, existing or pending legal proceedings
  against our company, nor are we involved as a plaintiff in any material proceeding
  or pending litigation. There are no proceedings in which any of our directors,
  officers or affiliates, or any registered or beneficial stockholder, is an adverse
party or has a material interest adverse to our interest. </P>
<P align=justify><B>ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY
HOLDERS</B></P>
<P align=justify>On April 1, 2008, we held our annual meeting of stockholders.
</P>
<P align=justify>At the annual meeting, our stockholders elected Panos
Kontzalis, Harvey Lalach, Alexandre Vamvakides and Cameron Durrant to serve as
directors of our company with the following votes: </P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="33%">For
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="33%">Withheld </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Panos Kontzalis </TD>
    <TD align=center width="33%" bgColor=#e6efff>10,377,500 </TD>
    <TD align=center width="33%" bgColor=#e6efff>0 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Harvey Lalach </TD>
    <TD align=center width="33%">10,377,500 </TD>
    <TD align=center width="33%">0 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Alexandre Vamvakides </TD>
    <TD align=center width="33%" bgColor=#e6efff>10,377,500 </TD>
    <TD align=center width="33%" bgColor=#e6efff>0 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Cameron Durrant </TD>
    <TD align=center width="33%">10,377,500 </TD>
    <TD align=center width="33%">0 </TD></TR></TABLE></DIV>
<P align=justify>At the annual meeting, our stockholders ratified the
appointment of BDO Dunwoody LLP as our independent auditors for the fiscal year
ending September 30, 2009 with the following votes: </P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center>For </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="25%">Against </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="25%">Abstain </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="25%">Broker Non-Votes </TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>10,377,500 </TD>
    <TD align=center width="25%" bgColor=#e6efff>0 </TD>
    <TD align=center width="25%" bgColor=#e6efff>0 </TD>
    <TD align=center width="25%" bgColor=#e6efff>0 </TD></TR></TABLE></DIV>
<P align=center><B>PART II</B></P>
<P align=justify><B>ITEM 5. MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</B></P>
<P align=justify><B><I>Market information </I></B></P>
<P align=justify>Our Common stock is quoted on the OTC Bulletin Board under the
Symbol &#147;AVXL&#148;. Our stock was originally approved for trading on the OTC Bulletin
Board on March 13, 2006 under the symbol &#147;TFYP&#148; and was changed to &#147;AVXL&#148; on
January 25, 2007 in connection with a change of name. </P>
<P align=justify>The following table reflects the high and low bid information
for our common stock obtained from Stockwatch and reflects inter-dealer prices,
without retail mark-up, markdown or commission, and may not necessarily
represent actual transactions. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_22></A>
<P align=center>- 19 - </P>
<P align=justify>The high and low bid prices of our common stock for the periods
indicated below are as follows: </P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="80%" border=1>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=center style="BORDER-BOTTOM: #000000 1px solid"><B>Quarter Ended</B>
      </TD>
      <TD
      width="33%" align=center style="BORDER-BOTTOM: #000000 1px solid"><B>Bid</B>
      </TD>
      <TD
      width="33%" align=center style="BORDER-BOTTOM: #000000 1px solid"><B>Ask</B>
      </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center style="BORDER-BOTTOM: #000000 1px solid">September 30,
        2008<br>
        June 30, 2008 <br>
        March 31, 2008 </TD>
      <TD
      width="33%" align=center style="BORDER-BOTTOM: #000000 1px solid">$3.23
        <br> $5.02 <br> $4.99 </TD>
      <TD
      width="33%" align=center style="BORDER-BOTTOM: #000000 1px solid">$3.56
        <br> $5.04 <br> $5.18 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center style="BORDER-BOTTOM: #000000 1px solid">December 31, 2007
        <br> September 30, 2007 </TD>
      <TD
      width="33%" align=center style="BORDER-BOTTOM: #000000 1px solid">$4.41
        <br> $3.73 </TD>
      <TD
      width="33%" align=center style="BORDER-BOTTOM: #000000 1px solid">$4.50
        <br> $3.80 </TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center>June 30, 2007
      </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="33%">$3.70 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="33%">$3.79 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center style="BORDER-BOTTOM: #000000 1px solid">March 31, 2007
        <br> December 31, 2006 </TD>
      <TD
      width="33%" align=center style="BORDER-BOTTOM: #000000 1px solid">$2.54
        <br> $2.11 </TD>
      <TD
      width="33%" align=center style="BORDER-BOTTOM: #000000 1px solid">$2,000<SUP>(1)</SUP> <br> $3.15 </TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify><SUP>(1) </SUP>Market makers often
maintain quotes in securities in which they have no real interest in dealing in
at certain times. In those instances they will widen their spreads to reflect
the fact that they aren't actively quoting at that specific time. For example
they might post a quote of .01-2000. No one is going to transact at those prices
when the inside quote is around 3-4. In addition, Anavex underwent a symbol
change during that time period. Effective 1/25/07 the change from THFY to AVXL
was made. Anything data prior to 1/25/07 is actually data for THFY. The value in
question actually refers to a quote in THFY from 1/10/07. </P>
<P align=justify>On January 8, 2009, the closing price for the common stock as
reported by the quotation service operated by the OTC Bulletin Board was $2.77.
</P>
<P align=justify><B><I>Transfer Agent</I></B></P>
<P align=justify>Our common shares are issued in registered form. The Nevada
Agency and Trust Company, 50 West Liberty Street, Reno, Nevada (Telephone: (775)
322-0626; Facsimile: (775) 322-5623) is the registrar and transfer agent for our
common shares.<FONT color=#808080> </FONT></P>
<P align=justify><B><I>Holders of Common Stock</I></B></P>
<P align=justify>As of January 9, 2009, there were 48 holders of record of our
common stock. As of such date, 19,982,420 of our common stock was issued and
outstanding.<FONT color=#808080> </FONT></P>
<P align=justify><B><I>Dividends</I></B></P>
<P align=justify>We have not paid any cash dividends on our common stock and
have no present intention of paying any dividends on the shares of our common
stock. Our current policy is to retain earnings, if any, for use in our
operations and in the development of our business. Our future dividend policy
will be determined from time to time by our board of directors. </P>
<P align=justify><B><I>Securities authorized for issuance under equity
compensation plans.</I></B></P>
<P align=justify>We have no long-term incentive plans, other than the Stock
Option Plan described below. </P>
<P align=justify><I>Stock Option Plan </I></P>
<P align=justify>On April 17, 2007, our directors adopted the 2007 Stock Option
Plan for our employees and consultants, reserving a total of 3,000,000 shares of
its common stock for issuance pursuant to grants to be made under the stock
option plan. On May 25, 2007, our stockholders ratified and approved the 2007
Stock Option Plan at the annual meeting of stockholders. As of September 30,
2008, 1,420,000 options have been granted to employees, directors and officers
of our company and 1,580,000 options were available for future grant under this
plan. </P>
<P align=justify>The purpose of the 2007 Stock Option Plan is to retain the
services of valued key employees and consultants of our company and such other
persons as shall be select in accordance with the 2007 Stock Option Plan, and to
encourage such persons to acquire a greater proprietary interest in our company,
thereby strengthening their incentive to achieve the objectives of the
shareholders of our company, and to serve as an aid and inducement in the hiring
of new employees and to provide an equity incentive to consultants. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_23></A>
<P align=center>- 20 - </P>
<P align=justify>The exercise price of shares subject to any option must be at
least 100% of the fair market value of the shares on the date of grant. The
maximum term of any stock option is 5 years from the date the option is
granted.</P>
<P align=justify>The following table summarizes certain information regarding
our equity compensation plan as at September 30, 2008:</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=center><BR>
        <BR><BR><BR><BR><BR><B>Plan Category</B> </TD>
      <TD width="25%" align=center><BR>
        <BR><BR><B>Number of Securities to</B>
      <BR><B>be Issued Upon Exercise</B> <BR><B>of Outstanding Options,</B>
      <BR><B>Warrants and Rights</B> </TD>
      <TD width="25%" align=center><BR>
        <BR><BR><B>Weighted-Average</B>
      <BR><B>Exercise Price of</B> <BR><B>Outstanding Options,</B>
      <BR><B>Warrants and Rights</B> </TD>
      <TD
      width="25%" align=center style="BORDER-BOTTOM: #000000 1px solid"><B>Number of Securities</B> <BR>
        <B>Remaining Available for</B>
      <BR><B>Future Issuance Under</B> <BR><B>Equity Compensation</B>
      <BR><B>Plans (Excluding</B> <BR><B>Securities Reflected in</B>
      <BR><B>Column)</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Equity compensation plans <BR>approved by security
      <BR>holders </TD>
    <TD align=right width="25%">1,420,000 <BR><BR></TD>
    <TD align=right width="25%">$4.54 <BR><BR></TD>
    <TD align=right width="25%">1,580,000 <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Equity
      compensation plans <BR>not approved by security <BR>holders </TD>
    <TD align=right width="25%">N/A <BR><BR></TD>
    <TD align=right width="25%">N/A <BR><BR></TD>
    <TD align=right width="25%">N/A <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Total </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="25%">1,420,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="25%">$4.54
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="25%">1,580,000 </TD></TR></TABLE></DIV>
<P align=justify><B><I>Recent Sales of Unregistered Securities; Use of Proceeds
from Registered Securities </I></B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">1. </TD>
    <TD colSpan=2>
      <P align=justify>On May 16, 2008 Dr. Panagiotis Kontzalis resigned as CEO
      and from our board of directors. As settlement of consideration for
      services provided by and in termination of Dr. Kontzalis&#146; contract we
      issued 65,000 common shares to Dr. Kontzalis. We issued the common shares
      to one non-U.S. person (as that term is defined in Regulation S of the
      Securities Act of 1933) in an offshore transaction relying on Regulation S
      and/or Section 4(2) of the Securities Act of 1933.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">2. </TD>
    <TD colSpan=2>
      <P align=justify>On May 20, 2008 we entered into a consulting agreement
      with Cameron Durrant to provide management services to our company.
      Consideration for Mr. Durrant&#146;s services is as follows:</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>the issuance of 200,000 shares of common stock to be paid
      installments of 25,000 shares every quarter;</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>the issuance of 400,000 stock options exercisable at US
      $5.25 per share for a period of 3 years, subject to vesting
    provisions;</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>a payment of a finders fee for any financing our company
      receives in the amount of 4% on the first $100,000,000 and 2% on the
      balance.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TR>
    <TD vAlign=top width="5%">3. </TD>
    <TD colSpan=2>
      <P align=justify>On June 3, 2008 we approved a compensation package for
      company directors. We issued 450,000 stock options to three directors to
      purchase shares of common stock at an exercise price of $5.00 expiring on
      June 3, 2013. The options are subject to vesting provisions.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD colSpan=2>
      <P align=justify>We issued the securities to one non-U.S. persons (as that
      term is defined in Regulation S, promulgated by the Securities and
      Exchange Commission pursuant to the <I>Securities Act of 1933, </I>as
      amended) in an offshore transaction relying on Regulation S and/or Section
      4(2) of the Securities Act and to two US persons, relying on the exemption
      from the registration requirements of the Securities Act provided by
      Section 4(2) of the Securities Act and/or by Rule 506 of Regulation D
      promulgated thereunder.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">4. </TD>
    <TD colSpan=2>
      <P align=justify>On August 19, 2008, pursuant to private placement
      subscription agreements to issue units at $4.25 each, our company raised
      $606,000. Each unit consists of one common share and one common share
      purchase warrant entitling the holder to purchase an additional common
      share for $5.00 for each warrant held for a period of up to one year from
      the date of closing.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_24></A>
<P align=center>- 21 - </P>
<P style="MARGIN-LEFT: 5%" align=justify>We issued the securities to six
non-U.S. persons (as that term is defined in Regulation S, promulgated by the
Securities and Exchange Commission pursuant to the <I>Securities Act of
1933,</I> as amended) in an offshore transaction relying on Regulation S and/or
Section 4(2) of the Securities Act.</P>
<P align=justify><B><I>Purchases of Equity Securities by the Issuer and
Affiliated Purchasers </I></B></P>
<P align=justify>The following table is a summary of purchases made by or on
behalf of our company or any "affiliated purchaser," of shares or other units of
any class of the our equity securities that is registered by the issuer pursuant
to section 12 of the Exchange Act. </P>
<P align=justify><B>Table 1 ISSUER PURCHASES OF EQUITY SECURITIES </B></P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="20%"><B>(a)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="20%"><B>(b)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="20%"><B>(c)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="20%"><B>(d)</B> </TD></TR>
  <TR vAlign=top>
    <TD align=center><BR><BR><BR><BR><BR><BR><BR><B>Period</B> </TD>
    <TD align=center width="20%"><BR><BR><BR><BR><BR><B>Total Number of</B>
      <BR><B>Shares (or Units)</B> <BR><B>Purchased</B> </TD>
    <TD align=center width="20%"><BR><BR><BR><BR><BR><BR><B>Average Price
      Paid</B> <BR><B>per Share (or Unit)</B> </TD>
    <TD align=center width="20%"><BR><BR><BR><B>Total Number of</B>
      <BR><B>Shares (or Units)</B> <BR><B>Purchased as Part of</B>
      <BR><B>Publicly Announced</B> <BR><B>Plans or Programs</B> </TD>
    <TD align=center width="20%"><B>Maximum Number</B> <BR><B>(or
      Approximate</B> <BR><B>Dollar Value) of</B> <BR><B>Shares (or Units)</B>
      <BR><B>that May Yet Be</B> <BR><B>Purchased Under</B> <BR><B>the Plans
      or</B> <BR><B>Programs</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>N/A </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="20%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="20%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="20%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="20%">Nil
    </TD></TR></TABLE></DIV>
<P align=justify><B>ITEM 6 SELECTED FINANCIAL DATA</B></P>
<P align=justify>Not applicable. </P>
<P align=justify><B>ITEM 7 MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATION</B></P>
<P align=justify><B><I>Overview </I></B></P>
<P align=justify>You should read the following discussion of our financial
condition and results of operations together with the audited financial
statements and the notes to audited financial statements included elsewhere in
this filing prepared in accordance with accounting principles generally accepted
in the United States. This discussion contains forward-looking statements that
reflect our plans, estimates and beliefs. Our actual results could differ
materially from those anticipated in these forward-looking statements. </P>
<P align=justify><B><I>Plan of Operations </I></B></P>
<P align=justify>We anticipate that we will require up to $5,180,000 for the 12
months ending September 30, 2009 to implement our plan of operation of
researching and developing our four patents, the related compounds and any
further intellectual property we may acquire. The majority of our capital
resources requirement is needed to enter some of our current compounds into
clinical trials.</P>
<P align=justify><I>Cash Requirements </I></P>
<P align=justify>We will require additional funds to plan of operation of
researching and developing our three patents and one patent application, the
related compounds and any further intellectual property we may acquire. The
majority of our capital resources requirement is needed to enter some our
current compounds into clinical trials. These funds may be raised through equity
financing, debt financing, or other sources, which may result in further
dilution in the equity ownership of our shares. There is still no assurance that
we will be able to maintain operations at a level sufficient for an investor to
obtain a return on his investment in our common stock. Further, we may continue
to be unprofitable. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_25></A>
<P align=center>- 22 - </P>
<P align=justify>Specifically, we estimate our operating expenses and working
capital requirements for the next 12 months to be as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="5%"  >&nbsp;</TD>
    <TD align=left><B><U>Estimated Funding Required During the 12 Month Period
      Ending September 30, 2008</U></B> </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="12%">&nbsp; </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Research and Development
      Activities </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;4,300,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left>&nbsp; &nbsp;Officer and Employee Compensation </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">400,000 </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Sales and Marketing </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>120,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left>&nbsp; &nbsp;Legal, Accounting and Professional Fees </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="12%">120,000 </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      bgColor=#e6efff>&nbsp; &nbsp;General and Administrative </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>240,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>&nbsp; &nbsp;Total
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">&nbsp;5,180,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD></TR></TABLE>
<P align=justify>There can be no assurance that additional financing will be
available to us when needed or, if available, that it can be obtained on
commercially reasonable terms. If we are not able to obtain the additional
financing on a timely basis, if and when it is needed, we will be forced to
scale down or perhaps even cease the operation of our business. </P>
<P align=justify><I>Purchase of Significant Equipment </I></P>
<P align=justify>We plan to conduct further research and development on our four
patents, and the related compounds over the next 12 months. We plan to conduct
research and development activities through engaging research individuals and
organizations on a contractual basis as well as in our own laboratory. </P>
<P align=justify>We will also incur costs for innovative new drug applications
to regulatory bodies, patent legal fees and consulting and collaborating fees.
We anticipate our research and development costs for the next 12 months will be
approximately $4,300,000.</P>
<P align=justify><I>Personnel Plan </I></P>
<P align=justify>We currently employ two executive officers including a
president, and a chief scientific officer. Additionally we have three full time
employees to assist in product research, strategic planning and business
development. We anticipate we may spend up to approximately $400,000 in officer
and employee compensation during the next 12 months.</P>
<P align=justify><I>General Administration </I></P>
<P align=justify>We anticipate spending approximately $240,000 on general and
administration costs in the next 12 months. These costs will consist primarily
of rent and facility support expenses as well as finance and administrative
support compensation but excluding legal fees and auditor&#146;s fees. </P>
<P align=justify><I>Off-Balance Sheet Arrangements </I></P>
<P align=justify>There are no off-balance sheet arrangements that have or are
reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that is material to
investors. </P>
<P align=justify>Our principal capital resources have been through the
subscription and issuance of common stock, although we have also used
stockholder loans and advances from related parties. </P>
<P align=justify><B><I>Liquidity and Capital Resources </I></B></P>
<P align=justify>Our financial condition for the years ended September 30, 2008
and 2007 and the changes between those periods for the respective items are
summarized as follows: </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_26></A>
<P align=center>- 23 - </P>
<P align=justify><I>Working Capital </I></P>
<DIV align=left>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="30%"><B>September 30, 2008</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="30%"><B>September 30, 2007</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Current Assets </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="30%" bgColor=#e6efff>&nbsp;6,357 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="30%" bgColor=#e6efff>&nbsp;25 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Current Liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="30%">2,299,389 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="30%">462,529 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Working Capital </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="30%"
    bgColor=#e6efff>&nbsp;(2,293,032</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="30%"
    bgColor=#e6efff>&nbsp;(462,504</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>) </TD></TR></TABLE></DIV>
<P align=justify>The decrease in our working capital was primarily due to
increased indebtedness of $1,550,000 in promissory notes payable as well as an
increase in Accounts Payable from $462,529 to $749,389. Included in these
promissory notes is a total of $1,450,000 due on December 31, 2008 which we do
not expect to be able to repay on that date. However, we expect that we will be
able to reach agreements with the respective note holders to extend the terms of
repayment. </P>
<P align=justify><I>Cash Flows</I></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="16%"><B>Year Ended</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="16%"><B>Year Ended</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="16%"><B>September 30,</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="16%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="16%"><B>2008</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="16%"><B>September 30, 2007</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net cash used in Operating Activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="16%" bgColor=#e6efff>&nbsp;(2,474,053</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="16%" bgColor=#e6efff>&nbsp;(325,250</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>Net cash used in Investing Activities </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="16%">(1,082</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="16%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net cash provided by Financing Activities
    </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="16%" bgColor=#e6efff>2,481,467 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="16%" bgColor=#e6efff>313,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Change in Cash and Cash Equivalents During the Period </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="16%">&nbsp;6,332 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="16%">&nbsp;(12,250</TD>
    <TD align=left width="2%" >) </TD></TR></TABLE>
<P align=justify><U>Cash Used In Operating Activities</U></P>
<P align=justify>During the year ended September 30, 2008 we used net cash in
operating activities in the amount of $2,474,053 compared to 325,000 in 2007 due
to increased Research and Development activities. </P>
<P align=justify><U>Cash from Financing Activities</U></P>
<P align=justify>We received net cash from financing activities in the amount
  of $2,481,467 during the year ended September 30, 2008 compared to $313,000
  during the year ended September 30, 2007. Net cash generated by financing activities
  is attributable to cash received from private placements and proceeds from Promissory
  notes issued. </P>
<P align=justify><B><I>Results of Operations</I></B></P>
<P align=justify>The following summary of our results of operations should be
read in conjunction with our audited financial statements for the year ended
September 30, 2008 which are included herein. </P>
<P align=justify>Our operating results for the year ended September 30, 2008 and
for the year ended September 30, 2007 are described below. </P>
<P align=justify><I>Revenue</I></P>
<P align=justify>We have not earned any revenues since our inception (January
23, 2004). We are still in the development stage and do not anticipate earning
any revenues until we can establish an alliance with targeted companies to
market or distribute the results of our research projects. </P>
<P align=justify><I>Expenses</I></P>
<P align=justify>Our expenses for the three and 12 months ended September 30,
2008 and 2007 were as follows:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>Year Ended</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>Year Ended</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="12%" align=center nowrap><b>September 30, </b> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD width="12%" align=center nowrap><B>September 30,</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>2008</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>2007</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Accounting and audit fees </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;73,785 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;20,167 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Amortization </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">220 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Bank Charges and Interest </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>11,474 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>3,308 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_27></A>
<P align=center>- 24 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>Year Ended</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>Year Ended</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD width="12%" align=center nowrap><b>September 30, </b> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD width="12%" align=center nowrap><B>September 30,</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>2008</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>2007</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Consulting fees </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>3,196,213 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>423,200 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Investor relations </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">263,560 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Legal fees </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>30,545 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>44,999 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Management fees </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Office and
      miscellaneous </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>141,993 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>41,957 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Registration and filing fees </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">7,517 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">12,635 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Rent and administration    </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>75,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>70,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Research and development </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,479,482 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">959,698 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Website design and
      maintenance </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,424 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>5,266 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Total expenses</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;<B>5,281,213</B> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;<B>1,581,230</B> </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=justify>Operating expenses for the 12 months ended September 30, 2008
increased by $3,699,983 compared to the same period in 2007 due to the increases
in administration and research and development.<FONT color=#808080> </FONT></P>
<P align=justify><I>Going Concern </I></P>
<P align=justify>We have historically incurred losses and have incurred a loss
of $5,351,269 for the year ended September 30, 2008. Because of these historical
losses, we will require additional working capital to develop our business
operations. We intend to raise additional working capital through private
placements, public offerings, bank financing and/or advances from related
parties or shareholder loans. </P>
<P align=justify>The continuation of our business is dependent upon obtaining
further financing and achieving a break even or profitable level of operations.
The issuance of additional equity securities by us could result in a significant
dilution in the equity interests of our current or future stockholders.
Obtaining commercial loans, assuming those loans would be available, will
increase our liabilities and future cash commitments. </P>
<P align=justify>There are no assurances that we will be able to either (i)
achieve a level of revenues adequate to generate sufficient cash flow from
operations; or (ii) obtain additional financing through either private
placements, public offerings and/or bank financing necessary to support our
working capital requirements. To the extent that funds generated from operations
and any private placements, public offerings and/or bank financing are
insufficient, we will have to raise additional working capital. No assurance can
be given that additional financing will be available, or if available, will be
on terms acceptable to us. If adequate working capital is not available we may
not increase our operations. </P>
<P align=justify>These conditions raise substantial doubt about our ability to
continue as a going concern. The financial statements do not include any
adjustments relating to the recoverability and classification of asset carrying
amounts or the amount and classification of liabilities that might be necessary
should we be unable to continue as a going concern. </P>
<P align=justify><B><I>Application of Critical Accounting Policies </I></B></P>
<P align=justify>Our financial statements and accompanying notes are prepared in
accordance with generally accepted accounting principles in the United States.
Preparing financial statements requires management to make estimates and
assumptions that affect the reported amounts of assets, liabilities, revenue and
expenses. These estimates and assumptions are affected by management&#146;s
application of accounting policies. We believe that understanding the basis and
nature of the estimates and assumptions involved with the following aspects of
our financial statements is critical to an understanding of our financials. </P>
<P align=justify>We base our assumptions and estimates on historical experience
and other sources that we believe to be reasonable at the time. Actual results
may vary from our estimates due to changes in circumstances, weather, politics,
global economics, mechanical problems, general business conditions and other
factors. Our significant estimates are related to the valuation of warrants and
options. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_28></A>
<P align=center>- 25 - </P>
<P align=justify>There are accounting policies that we believe are significant
to the presentation of our financial statements. The most significant of these
accounting policies relates to the valuation of intellectual property, the
accounting for our research and development expenses and stock-based
compensation expense.</P>
<P align=justify><I>Impairment of Long-Lived Assets </I></P>
<P align=justify>We review the recoverability of long-lived assets consisting of
our intellectual property as required by SFAS No. 144, <I>Accounting for the
Impairment or Disposal of Long-Lived Assets</I>, whenever events or changes in
circumstances indicate that the carrying amount of such assets may not be
recoverable. The estimated future cash flows from our intellectual property are
based upon, among other things, assumptions about future operating performance,
and may differ from actual cash flows. Long-lived assets evaluated for
impairment are grouped with other assets to the lowest level for which
identifiable cash flows are largely independent of the cash flows of other
groups of assets and liabilities. If the sum of the projected undiscounted cash
flows (excluding interest) is less than the carrying value of the assets, the
assets will be written down to the estimated fair value in the period in which
the determination is made.</P>
<P align=justify><I>Research and Development Expenses </I></P>
<P align=justify>Research and developments costs are expensed as incurred. These
expenses are comprised of the costs of our proprietary research and development
efforts, including salaries, facilities costs, overhead costs and other related
expenses as well as costs incurred in connection with third-party collaboration
efforts. Milestone payments to third parties are expensed when the specific
milestone has been achieved. </P>
<P align=justify>In addition, we incur expenses in respect of the acquisition of
intellectual property relating to patents and trademarks. The probability of
success and length of time to developing commercial applications of the drugs
subject to the acquired patents and trademarks is difficult to determine and
numerous risks and uncertainties exist with respect to the timely completion of
the development projects. There is no assurance the acquired patents and
trademarks will ever be successfully commercialized. Due to these risks and
uncertainties, we expense the acquisition of patents and trademarks.</P>
<P align=justify><I>Stock-based Compensation </I></P>
<P align=justify>We account for all of our stock-based payments and awards under
the fair value based method. </P>
<P align=justify>Stock-based payments to non-employees are measured at the fair
value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair
value of stock-based payments to non-employees is periodically re-measured until
the counterparty performance is complete, and any change therein is recognized
over the vesting period of the award and in the same manner as if the Company
had paid cash instead of paying with or using equity based instruments. The cost
of the stock-based payments to non-employees that are fully vested and
non-forfeitable as at the grant date is measured and recognized at that date,
unless there is a contractual term for services in which case such compensation
would be amortized over the contractual term.</P>
<P align=justify>We account for the granting of share purchase options to
employees using the fair value method whereby all awards to employees will be
recorded at fair value on the date of the grant. The fair value of all share
purchase options are expensed over their vesting period with a corresponding
increase to additional capital surplus. Upon exercise of share purchase options,
the consideration paid by the option holder, together with the amount previously
recognized in additional capital surplus, is recorded as an increase to share
capital. </P>
<P align=justify>We use the Black-Scholes option valuation model to calculate
the fair value of share purchase options at the date of the grant. Option
pricing models require the input of highly subjective assumptions, including the
expected. </P>
<P align=justify>The summary of significant accounting policies should be read
in conjunction with our consolidated financial statements and related notes and
this discussion of our results of operations.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_29></A>
<P align=center>- 26 - </P>
<P align=justify><I>Recent accounting pronouncements </I></P>
<P align=justify>In June 2006, the Financial Accounting Standards Board (&#147;FASB&#148;)
issued FASB Interpretation No. 48, &#147;Accounting for Uncertainty in Income Taxes&#148;.
The interpretation clarifies the accounting for uncertainty in income taxes
recognized in a company&#146;s financial statements in accordance with Statement of
Financial Accounting Standards No. 109, &#147;Accounting for Income Taxes&#148;.
Specifically, the pronouncement prescribes a recognition threshold and a
measurement attribute for the financial statement recognition and measurement of
a tax position taken or expected to be taken in a tax return. The interpretation
also provides guidance on the related derecognition, classification, interest
and penalties, accounting for interim periods, disclosure and transition of
uncertain tax position. The interpretation is effective for fiscal years
beginning after December 15, 2006. Effective October 1, 2007, we adopted the
provisions of FIN 48. Based on our assessment of FIN 48, as at October 1, 2007,
there were no significant impact on the results of operations or financial
position and required no adjustment to the opening balance sheet accounts. Our
analysis supports the same conclusion, and there is no accrual for uncertain tax
positions as of September 30, 2008. As a result, tabular reconciliation of
beginning and ending balances would not be meaningful. If interest and penalties
were to be assessed, we would charge interest to interest expense, and penalties
to other operating expense. It is not anticipated that unrecognized tax benefits
would significantly increase or decrease within 12 months of the reporting
date.</P>
<P align=justify>In September 2006, the Financial Accounting Standards Board
(&#147;FASB&#148;) issued SFAS No. 157, Fair Value Measurements (SFAS 157&#148;). SFAS 157
defines fair value, establishes a framework for measuring fair value in
accordance with generally accepted accounting principles, and expands
disclosures about fair value measurements. SFAS 157 does not require any new
fair value measurements; rather, it applies under other accounting
pronouncements that require or permit fair value measurements. The provisions of
SFAS 157are to be applied prospectively as of the beginning of the fiscal year
in which it is initially applied, with any transition adjustment recognized as a
cumulative-effect adjustment to the opening balance of retained earnings. The
provisions of SFAS 157 are effective for fiscal years beginning after November
15, 2007; therefore, we anticipate adopting SFAS 157 as of October 1, 2008. We
expect that the adoption of SFAS 157 will have minimal, if any, impact on our
financial statements except for additional disclosure.</P>
<P align=justify>In February 2007, the FASB issued SFAS 159, The Fair Value
Option for Financial Assets and Financial Liabilities, Including an Amendment of
FASB Statement No. 115, which permits the measurement of many financial
instruments and certain other asset and liabilities at fair value on an
instrument-by-instrument basis (the fair value option). The guidance is
applicable for fiscal years beginning after November 15, 2007; therefore, we
anticipate adopting SFAS 159 as of October 1, 2008. We expect that the adoption
of SFAS 159 will have minimal, if any, impact on our financial position and
results of operations.</P>
<P align=justify>In June 2007, the Emerging Issues Task Force (&#147;EITF&#148;) reached a
consensus on EITF No. 07-03, Accounting for Nonrefundable Advance Payments for
Goods or Services to Be Used in Future Research and Development Activities
(&#147;EITF 07-03&#148;). EITF 07-03 specifies the timing of expense recognition for
non-refundable advance payments for goods or services that will be used or
rendered for research and development activities. EITF 07-03 was effective for
fiscal years beginning after December 15, 2007, and early adoption is not
permitted; therefore, the Company anticipates adopting EITF 07-03 as of October
1, 2008. The Company expects that the adoption of EITF 07-03 will have minimal,
if any, on its financial position and results of operations.</P>
<P align=justify>In December 2007, the EITF reached a consensus on EITF No.
07-01, Accounting for Collaborative Arrangements Related to the Development and
Commercialization of Intellectual Property (&#147;EITF 07-01&#148;). EITF 07-01 discusses
the appropriate income statement presentation and classification for the
activities and payments between the participants in arrangements related to the
development and commercialization of intellectual property. The sufficiency of
disclosure related to these arrangements is also specified. EITF 07-01 is
effective for fiscal years beginning after December 15, 2008. As a result, EITF
07-01 is effective for the Company as of October 1, 2009. The Company expects
that the adoption of EITF 07-01 will have minimal, if any, impact on its
financial position and results of operations. However, based upon the nature of
the Company&#146;s business, EITF 07-01 could have a material impact on its financial
position and results of operations in future years.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_30></A>
<P align=center>- 27 - </P>
<P align=justify>In December 2007, the FASB issued SFAS No. 160,
&#147;Non-controlling Interests in Consolidated Financial Statements&#148; (&#147;SFAS No.
160&#148;). This Statement amends Accounting Research Bulletin (ARB) No. 51 to
establish accounting and reporting standards for the non-controlling (minority)
interest in a subsidiary and for the deconsolidation of a subsidiary. It
clarifies that a non-controlling interest in a subsidiary is an ownership
interest in the consolidated entity that should be reported as equity in the
consolidated financial statements will have no impact. SFAS No. 160 is effective
for the Company&#146;s fiscal year beginning March 1, 2009. Management has determined
that the adoption of this standard will not have an impact on our financial
statements. </P>
<P align=justify>In December 2007, the FASB issued SFAS 141R, Business
Combinations, SFAS 141R replaces SFAS 141. The statement retains the purchase
method of accounting for acquisitions, but requires a number of changes,
including changes in the way assets and liabilities are recognized. Management
has determined that the accounting standard will have no effect on the Company.
</P>
<P align=justify>On December 21, 2007, the Securities and Exchange Commission
issued Staff Accounting Bulletin (&#147;SAB&#148;) No. 110. SAB 110 provides guidance to
issuers on the method allowed in developing estimates of expected term of "plain
vanilla" share options in accordance with SFAS No. 123(R), "Share-Based
Payment". The staff will continue to accept, under certain circumstances, the
use of a simplified method beyond December 31, 2007 which amends question 6 of
Section D.2 as included in SAB 107, "Valuation of Share-Based Payment
Arrangements for Public Companies", which stated that the simplified method
could not be used beyond December 31, 2007. SAB 110 is effective January 1, 2008
for the Company. We are currently evaluating the potential impact, if any, that
the adoption of SAB 110 will have on our financial statements. </P>
<P align=justify>In April 2008, the FASB issued FSP 142-3, &#147;Determination of the
Useful Life of Intangible Assets.&#148; This FSP amends the factors that should be
considered in developing renewal or extension assumptions used to determine the
useful life of a recognized intangible asset under FASB Statement No. 142,
&#147;Goodwill and Other Intangible Assets.&#148; The intent of this FSP is to improve the
consistency between the useful life of a recognized intangible asset under
Statement 142 and the period of expected cash flows used to measure the fair
value of the asset under FASB Statement No. 141 (Revised 2007), &#147;Business
Combinations,&#148; and other U.S. generally accepted accounting principles (GAAP).
This FSP is effective for financial statements issued for fiscal years beginning
after December 15, 2008, and interim periods within those fiscal years. Early
adoption is prohibited. We do not expect the adoption of FAS 142-3 to have a
material effect on our results of operations and financial condition. </P>
<P align=justify>In May 2008, FASB issued SFAS No. 162, The Hierarchy of
Generally Accepted Accounting Principles (&#147;SFAS 162&#148;). This standard is intended
to improve financial reporting by identifying a consistent framework, or
hierarchy, for selecting accounting principles to be used in preparing financial
statements that are presented in conformity with U.S. GAAP for non-governmental
entities. SFAS No. 162 is effective 60 days following the U.S. Securities and
Exchange Commission&#146;s approval of the Public Company Accounting Oversight Board
amendments to AU Section 411, the meaning of &#147;Present Fairly in Conformity with
GAAP&#148;. We are in the process of evaluating the impact, if any, of SFAS 162 on
our financial statements.</P>
<P align=justify><B>ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK </B></P>
<P align=justify>Not Applicable </P>
<P align=justify><B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_F-2">Report
      of Independent Registered Public Accounting firm </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_F-4">Balance
      Sheets </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_F-5">Statements
      of Operations </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_F-6">Statements
      of Cash Flows </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_F-7">Statements
      of Stockholders&#146; Equity (Deficiency) </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_F-9">Notes
      to the Financial Statements </A></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_31></A>
<P align=center>- 28 - </P>
<P align=justify>&nbsp;</P>
<P align=justify>&nbsp;</P>
<P align=justify>&nbsp;</P>
<P align=center><B>ANAVEX LIFE SCIENCES CORP. </B></P>
<P align=center>(A Development Stage Company) </P>
<P align=center>FINANCIAL STATEMENTS </P>
<P align=center>September 30, 2008 and 2007 </P>
<P align=center>(<U>Stated in US Dollars</U>) </P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-2></A>
<P align=center><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P align=justify>To the Directors and Stockholders, <BR>
  Anavex Life Sciences
  Corp. <BR>
  (a Development Stage Company) </P>
<P align=justify>We have audited the accompanying balance sheet of Anavex Life
  Sciences Corp. (the &#147;Company&#148;) (A Development Stage Company) as of September 30,
  2008 and the related statements of operations and comprehensive loss, cash flows
  and changes in capital deficit for the year then ended and for the period from
  January 23, 2004 (Date of Inception) to September 30, 2008. These financial
  statements are the responsibility of the Company's management. Our
  responsibility is to express an opinion on these financial statements based on
  our audit. We did not audit the financial statements of the Company for the
  period from January 23, 2004 (Date of Inception) to September 30, 2007. Such
  statements are included in the cumulative from inception to September 30, 2008
  totals of the statements of operations and comprehensive loss, cash flows and
  changes in capital deficit and reflect a net loss of 24% of the related
  cumulative totals. Those financial statements were audited by other auditors
  whose report has been furnished to us and our opinion, insofar as it relates to
  the amount for the period from January 23, 2004 (Date of Inception) to September
  30, 2007 included in the cumulative totals, is based solely upon the report of
  the other auditors. </P>
<P align=justify>We conducted our audit in accordance with the standards of the
  Public Company Accounting Oversight Board (United States). Those standards
  require that we plan and perform an audit to obtain reasonable assurance about
  whether the financial statements are free of material misstatement. The Company
  is not required to have, nor were we engaged to perform, an audit of its
  internal control over financial reporting. Our audit included consideration of
  internal control over financial reporting as a basis for designing audit
  procedures that are appropriate in the circumstances, but not for the purpose of
  expressing an opinion on the effectiveness of the Company&#146;s internal control
  over financial reporting. Accordingly, we express no such opinion. An audit also
  includes examining, on a test basis, evidence supporting the amounts and
  disclosures in the financial statements. An audit also includes assessing the
  accounting principles used and significant estimates made by management, as well
  as evaluating the overall presentation of the financial statements. We believe
  that our audit provides a reasonable basis for our opinion. </P>
<P align=justify>In our opinion, based on our audit and the report of other
  auditors, these financial statements referred to above present fairly, in all
  material respects, the financial position of Anavex Life Sciences Corp. (A
  Development Stage Company) as of September 30, 2008 and the results of its
  operations and its cash flows for the year then ended and for the period from
  January 23, 2004 (Date of Inception) to September 30, 2008 in conformity with
  accounting principles generally accepted in the United States of America. </P>
<P align=justify>The accompanying financial statements have been prepared
  assuming that the Company will continue as a going concern. As discussed in Note
  1 to the financial statements, the Company had an accumulated deficit of $
  7,062,814 at September 30, 2008 and incurred a net loss of $5,351,269 for the
  year then ended. These conditions raise substantial doubt about the Company&#146;s
  ability to continue as a going concern. Management&#146;s plans in regard to these
  matters are also described in Note 1. The financial statements do not include
  any adjustments that might result from the outcome of this uncertainty. </P>
<P align=justify>/s/ BDO Dunwoody LLP<BR>
  Chartered Accountants </P>
<P align=justify>Vancouver, Canada <BR>
  January 6, 2009 </P>
<P align=center>F-1</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-3></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD vAlign=bottom align=left><B>A P</B><B>ARTNERSHIP </B><B>O</B><B>F </B><B>I</B><B>NCORPORATED </B><B>P</B><B>ROFESSIONALS </B></TD>
    <TD align=right width="35%" ><B><FONT size=4><FONT
      size=6>A</FONT>MISANO <FONT size=6>H</FONT>ANSON </FONT></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=right width="35%" ><B>C</B><B>HARTERED </B><B>A</B><B>CCOUNTANTS </B></TD>
  </TR>
</TABLE>
<P align=center><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P align=justify>To the Stockholders, <BR>
  Anavex Life Sciences Corp. <BR>
  (A
  Development Stage Company) </P>
<P align=justify>We have audited the accompanying balance sheet of Anavex Life
  Sciences Corp. (A Development Stage Company) as of September 30, 2007 and the
  related statements of operations and comprehensive loss, cash flows and changes
  in capital deficit for the year then ended and for the period from January 23,
  2004 (Date of Inception) to September 30, 2007. These financial statements are
  the responsibility of the Company&#146;s management. Our responsibility is to express
  an opinion on these financial statements based on our audits. </P>
<P align=justify>We conducted our audits in accordance with the standards of the
  Public Company Accounting Oversight Board (United States of America). Those
  standards require that we plan and perform an audit to obtain reasonable
  assurance about whether the financial statements are free of material
  misstatement. An audit includes examining on a test basis, evidence supporting
  the amounts and disclosures in the financial statements. An audit also includes
  assessing the accounting principles used and significant estimates made by
  management, as well as evaluating the overall financial statement presentation.
  We believe that our audits provide a reasonable basis for our opinion. </P>
<P align=justify>In our opinion, these financial statements referred to above
  present fairly, in all material respects, the financial position of Anavex Life
  Sciences Corp. as of September 30, 2007 and the results of its operations and
  its cash flows for the year then ended and for the period from January 23, 2004
  (Date of Inception) to September 30, 2007, in conformity with accounting
  principles generally accepted in the United States of America.</P>
<P align=justify>The accompanying financial statements referred to above have
  been prepared assuming that the Company will continue as a going concern. As
  discussed in Note 1 to the financial statements, the Company is in the
  development stage, has no established source of revenue and is dependent on its
  ability to raise capital from stockholders or other sources to sustain
  operations. These factors, along with other matters as set forth in Note 1,
  raise substantial doubt that the Company will be able to continue as a going
  concern. These financial statements do not include any adjustments that might
  result from the outcome of these uncertainties. </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Vancouver, Canada </TD>
    <TD align=right width="25%"><B><I>&#147;AMISANO HANSON&#148; </I></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>January 11, 2008 </TD>
    <TD align=right width="25%">Chartered Accountants </TD>
  </TR>
</TABLE>
<P>&nbsp;</P>
<P><BR>
  &nbsp;</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
    <TR vAlign=top>
      <TD align=left>750 WEST PENDER STREET, SUITE 604 </TD>
      <TD align=left width="10%" >TELEPHONE: </TD>
      <TD align=left width="10%" >604-689-0188 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>VANCOUVER CANADA </TD>
      <TD align=left width="10%" >FACSIMILE: </TD>
      <TD align=left width="10%" >604-689-9773 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>V6C 2T7 </TD>
      <TD align=left width="10%" >E-MAIL: </TD>
      <TD align=left width="10%" >amishan@telus.net </TD>
    </TR>
  </TABLE>
  <p align="center">F-2</p>
</DIV>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-4></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP. <BR>
  </B>(A Development Stage
  Company) <BR>
  BALANCE SHEETS <BR>
  September 30, 2008 and 2007 <BR>
  (<U>Stated in US
    Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp;<B><U>ASSETS </U></B></TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2008 </U></TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2007 </U></TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Current </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Cash </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;6,357 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;25 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Equipment &#150; Note 3 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">862 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;7,219 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;25 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center bgColor=#e6efff
      colSpan=6><B><U>LIABILITIES</U></B>&nbsp;&nbsp; </TD>
    <TD align=center width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Current </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Accounts payable and accrued
      liabilities &#150; Note 4 </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;749,389 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;462,529 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Promissory notes
      payable &#150; Note 5 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,550,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">2,299,389 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">462,529 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center colSpan=6><B><U>CAPITAL DEFICIT</U></B>&nbsp;&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Capital stock &#150; Note 6 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Authorized: </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;150,000,000 common
      shares, par value $0.001 per share </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Issued and outstanding: </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;19,957,420
      common shares (2007: 19,514,722) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">19,957 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">19,515 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Shares to be issued &#150; Notes 4 and 8 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>125,849 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Additional paid-in capital </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">4,624,838 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,229,526 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Deficit accumulated during the development
      stage </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(7,062,814</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(1,711,545</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(2,292,170</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(462,504</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;7,219 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;25 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=justify>Nature of Operations and Ability to Continue as a Going Concern
  &#150; Note 1 <BR>
  Commitments &#150; Note 8 <BR>
  Subsequent Event &#150; Note 10 </P>
<P align=center>SEE ACCOMPANYING NOTES <br>
F-3</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-5></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP. <BR>
  </B>(A Development Stage
  Company) <BR>
  STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS <BR>
  for the years
  ended September 30, 2008 and 2007 and <BR>
  for the period from January 23, 2004
  (Date of Inception) to September 30, 2008 <BR>
  (<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">January 23, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">2004 (Date of </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD colspan="4" align=center>Years Ended </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Inception) to </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD colspan="4" align=center>September 30, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">September 30, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2008</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2007</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2008</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Accounting and audit fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;73,785 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;20,167 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;123,416 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Amortization and depreciation </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>220 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>220 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Bank charges and interest </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">11,474 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">3,308 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">15,106 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Consulting fees &#150;
      Notes 4 and 8(b) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>3,196,213 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>423,200 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>3,637,136 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Investor relations &#150; Note 8(b) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">263,560 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">263,560 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Legal fees </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>30,545 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>44,999 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>118,329 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Management fees </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">14,625 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Office and miscellaneous </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>141,993 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>41,957 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>184,328 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Registration and filing fees </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">7,517 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">12,635 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">24,330 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Rent and administration </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>75,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>70,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>148,750 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Research and development &#150; Note 4 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,479,482 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">959,698 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">2,439,180 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Website design and maintenance </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,424 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>5,266 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>25,270 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Loss before other income (expenses) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(5,281,213</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(1,581,230</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(6,994,250</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Other income (expenses) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Interest </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(60,284</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(60,284</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Foreign exchange gain (loss) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="12%">(9,772</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">1,237 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="12%">(8,280</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net loss and comprehensive loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">&nbsp;(5,351,269</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">&nbsp;(1,579,993</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">&nbsp;(7,062,814</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Basic and diluted loss per share </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">&nbsp;(0.27</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">&nbsp;(0.08</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Weighted average number of shares outstanding </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">19,707,708 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">19,204,565 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES <br>
F-4</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-6></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.&nbsp;<BR>
  </B>(A Development Stage
  Company) <BR>
  STATEMENTS OF CASH FLOWS <BR>
  for the years ended September 30, 2008
  and 2007 and <BR>
  for the period from January 23, 2004 (Date of Inception) to
  September 30, 2007 <BR>
  (<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">January 23, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">2004 (Date of </TD>
    <TD align=center width="2%" ></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD colspan="4" align=center>Years ended </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Inception) to </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD colspan="4" align=center>September 30, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD width="12%" align=center nowrap>September 30, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2008</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2007</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2008</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash Flows used in Operating Activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Net loss for the period </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;(5,351,269</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;(1,579,993</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;(7,062,814</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Adjustments to reconcile
      net loss to net cash used in </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;operations: </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Amortization
      and depreciation </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>220 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>220 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stock-based compensation </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,684,786 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,684,786 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Common
      shares issued for consulting expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>319,750 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>319,750 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Promissory note issued
      for severance &#150; Notes 5 and 6 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">71,500 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">71,500 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Common
      shares issued for severance </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>340,600 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>340,600 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Common shares issued
      for research and development </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>800,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>800,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Management fees contributed </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">14,625 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Rent
      contributed </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>3,750 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Changes in non-cash working capital balances
      related to </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;operations: </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Prepaid expenses </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">220 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Accounts
      payable and accrued liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>460,360 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>454,523 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>922,890 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net cash used in operating activities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(2,474,053</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(325,250</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(2,904,693</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash Flows provided by Financing Activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Issuance of common shares </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,131,467 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,195,467 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Proceeds from promissory
      notes </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,450,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,450,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Repayment of promissory note </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(100,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(100,000</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Due to related parties </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>33,665 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp;Shareholder advances </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">313,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">333,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net cash provided by financing activities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">2,481,467 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">313,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">2,912,132 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Cash Flows used in Investing Activities </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Acquisition of equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(1,082</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(1,082</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net cash used in investing activities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(1,082</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(1,082</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Increase (decrease) in cash during the period </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>6,332 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(12,250</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>6,357 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash, beginning of period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>25 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>12,275 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash, end of period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;6,357 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;25 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;6,357 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Supplemental Cash Flow Information &#150; Note
      9 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES <br>
F-5</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-7></A>
<P align=center><B>ANAVEX</B><B> LIFE </B><B>SCIENCES</B><B> </B><B>CORP.</B><B>&nbsp;<BR>
  </B>(A Development Stage Company) <BR>
  STATEMENT OF
  CHANGES IN CAPITAL DEFICIT <BR>
  for the period January 23, 2004 (Date of
  Inception) to September 30, 2008 <BR>
  (Stated in US Dollars) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">Deficit </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD colspan="10" align=center style="BORDER-BOTTOM: #000000 1px solid"> Common
      Stock </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">Accumulated </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">Additional </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">Common </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">During the </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">Paid-in </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">Shares to be </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">Development </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">Shares </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="7%">Par Value </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">Capital </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">Issued </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="7%">Stage </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="7%">Total </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Capital stock issued for cash on January 23,
      2004 - at $0.0033 </TD>
    <TD align=right width="7%" bgColor=#e6efff>12,000,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;12,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;28,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;40,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Net loss from January 23, 2004 to September 30,
      2004 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="7%">(14,395</TD>
    <TD align=left width="2%">) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="7%">(14,395</TD>
    <TD align=left width="2%">) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Balance, September 30, 2004 </TD>
    <TD align=right width="7%">12,000,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">12,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">28,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">(14,395</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">25,605 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Capital stock issued for cash
      on December 31, 2004 - at $0.0033 </TD>
    <TD align=right width="7%" bgColor=#e6efff>7,200,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>7,200 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>16,800 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>24,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Management fees contributed </TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">13,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">13,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Rent contributed </TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>3,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>3,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="7%">(91,625</TD>
    <TD align=left width="2%">) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="7%">(91,625</TD>
    <TD align=left width="2%">) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Balance, September 30, 2005 </TD>
    <TD align=right width="7%">19,200,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">19,200 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">60,800 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">(106,020</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">(26,020</TD>
    <TD align=left width="2%">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Management fees contributed </TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>1,625 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>1,625 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Rent contributed </TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">750 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">750 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Debt forgiven by directors </TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>33,666 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>33,666 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="7%">(25,532</TD>
    <TD align=left width="2%">) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="7%">(25,532</TD>
    <TD align=left width="2%">) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Balance, September 30, 2006 </TD>
    <TD align=right width="7%">19,200,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">19,200 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">96,841 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">(131,552</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">(15,511</TD>
    <TD align=left width="2%">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Capital stock issued for research
      and development services on </TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;September 24, 2007
      - at $3.60 </TD>
    <TD align=right width="7%">222,222 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">222 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">799,778 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">800,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Capital stock issued for settlement
      of loan payable on </TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD
      align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;September 25, 2007 - at $3.60 </TD>
    <TD align=right width="7%">92,500 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">93 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">332,907 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="7%">333,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>(1,579,993</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%"
    bgColor=#e6efff>(1,579,993</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Balance, September 30, 2007 &#150; carried
      forward </TD>
    <TD align=right width="7%" bgColor=#e6efff>19,514,722 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;19,515 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;1,229,526 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;(1,711,545</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;(462,504</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES <br>
F-6</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-8></A>
<P align=center><B>ANAVEX</B><B> LIFE </B><B>SCIENCES</B><B> </B><B>CORP.</B><B>&nbsp;<BR>
  </B>(A Development Stage Company) <BR>
  STATEMENT OF
  CHANGES IN CAPITAL DEFICIT <BR>
  for the period January 23, 2004 (Date of
  Inception) to September 30, 2008 <BR>
  (Stated in US Dollars) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">Deficit </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD colspan="10" align=center style="BORDER-BOTTOM: #000000 1px solid"> Common Stock </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">Accumulated </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">Additional </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">Common </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">During the </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">Paid-in </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">Shares to be </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">Development </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">Shares </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="7%">Par
      Value </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">Capital </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">Issued </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="7%">Stage </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="7%">Total </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Balance, September 30, 2007 &#150;
      brought forward </TD>
    <TD align=right width="7%" bgColor=#e6efff>19,514,722 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;19,515 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;1,229,526 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;(1,711,545</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="7%" bgColor=#e6efff>&nbsp;(462,504</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Capital stock issued for cash on
      December 10, 2007 - at $3.50 </TD>
    <TD align=right width="7%">150,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">150 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">524,850 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">525,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >&nbsp; &nbsp;Capital stock
      issued for consulting services on December 18, 2007 -</TD>
    <TD align=right width="7%" bgColor=#e6efff>50,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>50 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>192,950 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>193,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;at
      $3.86 </TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >&nbsp; &nbsp;Capital stock
      issued in settlement of debt on December 18, 2007 - </TD>
    <TD align=right width="7%" bgColor=#e6efff>10,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>10 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>44,990 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>45,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp;at $4.50 </TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >&nbsp; &nbsp;Stock-based
      compensation for shares issued at a discount &#150; Note 6 </TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>65,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>65,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Capital stock issued for
      severance on May 15, 2008 - at $5.24 </TD>
    <TD align=right width="7%">65,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">65 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">340,535 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">340,600 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >&nbsp; &nbsp;Common shares to
      be issued for consulting services &#150; Notes 4 and 8 </TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>252,599 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>252,599 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Capital stock issued for
      consulting services on August 19, 2008 - </TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="7%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >&nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp;at $5.07 </TD>
    <TD align=right width="7%" bgColor=#e6efff>25,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>25 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>126,725 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>(126,750</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Capital stock issued for cash on
      August 19, 2008 - at $4.25 </TD>
    <TD align=right width="7%">142,698 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">142 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">606,325 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="7%">606,467 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >&nbsp; &nbsp;Stock based
      compensation &#150; Note 8 </TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>1,493,937 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="7%" bgColor=#e6efff>1,493,937 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Net loss for the year </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="7%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="7%">(5,351,269</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="7%">(5,351,269</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff >&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="7%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Balance, September 30, 2008 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="7%">19,957,420 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="7%">&nbsp;19,957 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="7%">&nbsp;4,624,838 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="7%">&nbsp;125,849 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="7%">&nbsp;(7,062,814</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="7%">&nbsp;(2,292,170</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES <br>
F-7</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-9></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.&nbsp;<BR>
  </B>(A Development Stage
  Company) <BR>
  NOTES TO THE FINANCIAL STATEMENTS <BR>
  September 30, 2008 and 2007 <BR>
  (<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 1 </TD>
    <TD align=left width="90%" ><P align=justify><U>Nature of Operations and Ability to Continue as a
      Going Concern</U> </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company is in the development stage as defined by
      Statement of Financial Accounting Standard (&#147;SFAS&#148;) No. 7 <I>&#147;Accounting
        and Reporting by Development Stage Enterprises</I>&#148; and has not yet
      realized any revenues from its planned operations. The Company is seeking
      to develop and market proprietary drug targets for the treatment of cancer
      and diseases of the central nervous system. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>These financial statements have been prepared in
      accordance with generally accepted accounting principles in the United
      States of America on a going concern basis, which assumes that the Company
      will continue to realize its assets and discharge its obligations and
      commitments in the normal course of operations. Realization values may be
      substantially different from carrying values as shown and these financial
      statements do not give effect to adjustments that would be necessary to
      the carrying values and classification of assets and liabilities should
      the Company be unable to continue as a going concern. At September 30,
      2008, the Company had not yet achieved profitable operations, had an
      accumulated deficit of $7,062,814 (2007 - $1,711,545) since its inception
      and incurred a net loss of $5,351,269 (2007 - $ 1,579,993) for the year
      then ended and expects to incur further losses in the development of its
      business, all of which casts substantial doubt about the Company&#146;s ability
      to continue as a going concern. The Company&#146;s ability to continue as a
      going concern is dependent upon its ability to generate future profitable
      operations and/or to obtain the necessary financing to meet its
      obligations and repay its liabilities arising from normal business
      operations when they come due. Management has no formal plan in place to
      address this concern but considers obtaining additional funds by equity
      financing and/or from issuing promissory notes. Management expects the
      Company&#146;s cash requirement over the twelve-month period ended September
      30, 2009 to be $5,180,000. While the Company is expending its best efforts
      to achieve the above plans, there is no assurance that any such activity
      will generate funds for operations. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company was incorporated in the State of Nevada,
      United States of America on January 23, 2004 as Thrifty Printing Inc. On
      January 25, 2007, the Company changed its business from developing online
      photofinishing services to its current business and changed its name to
      Anavex Life Sciences Corp. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><P align=justify><U>Significant Accounting Policies</U> </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The preparation of financial statements in accordance
      with United States generally accepted accounting principles requires
      management to make estimates and assumptions that affect the reported
      amounts of assets and liabilities at the date of the financial statements
      and the reported amounts of revenue and expenses in the reporting period.
      The Company regularly evaluates estimates and assumptions related to
      deferred income tax asset valuations, asset impairment, stock based
      compensation and loss contingencies. The Company bases its estimates and
      assumptions on current facts, historical experience and various other
      factors that it believes to be reasonable under the circumstances, the
      results of which form the basis for making judgments about the carrying
      values of assets and liabilities and the accrual of costs and expenses
      that are not readily apparent from other sources. The actual results
      experienced by the Company may differ materially and adversely from the
      Company&#146;s estimates. To the extent there are material differences between
      the estimates and the actual results, future results of operations will be
      affected. </P></TD>
  </TR>
</TABLE>
<p align="center">F-8</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-10></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Significant Accounting
      Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The financial statements have, in management&#146;s opinion,
      been properly prepared within the framework of the significant accounting
      policies summarized below: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify><U>Development Stage Company</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company is devoting substantially all of its present
      efforts to establish a new business and none of its planned principal
      operations have commenced. All losses accumulated since inception has been
      considered as part of the Company&#146;s development stage
      activities.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify><U>Equipment</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Equipment is recorded at cost and is depreciated at 33%
      per annum on the straight-line basis.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD><P align=justify><U>Impairment of Long-Lived Assets</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company reviews the recoverability of its long-lived
      assets as required by SFAS No. 144, <I>Accounting for the Impairment or
        Disposal of Long-Lived Assets</I>, whenever events or changes in
      circumstances indicate that the carrying amount of such assets may not be
      recoverable. The estimated future cash flows are based upon, among other
      things, assumptions about future operating performance, and may differ
      from actual cash flows. Long-lived assets evaluated for impairment are
      grouped with other assets to the lowest level for which identifiable cash
      flows are largely independent of the cash flows of other groups of assets
      and liabilities. If the sum of the projected undiscounted cash flows
      (excluding interest) is less than the carrying value of the assets, the
      assets will be written down to the estimated fair value in the period in
      which the determination is made.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD><P align=justify><U>Financial Instruments</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The carrying value of the Company&#146;s financial
      instruments, consisting of cash and accounts payable and accrued
      liabilities approximate their fair value due to the short-term maturity of
      such instruments. Based on borrowing rates currently available to the
      Company for similar terms and based on the short term duration of the debt
      instruments, the carrying value of the promissory notes payable
      approximate their fair value. Unless otherwise noted, it is management&#146;s
      opinion that the Company is not exposed to significant interest, currency
      or credit risks arising from these financial instruments.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD><P align=justify><U>Foreign Currency Translation</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Monetary items denominated in a foreign currency are
      translated into US dollars, the reporting currency, at exchange rates
      prevailing at the balance sheet date and non-monetary items are translated
      at exchange rates prevailing when the assets were acquired or obligations
      incurred. Foreign currency denominated expense items are translated at
      exchange rates prevailing at the transaction date. Gains or losses arising
      from the translations are included in
      operations.</P></TD>
  </TR>
</TABLE>
<p align="center">F-9<BR>
</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-11></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Significant Accounting
      Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">g) </TD>
    <TD><P align=justify><U>Research and Development Expenses</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Research and developments costs are expensed as incurred.
      These expenses are comprised of the costs of the Company&#146;s proprietary
      research and development efforts, including salaries, facilities costs,
      overhead costs and other related expenses as well as costs incurred in
      connection with third-party collaboration efforts. Milestone payments made
      by the Company to third parties are expensed when the specific milestone
      has been achieved.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In addition, the Company incurs expenses in respect of
      the acquisition of intellectual property relating to patents and
      trademarks. The probability of success and length of time to developing
      commercial applications of the drugs subject to the acquired patents and
      trademarks is difficult to determine and numerous risks and uncertainties
      exist with respect to the timely completion of the development projects.
      There is no assurance the acquired patents and trademarks will ever be
      successfully commercialized. Due to these risks and uncertainties, the
      Company expenses the acquisition of patents and trademarks.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">h) </TD>
    <TD><P align=justify><U>Income Taxes</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company has adopted SFAS No. 109 &#150; &#147;Accounting for
      Income Taxes&#148;. SFAS No. 109 requires the use of the asset and liability
      method of accounting for income taxes. Under the asset and liability
      method of SFAS No. 109, deferred tax assets and liabilities are recognized
      for the future tax consequences attributable to temporary differences
      between the financial statements carrying amounts of existing assets and
      liabilities and their respective tax bases. Deferred tax assets and
      liabilities are measured using enacted tax rates expected to apply to
      taxable income in the years in which those temporary differences are
      expected to be recovered or settled.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD><P align=justify><U>Basic and Diluted Loss Per Share</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In accordance with SFAS No. 128 &#150; &#147;Earnings Per Share&#148;,
      the basic loss per common share is computed by dividing net loss available
      to common stockholders by the weighted average number of common shares
      outstanding. Diluted loss per common share is computed similar to basic
      loss per common share except that the denominator is increased to include
      the number of additional common shares that would have been outstanding if
      the potential common shares had been issued and if the additional common
      shares were dilutive. For the year ended September 30, 2008, loss per
      share excludes 1,712,698 (September 30, 2007 &#150; 770,000) potentially
      dilutive common shares (related to outstanding options and warrants) as
      their effect was anti-dilutive.</P></TD>
  </TR>
</TABLE>
<p align="center">F-10</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-12></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Significant Accounting
      Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">j) </TD>
    <TD><P align=justify><U>Stock-based Compensation</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company accounts for all stock-based payments and
      awards under the fair value based method.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Stock-based payments to non-employees are measured at the
      fair value of the consideration received, or the fair value of the equity
      instruments issued, or liabilities incurred, whichever is more reliably
      measurable. The fair value of stock-based payments to non-employees is
      periodically re-measured until the counterparty performance is complete,
      and any change therein is recognized over the vesting period of the award
      and in the same manner as if the Company had paid cash instead of paying
      with or using equity based instruments. Compensation costs for stock-based
      payments with graded vesting are recognized on a straight-line basis. The
      cost of the stock-based payments to non-employees that are fully vested
      and non-forfeitable as at the grant date is measured and recognized at
      that date, unless there is a contractual term for services in which case
      such compensation would be amortized over the contractual term.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company accounts for the granting of share purchase
      options to employees using the fair value method whereby all awards to
      employees will be recorded at fair value on the date of the grant. The
      fair value of all share purchase options are expensed over their vesting
      period with a corresponding increase to additional capital surplus. Upon
      exercise of share purchase options, the consideration paid by the option
      holder, together with the amount previously recognized in additional
      capital surplus, is recorded as an increase to share capital The Company
      uses the Black-Scholes option valuation model to calculate the fair value
      of share purchase options at the date of the grant. Option pricing models
      require the input of highly subjective assumptions, including the expected
      price volatility. Changes in these assumptions can materially affect the
      fair value estimate</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">k) </TD>
    <TD><P align=justify><U>Website Costs</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company recognizes the costs incurred in the
      development of the Company's website in accordance with Emerging Issues
      Task Force Issue No. 00-2 (&#147;EITF 00-2&#148;), "Accounting for Website
      Development Costs" and, with the provisions of AICPA Statement of Position
      No. 98-1, "Accounting for the Costs of Computer Software Developed or
      Obtained for Internal Use". Accordingly, direct costs incurred during the
      application stage of development are capitalized and amortized over the
      estimated useful life. Fees incurred for web site hosting are expensed
      over the period of the benefit. Costs of operating a web site are expensed
      as incurred.</P></TD>
  </TR>
</TABLE>
<p align="center">F-11<BR>
</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-13></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%"><U>Significant Accounting Policies </U>&#150;
      (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">l) </TD>
    <TD><P align=justify><U>Recent Accounting Pronouncements</U></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In June 2006, the Financial Accounting Standards Board
      (&#147;FASB&#148;) issued FASB Interpretation No. 48, &#147;Accounting for Uncertainty in
      Income Taxes&#148;. The interpretation clarifies the accounting for uncertainty
      in income taxes recognized in a company&#146;s financial statements in
      accordance with Statement of Financial Accounting Standards No. 109,
      &#147;Accounting for Income Taxes&#148;. Specifically, the pronouncement prescribes
      a recognition threshold and a measurement attribute for the financial
      statement recognition and measurement of a tax position taken or expected
      to be taken in a tax return. The interpretation also provides guidance on
      the related derecognition, classification, interest and penalties,
      accounting for interim periods, disclosure and transition of uncertain tax
      position. The interpretation is effective for fiscal years beginning after
      December 15, 2006. Effective October 1, 2007, the Company adopted the
      provisions of FIN 48. Based on the Company&#146;s assessment of FIN 48, as at
      October 1, 2007, there was no significant impact on the results of
      operations or financial position and required no adjustment to the opening
      balance sheet accounts. The Company&#146;s analysis supports the same
      conclusion, and there is no accrual for uncertain tax positions as of
      September 30, 2008. As a result, tabular reconciliation of beginning and
      ending balances would not be meaningful. If interest and penalties were to
      be assessed, we would charge interest to interest expense, and penalties
      to other operating expense. It is not anticipated that unrecognized tax
      benefits would significantly increase or decrease within 12 months of the
      reporting date.</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In September 2006, the Financial Accounting Standards
      Board (&#147;FASB&#148;) issued SFAS No. 157, Fair Value Measurements (SFAS 157&#148;).
      SFAS 157 defines fair value, establishes a framework for measuring fair
      value in accordance with generally accepted accounting principles, and
      expands disclosures about fair value measurements. SFAS 157 does not
      require any new fair value measurements; rather, it applies under other
      accounting pronouncements that require or permit fair value measurements.
      The provisions of SFAS 157 are to be applied prospectively as of the
      beginning of the fiscal year in which it is initially applied, with any
      transition adjustment recognized as a cumulative-effect adjustment to the
      opening balance of retained earnings. The provisions of SFAS 157 are
      effective for fiscal years beginning after November 15, 2007; therefore,
      the Company anticipates adopting SFAS 157 as of October 1, 2008. The
      Company expects that the adoption of SFAS 157 will have minimal, if any,
      impact on its financial statements except for additional
      disclosure.</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In February 2007, the FASB issued SFAS 159, The Fair
      Value Option for Financial Assets and Financial Liabilities, Including an
      Amendment of FASB Statement No. 115, which permits the measurement of many
      financial instruments and certain other asset and liabilities at fair
      value on an instrument-by-instrument basis (the fair value option). The
      guidance is applicable for fiscal years beginning after November 15, 2007;
      therefore, the Company anticipates adopting SFAS 159 as of October 1,
      2008. The Company expects that the adoption of SFAS 159 will have minimal,
      if any, impact on its financial position and results of
      operations.</P></TD>
  </TR>
</TABLE>
<p align="center">F-12<BR>
</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-14></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Significant Accounting
      Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify><U>Recent Accounting
  Pronouncements</U> &#150; (cont&#146;d) </P>
<P style="MARGIN-LEFT: 15%" align=justify>In June 2007, the Emerging Issues Task
  Force (&#147;EITF&#148;) reached a consensus on EITF No. 07-03, Accounting for
  Nonrefundable Advance Payments for Goods or Services to Be Used in Future
  Research and Development Activities (&#147;EITF 07-03&#148;). EITF 07-03 specifies the
  timing of expense recognition for non-refundable advance payments for goods or
  services that will be used or rendered for research and development activities.
  EITF 07-03 was effective for fiscal years beginning after December 15, 2007, and
  early adoption is not permitted; therefore, the Company anticipates adopting
  EITF 07-03 as of October 1, 2008. The Company expects that the adoption of EITF
  07-03 will have minimal, if any, on its financial position and results of
  operations.</P>
<P style="MARGIN-LEFT: 15%" align=justify>In December 2007, the EITF reached a
  consensus on EITF No. 07-01, Accounting for Collaborative Arrangements Related
  to the Development and Commercialization of Intellectual Property (&#147;EITF
  07-01&#148;). EITF 07-01 discusses the appropriate income statement presentation and
  classification for the activities and payments between the participants in
  arrangements related to the development and commercialization of intellectual
  property. The sufficiency of disclosure related to these arrangements is also
  specified. EITF 07-01 is effective for fiscal years beginning after December 15,
  2008. As a result, EITF 07-01 is effective for the Company as of October 1,
  2009. The Company expects that the adoption of EITF 07-01 will have minimal, if
  any, impact on its financial position and results of operations. However, based
  upon the nature of the Company&#146;s business, EITF 07-01 could have a material
  impact on its financial position and results of operations in future years.</P>
<P style="MARGIN-LEFT: 15%" align=justify>In December 2007, FASB issued
  Statement No. 141 (Revised 2007), Business Combinations (&#147;SFAS 141(R)&#148;) and SFAS
  No. 160, Accounting and Reporting of Non-controlling Interests in Consolidated
  Financial Statements, an amendment of ARB No. 51 (&#147;SFAS 160&#148;). These statements
  will significantly change the financial accounting and reporting of business
  combination transactions and non-controlling (or minority) interests in
  consolidated financial statements. SFAS 141(R) requires companies to: (i)
  recognize, with certain exceptions, 100% of the fair values of assets acquired,
  liabilities assumed, and non-controlling interests in acquisitions of less than
  a 100% controlling interest when the acquisition constitutes a change in control
  of the acquired entity; (ii) measure acquirer shares issued in consideration for
  a business combination at fair value on the acquisition date; (iii) recognize
  contingent consideration arrangements at their acquisition-date fair values,
  with subsequent changes in fair value generally reflected in earnings; (iv) with
  certain exceptions, recognize pre-acquisition loss and gain contingencies at
  their acquisition-date fair values; (v) capitalize in-process research and
  development (&#147;IPR&amp;D&#148;) assets acquired; (vi) expense, as incurred,
  acquisition-related transaction costs; (vii) capitalize acquisition-related
  restructuring costs only if the criteria in SFAS No. 146, Accounting for Costs
  Associated with Exit or Disposal Activities , are met as of the acquisition
  date; and (viii) recognize changes that result from a business combination
  transaction in an acquirer&#146;s existing income tax valuation allowances and tax
  uncertainty accruals as adjustments to income tax expense. SFAS 141(R) is
  required to be adopted concurrently with SFAS 160 and is effective for business
  combination transactions for which the acquisition date is on or after the
  beginning of the first annual reporting period beginning on or after December
  15, 2008. Early adoption of these statements is prohibited. The Company has
  determined the adoption of these statements will not have a material impact on
  significant acquisitions completed after September 1, 2009.</P>
<p align="center">F-13</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-15></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Significant Accounting
      Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">l) </TD>
    <TD><P align=justify><U>New Accounting Standards </U>&#150; (cont&#146;d)</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In December 2007, the SEC issued Staff Accounting
      Bulletin (&#147;SAB&#148;) No. 110. SAB 110 expresses the views of the SEC regarding
      the use of a &#147;simplified&#148; or &#147;shortcut&#148; method, as discussed in SAB No.
      107, &#147;Share-Based Payment&#148;, in developing an estimate of expected term of
      &#147;plain vanilla&#148; share options in accordance with SFAS No. 123R. The
      Company adopted SAB 110 on the date it became effective, January 1,
      2008.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In April 2008, the FASB issued FSP 142-3, &#147;Determination
      of the Useful Life of Intangible Assets.&#148; This FSP amends the factors that
      should be considered in developing renewal or extension assumptions used
      to determine the useful life of a recognized intangible asset under FASB
      Statement No. 142, &#147;Goodwill and Other Intangible Assets.&#148; The intent of
      this FSP is to improve the consistency between the useful life of a
      recognized intangible asset under Statement 142 and the period of expected
      cash flows used to measure the fair value of the asset under FASB
      Statement No. 141 (Revised 2007), &#147;Business Combinations,&#148; and other U.S.
      generally accepted accounting principles (GAAP). This FSP is effective for
      financial statements issued for fiscal years beginning after December 15,
      2008, and interim periods within those fiscal years. Early adoption is
      prohibited. The Company does not expect the adoption of FAS 142-3 to have
      a material effect on its results of operations and financial
      condition.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In May 2008, FASB issued SFAS No. 162, The Hierarchy of
      Generally Accepted Accounting Principles (&#147;SFAS 162&#148;). This standard is
      intended to improve financial reporting by identifying a consistent
      framework, or hierarchy, for selecting accounting principles to be used in
      preparing financial statements that are presented in conformity
      with U. S. GAAP for non-governmental entities. SFAS
      No. 162 is effective 60 days following the U. S. Securities and Exchange Commission&#146;s
      approval of the Public Company Accounting Oversight Board amendments to AU
      Section 411, the meaning of &#147;Present Fairly in Conformity with GAAP&#148;. The
      Company is in the process of evaluating the impact, if any, of SFAS 162 on
      its financial statements.</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 3 </TD>
    <TD align=left width="90%" >Equipment </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD colspan="7" align=center style="BORDER-BOTTOM: #000000 1px solid"> September
      30, 2008 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Accumulated </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Cost</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Depreciation</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Net</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;1,082 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;220 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;&nbsp;&nbsp;862 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD colspan="7" align=center style="BORDER-BOTTOM: #000000 1px solid"> September
      30, 2007 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Accumulated </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Cost</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Depreciation</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Net</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;-</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<p align="center">F-14</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-16></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 4 </TD>
    <TD align=left width="90%"><U>Related Party Transactions</U> </TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%">The following amounts have been donated to the
      Company by the directors: </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="11%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="11%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="11%">January 23, </TD>
    <TD align=center width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="11%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="11%">&nbsp;</TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="11%">2004&nbsp; (Date of</TD>
    <TD align=center width="2%"></TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD colspan="4" align=center>Years ended </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="11%">Inception) to </TD>
    <TD align=center width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD colspan="4" align=center>September 30, </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="11%">September 30, </TD>
    <TD align=center width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="11%"><U>2008</U> </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="11%"><U>2007</U> </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="11%"><U>2008</U> </TD>
    <TD align=center width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Management fees </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="11%" bgColor=#e6efff>&nbsp;-</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="11%" bgColor=#e6efff>&nbsp;-</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="11%" bgColor=#e6efff>14,625 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Rent </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="11%">-</TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="11%">-</TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="11%">3,750 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Debt forgiven by directors </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="11%"
    bgColor=#e6efff>-</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="11%"
    bgColor=#e6efff>-</TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="11%"
    bgColor=#e6efff>33,666 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="11%">&nbsp;-</TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="11%">-</TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="11%">52,041 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2008, the Company was charged consulting fees totaling $352,382 (2007: $278,000)
  by directors and officers of the Company. </P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2008, the Company acquired the ownership rights to four Greek patents for
  consideration of $72,000 pursuant to a patent transfer agreement with an officer
  of the Company. The charge in respect of the acquisition of these patents has
  been expensed to research and development. </P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2008, the Company terminated the services of its CEO and agreed to a severance
  package consisting of the issuance of 65,000 common shares at $5.24 per share
  totaling $340,600. The common shares were valued using the quoted market price
  of the Company&#146;s common stock on the agreement date. In addition, the Company
  issued a promissory note payable to the former CEO in the amount of $200,000 of
  which $128,500 was applied to unpaid consulting fees and the remaining $71,500
  was charged as severance pay in the current year.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On May 20, 2008, the Company executed
  an agreement with a director of the Company (Note &#150; 8(d)) to provide consulting
  services for consideration consisting of 200,000 common shares to be issued
  every quarter at the rate of 25,000 per quarter commencing August 20, 2008 and
  by granting 400,000 share purchase options which vest at the rate of 100,000 per
  quarter commencing August 20, 2008. The Company calculated compensation expense
  associated with this agreement as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD><P align=justify>The Company calculated the compensation expense
      associated with the share issuance to be $1,010,000 based on the quoted
      closing price of the Company&#146;s common shares on May 20, 2008. On August
      20, 2008, the Company issued 25,000 common shares in respect of this
      agreement for which it recorded a compensation expense of $126,750. At
      September 30, 2008, the remaining 175,000 shares to be issued were
      re-measured with their fair value determined to be $353,500 for which the
      Company recognized a compensation expense of $125,849 recorded as shares
      to be issued.</P></TD>
  </TR>
</TABLE>
<p align="center">F-15<BR>
</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-17></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 4 </TD>
    <TD align=left width="90%" ><U>Related Party Transactions &#150;
      (cont&#146;d) </U></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD><P align=justify>The Company calculated a grant-date fair value of the
      400,000 options granted in conjunction with this agreement to be
      $1,031,800. During the year ended September 30, 2008, 100,000 of these
      options vested for which the Company recognized a compensation expense of
      $257,950. The remaining 300,000 unvested options were re-measured on
      September 30, 2008 with their fair value determined to be $172,350 for
      which the Company recognized compensation expense of $62,802. As at
      September 30, 2008, there remains $109,548 to be recognized over the
      remaining term of the agreement.</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>During the year ended September 30, 2007, the Company
      issued 92,500 shares of common stock at $3.60 per share to a significant
      shareholder for settlement of a loan payable of $333,000. The common
      shares were valued using the quoted market price of the Company&#146;s common
      stock on the settlement date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>As at September 30, 2008, included in accounts payable
      and accrued liabilities is $10,114 (2007: $167,824) owing to directors and
      officers of the Company. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><P align=justify><U>Promissory Notes Payable </U></P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2008 </U></TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2007 </U></TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Promissory notes payable, unsecured,
      bearing interest at </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>the rate of 8% per annum repayable on December 31, 2008 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%" >&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>(1) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;1,450,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>$100,000 promissory note payable,
      unsecured, non-</TD>
    <TD align=right width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>interest bearing, repayable in four monthly instalments of </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%" >&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>$25,000 due on July 4, 2008, August 1,
      2008, September </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>5, 2008 and October 3, 2008 <SUP>(2) </SUP></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">100,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Total promissory notes payable </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">&nbsp;1,550,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">&nbsp;- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(1) </SUP></TD>
    <TD><P align=justify>The Company does not expect to have the funds available
      to satisfy the promissory note obligations when they become due on
      December 31, 2008 but expects to reach agreements with the note holders to
      extend the repayment date.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(2) </SUP></TD>
    <TD><P align=justify>The Company issued a promissory note to the former CEO of
      the Company in the amount of $200,000, pursuant to a termination agreement
      (Note 5). The note is non-interest bearing and had specified repayment
      terms. $100,000 was paid in accordance with the terms of the note. As at
      September 30, 2008 the Company is in default of the payment terms in the
      amount of $75,000. Subsequent to September 30, 2008 the Company was in
      default for the entire $100,000 balance owing.</P></TD>
  </TR>
</TABLE>
<p align="center">F-16</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-18></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock</U> </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On May 24, 2006, the board of directors approved a six
      (6) for one (1) forward split of the authorized issued and outstanding
      common stock. The Company&#146;s authorized capital increased from 25,000,000
      shares of common stock to 150,000,000 shares of common stock. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 24, 2007, the Company issued 222,222 common
      shares common shares at $3.60 per share for a total of $800,000 for
      research and development expenses. The common shares were recorded based
      upon the quoted market price of the Company&#146;s common stock on the
      agreement date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On September 25, 2007, the Company settled a loan payable
      in the amount of $333,000 by issuing 92,500 common shares at $3.60 per
      share, being the quoted market price of the Company&#146;s common stock on the
      settlement date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On December 10, 2007, the Company issued 150,000 units at
      $3.50 per unit for proceeds of $525,000. Each unit consisted of one common
      share and one common share purchase warrant entitling the holder to
      purchase an additional common share at $5.00 per share until December 10,
      2009. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On December 18, 2007, the Company issued 10,000 shares at
      $4.50 per share for a total of $45,000 pursuant to an agreement to settle
      a debt and issued 50,000 shares at $3.86 per share for a total of $193,000
      pursuant to a consulting agreement. The Company recorded compensation
      expense of $65,000 in respect of these issuances based on the excess of
      the fair value of these shares over the balances at which they were
      recorded by the Company. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On May 15, 2008, the Company issued 65,000 common shares
      at $5.24 per share for a total of $340,600 to its former CEO in accordance
      with the terms of a severance agreement upon the termination of his
      services. (Notes 5 and 10) The common shares were recorded based upon the
      quoted market price of the Company&#146;s common stock on the agreement date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On August 19, 2008, the Company issued 25,000 common
      shares at $5.07 per share for a total of $126,750 to a director of the Company
      pursuant to an agreement to provide consulting services. The common shares
      were recorded based upon the quoted market price of the Company&#146;s common
      stock on the agreement date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On August 19, 2008, the Company issued 142,698 units at
      $4.25 per unit for proceeds of $606,467 pursuant to private placement
      agreements. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase an additional common
      share at $5.00 per share until August 19, 2009. </P></TD>
  </TR>
</TABLE>
<p align="center">F-17<BR>
</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-19></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 7 </TD>
    <TD align=left width="90%" ><U>Income Taxes</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>The tax effects of the temporary
  differences that give rise to the Company's estimated deferred tax assets and
  liabilities are as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2008</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2007</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">(34.00%</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">(34.00%</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Net operating loss carryforwards </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;1,639,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;582,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Accrued expenses not currently deductible for tax </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">189,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Valuation allowance for deferred tax assets </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(1,828,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(582,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Net deferred tax assets </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>The provision for income taxes differ
  from the amount established using the statutory income tax rate as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2008</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2007</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Income benefit at statutory rate </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;(1,819,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;(553,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Stock-based compensation </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">573,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Increase in valuation allowance </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,246,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>553,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Deferred income tax recovery </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>As of September 30, 2008, the Company
  had net operating loss carryforwards of approximately $4,821,000 available to
  offset future taxable income. The carryforwards will begin expiring in 2024
  unless utilized in earlier years.</P>
<P style="MARGIN-LEFT: 15%" align=justify>The Company evaluates its valuation
  allowance requirements based on projected future operations. When circumstances
  change and this causes a change in management&#146;s judgment about the
  recoverability of deferred tax assets, the impact of the change on the valuation
  allowance is reflected in current income. As management of the Company does not
  currently believe that it is more likely than not that the Company will receive
  the benefit of this asset, a valuation allowance equal to the deferred tax asset
  has been established at both September 30, 2008 and September 30, 2007. </P>
<p align="center">F-18</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-20></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 7 </TD>
    <TD align=left width="90%" ><P align=justify><U>Income Taxes </U>&#150; (cont&#146;d) </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>Uncertain Tax Positions </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On October 1, 2007, the Company adopted FASB
      Interpretation No. 48, "Accounting for Uncertainty in Income Taxes" ("FIN
      48"). FIN 48 prescribes a recognition threshold and measurement attribute
      for the recognition and measurement of tax positions taken or expected to
      be taken in income tax returns. FIN 48 also provides guidance on
      de-recognition of income tax assets and liabilities, classification of
      current and deferred income tax assets and liabilities, and accounting for
      interest and penalties associated with tax positions. </P>
        <P align=justify>The Company files income tax returns in the U.S. federal
          jurisdiction, various state and foreign jurisdictions. The Company&#146;s tax
          returns are subject to tax examinations by U.S. federal and state tax
          authorities, or examinations by foreign tax authorities until respective
          statue of limitation. It is subject to tax examinations by tax authorities
          for all taxation years commencing on or after 2004. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" ><P align=justify> </P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Based on the management&#146;s assessment of FIN 48, it was
      concluded that the adoption of FIN 48, as of October 1, 2007, had no
      significant impact on the Company&#146;s results of operations or financial
      position, and required no adjustment to the opening balance sheet
      accounts. The year-end analysis supports the same conclusion, and the
      Company does not have an accrual for uncertain tax positions as of
      September 30, 2008. As a result, tabular reconciliation of beginning and
      ending balances would not be meaningful. If interest and penalties were to
      be assessed, we would charge interest to interest expense, and penalties
      to other operating expense. It is not anticipated that unrecognized tax
      benefits would significantly increase or decrease within 12 months of the
      reporting date. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company is in arrears on filing its statutory income
      tax returns and is therefore has estimated the expected amount of loss
      carry forwards available once the outstanding returns are filed. The
      Company expects to have significant net operating loss carry forwards for
      income tax purposes available to offset future taxable income. </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%" ><U>Commitments</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify><U>Share Purchase Warrants</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>A summary of the Company&#146;s share purchase warrants
      outstanding is presented below:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="20%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Number of </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Exercise </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="20%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Shares</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Price</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="20%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="20%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Balance, September 30, 2006 and September
      30, 2007 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="20%" >&nbsp;</TD>
    <TD align=left>Issued </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">292,698 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=center width="12%">$5.00 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="20%" >&nbsp;</TD>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="20%" >&nbsp;</TD>
    <TD align=left>Balance, September 30, 2008 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">292,698 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=center width="12%">$5.00 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<p align="center">F-19</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-21></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%" ><U>Commitments &#150; (cont&#146;d) </U></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify><U>Share Purchase Warrants &#150; (cont&#146;d)</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>At September 30, 2008, the Company has 292,698 currently
      exercisable share purchase warrants outstanding as
      follows:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="60%" border=0>
    <TR vAlign=top>
      <TD align=center><U>Number </U></TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="30%"><U>Exercise Price </U></TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="30%"><U>Expiry Date </U></TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="30%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="30%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>142,698 </TD>
      <TD align=left width="2%"  bgColor=#e6efff></TD>
      <TD align=center width="30%" bgColor=#e6efff>$5.00 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="30%" bgColor=#e6efff>August 2009 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>150<U>,</U>000</TD>
      <TD align=left width="2%" ></TD>
      <TD align=center width="30%">$5.00 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=right width="30%">December 2009 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      bgColor=#e6efff>292,698 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=center width="30%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="30%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify><U>Stock&#150;based Compensation Plan</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In April, 2007, the Company adopted a stock option plan
      which provides for the granting of stock options to selected directors,
      officers, employees or consultants in an aggregate amount of up to
      3,000,000 common shares of the Company and, in any case, the number of
      shares to be issued to any one individual pursuant to the exercise of
      options shall not exceed 10% of the issued and outstanding share capital.
      The granting of stock options, exercise prices and terms are determined by
      the Company's Board of Directors. If no vesting schedule is specified by
      the Board of Directors on the grant of options, then the options shall
      vest over a 4-year period with 25% the granted vesting each year
      commencing 1 year from the grant date. For stockholders who have greater
      than 10% of the outstanding common shares of the Company and who have
      granted options, the exercise price of their options shall not be less
      than 110% of the fair of the stock on grant date. Otherwise, options
      granted shall have an exercise price equal to their fair value on grant
      date.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>A summary of the status of company&#146;s outstanding stock
      purchase options for the year ended September 30, 2008 is presented
      below:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Weighted </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Average </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Number of </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Exercise </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Shares </U></TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Price </U></TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Outstanding at September 30, 2006 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;&nbsp;&nbsp;&nbsp; Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">770,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=center width="12%">$3.00 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Outstanding at September 30, 2007 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>770,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>$3.00 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp; &nbsp; &nbsp;Forfeited </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(500,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=center width="12%">$3.00 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp;&nbsp;&nbsp;&nbsp; Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,150,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%"
    bgColor=#e6efff>$4.78 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Outstanding at September 30, 2008 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>1,420,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=center width="12%"
    bgColor=#e6efff>$4.44 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Exercisable at September 30, 2008 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>450,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>$4.73 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Exercisable at September 30, 2007 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=center width="12%">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<p align="center">F-20</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-22></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%"><U>Commitments &#150; (cont&#146;d)</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</U></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>At September 30, 2008, the following stock options were
      outstanding:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=right>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="85%" border=0>
    <TR vAlign=top>
      <TD colspan="3" align=center style="BORDER-BOTTOM: #000000 1px solid">Number
        of Shares </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
      <TD align=center width="13%">&nbsp;</TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="16%">&nbsp;</TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="13%">Aggregate </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="13%">Intrinsic Value </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center>&nbsp;Total </TD>
      <TD align=center width="3%">&nbsp;</TD>
      <TD align=center width="13%">Number </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="13%">Exercise </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="16%">&nbsp;</TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="13%">Intrinsic </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="13%">Of Vested </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center><U>Number</U> </TD>
      <TD align=center width="3%">&nbsp;</TD>
      <TD align=center width="13%"><U>Vested</U> </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="13%"><U>Price</U> </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="16%"><U>Expiry Date</U> </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="13%"><U>Value</U> </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="13%"><U>Options</U> </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD width="3%">&nbsp;</TD>
      <TD width="13%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="13%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD align=right width="1%">&nbsp;</TD>
      <TD align=right width="16%">&nbsp;</TD>
      <TD align=right width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="13%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="13%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>100,000 <SUP>(1)</SUP> </TD>
      <TD align=left width="3%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="13%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=center width="13%" bgColor=#e6efff>$3.86 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="16%" bgColor=#e6efff>December 1, 2010 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=right width="13%" bgColor=#e6efff>&nbsp;184,000 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=right width="13%" bgColor=#e6efff>&nbsp;- </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>400,000 <SUP>(2)</SUP> </TD>
      <TD align=left width="3%">&nbsp;</TD>
      <TD align=right width="13%">100,000 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=center width="13%">$5.25 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="16%">May 20,2011 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="13%">1,292,000 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="13%">323,000 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>50,000 <SUP>(3)</SUP> </TD>
      <TD align=left width="3%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="13%" bgColor=#e6efff>50,000 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=center width="13%" bgColor=#e6efff>$3.75 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="16%" bgColor=#e6efff>November 1, 2012 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="13%" bgColor=#e6efff>86,500 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="13%" bgColor=#e6efff>86,500 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>150,000 <SUP>(4)</SUP> </TD>
      <TD align=left width="3%">&nbsp;</TD>
      <TD align=right width="13%">75,000 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=center width="13%">$3.85 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="16%">December 3, 2012 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="13%">274,500 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="13%">137,250 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>450,000 <SUP>(5)</SUP> </TD>
      <TD align=left width="3%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="13%" bgColor=#e6efff>225,000 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=center width="13%" bgColor=#e6efff>$5.00 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="16%" bgColor=#e6efff>June 3, 2013 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="13%" bgColor=#e6efff>1,341,000 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="13%" bgColor=#e6efff>670,500 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>270,000 <SUP>(6)</SUP> </TD>
      <TD align=left width="3%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="13%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
      <TD align=center width="13%">$3.00 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="16%">February 8, 2017 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="13%">264,600 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="13%">- </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff>&nbsp;</TD>
      <TD width="3%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="16%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" bgColor=#e6efff>&nbsp;</TD>
      <TD width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right>1,420,000 </TD>
      <TD align=left width="3%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="13%">450,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left
    width="2%">&nbsp;</TD>
      <TD align=left width="13%">&nbsp;</TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=right width="1%">&nbsp;</TD>
      <TD align=right width="16%">&nbsp;</TD>
      <TD align=right width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%">$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="13%">3,442,600 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%">$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="13%">1,217,250 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD><P align=justify>As at September 30, 2008, these options have not vested.
      The options vest upon the Company listing its shares on the American Stock
      Exchange or any other nationally recognized stock exchange by December 1,
      2012 or in the event of a change of control and a listing on a nationally
      recognized stock exchange is not required. No stock-based compensation has
      been recorded in the financial statements as the performance condition has
      not yet been met.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD><P align=justify>As at September 30, 2008, 100,000 of these options have
      vested. The remaining 300,000 shares vest as follows: 100,000 on November
      20, 2008, 100,000 on February 20, 2009 and 100,000 on May 20, 2009. The
      fair value of the options on the grant date was calculated to be
      $1,031,800 for which the Company has recognized stock-based compensation
      for the options that vested in the amount of $257,950 included with
      consulting fees in the financial statements for the year ended September
      30, 2008. The remaining 300,000 unvested options were re-measured on
      September 30, 2008 with their fair value determined to be $172,350 for
      which the Company recognized compensation expense of $62,802 included with
      consulting fees in the financial statements for the year ended September
      30, 2008.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD><P align=justify>As at September 30, 2008 these options were fully vested.
      The fair value of these options was calculated to be $122,150 which amount
      has been recognized as stock-based compensation and included with investor
      relations expense in the financial statements for the year ended September
      30, 2008.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD><P align=justify>As at September 30, 2008, 75,000 of these options had
      vested. The remaining 75,000 options vest on December 4, 2008. The fair
      value of the options on the grant date was calculated to be $269,910 for
      which the Company has recognized stock-based compensation in the amount of
      $256,954 included with consulting fees in the financial statements for the
      year ended September 30, 2008</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">5. </TD>
    <TD><P align=justify>As at September 30, 2008, 225,000 of these options have
      vested. The remaining 225,000 options vest on June 3, 2009. The fair value
      of the options on the grant date was calculated to be $1,136,025 for which
      the Company has recognized stock-based compensation in the amount of
      $794,081 included with consulting fees in the financial statements for the
      year ended September 30, 2008.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">6. </TD>
    <TD><P align=justify>As at September 30, 2008, these options have not vested.
      The options vest upon one or more compounds: entering Phase 2 Trial &#150;
      90,000 options; entering Phase 3 Trial &#150; 90,000 options; and receiving FDA
      approval &#150; 90,000 options. No stock-based compensation has been recorded
      in the financial statements as none of the performance conditions have yet
      been met.</P></TD>
  </TR>
</TABLE>
<p align="center">F-21</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-23></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%" ><U>Commitments &#150; (cont&#146;d)</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The fair value of stock options granted has been
      determined using the Black-Scholes option pricing model using the
      following weighted average assumptions applied to stock options granted
      during the years:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%"><U>2008</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%"><U>2007</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Risk-free interest rate </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>2.28% - 3.785% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Expected life of options </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">2.25 - 5 years </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Annualized volatility </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>77.82% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Dividend rate </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">0% </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>The volatility was determined based on
  an index of volatility from comparable companies. The expected term of the
  options granted to employees is derived from the simplified method as prescribed
  by SEC Staff Accounting Bulletin No. 110 given that the Company has no
  historical experience with the exercise of options for which to base an estimate
  of the expected term of options granted. The Company anticipates it will
  discontinue the use of the simplified method of SAB 110 once sufficient
  historical option exercise behavior becomes apparent. The expected term of
  options granted to non-employees was determined to be the option term. </P>
<P style="MARGIN-LEFT: 15%" align=justify>At September 30, 2008, the following
  summarizes the unvested stock options: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Weighted </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Weighted </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Average </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Average </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Number of </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Exercise </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">Grant-date </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Shares</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Price</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%"><U>Fair value</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Unvested options at September 30, 2006 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>- </TD>
    <TD align=center width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp;Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">770,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=center width="12%">$3.00 </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">$2.21 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Unvested options at September 30, 2007 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>770,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>$3.00 </TD>
    <TD align=center width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp;Forfeited </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(500,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=center width="12%">$3.00 </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">$2.21 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp;Granted </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,150,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>$4.78 </TD>
    <TD align=center width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff>$2.47 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp; &nbsp; &nbsp; &nbsp;Vested </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">(450,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">$4.73 </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="12%">$2.46 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%" align="center"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" bgColor=#e6efff>&nbsp;</TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Unvested options at September 30, 2008 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">970,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=center width="12%">$4.31 </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=center width="12%">$2.42 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
  </TR>
</TABLE>
<p align="center">F-22<BR>
</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-24></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%" ><U>Commitments &#150; (cont&#146;d)</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>As at September 30, 2008, there was a total of $ 464,447
      of unrecognized compensation cost associated with unvested share-based
      compensation awards that will become vested exclusive of achieving any
      performance milestones. This unrecognized compensation cost is expected to
      be recognized during the year ended September 30, 2009. There has been no
      stock-based compensation recognized in the financial statements for the
      year ended September 30, 2008 for options that vest upon the achievement
      of performance milestones because the Company has determined that
      satisfaction of the performance milestones was not probable. Compensation
      relating to stock options exercisable upon achieving performance
      milestones will be recognized in the period the milestones are
      achieved.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Stock-based compensation amounts, including those
      relating to shares issued for non-cash consideration during the year (Note
      6), are classified in the Company&#146;s Statement of Operations as
      follows:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2008</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2007</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Consulting </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;2,218,488 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Investor relations </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">127,650 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;2,346,138 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD colSpan=2><P align=justify><U>Patent and Collaboration Agreement</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD colSpan=2><P align=justify>On February 1, 2007, the Company signed a contract with
      an officer of the Company to acquire property for the development of a new
      drug compound including three patents and one patent application. Pursuant
      to the agreement, the Company agreed to the following:</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD><P align=justify>Invest a minimum of $200,000 every fiscal year into
      scientific research and;</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">ii) </TD>
    <TD><P align=justify>Hire the director as a consultant to carry out the
      Company&#146;s Research and Development program at $6,000 per month
      and;</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">iii) </TD>
    <TD><P align=justify>Pay to the director 6% of the net income earned from the
      exploitation of the patent and patent application; and</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">iv) </TD>
    <TD><P align=justify>Disburse a one-time payment to the director an amount of
      $72,000 before December 31, 2007 as consideration for the transfer of the
      patents and the patent application. (paid)</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>Effective January 1, 2008, the monthly
  salary paid to the director was increased to 7,000 Euros. As at September 30,
  2008, the Company has complied with the terms of the Patent and Collaboration
  Agreement and it remains in good standing </P>
<p align="center">F-23</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-25></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
(A Development Stage Company) <BR>
Notes to the Financial Statements <BR>
September 30, 2008 and 2007 <BR>
(<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%" ><U>Commitments &#150; (cont&#146;d)</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD colSpan=2><P align=justify><U>Consulting Agreement &#150; Note 4</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD colSpan=2><P align=justify>On May 20, 2008, the Company signed an agreement with a
      director of the Company to provide consulting services. Pursuant to the
      terms of the agreement, the Company:</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top align=left width="5%">i) </TD>
    <TD><P align=justify>will issue 200,000 common shares at the rate of 25,000
      common shares per quarter commencing August 20, 2008.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD align=left width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top align=left width="5%">ii) </TD>
    <TD><P align=justify>issued 400,000 common stock options entitling the
      consultant to purchase an additional common share for each option held at
      $5.25 per share for a period of 3 years. These options vest at the rate of
      100,000 options per quarter commencing August 20, 2008.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD align=left width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top align=left width="5%">iii) </TD>
    <TD><P align=justify>will pay a 4% finder&#146;s fee for up to $100 million on
      funds raised from any source except from investment banking enterprises
      and 2% for funds raised in excess of $100 million.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>The consulting agreement with the
  director is being accounted for in accordance with the provisions of EITF 96-18, <I>&#147;Accounting for Equity Instruments That are Issued Other Than Employees for
    Acquiring, or in Conjunction with Selling, Goods or Services&#148;</I> whereby the
  fair values of the shares to be issued and the unvested options are recognized
  ratably over the period for the consulting services are provided.</P>
<P style="MARGIN-LEFT: 15%" align=justify>During the year ended September 30,
  2008, the Company recognized stock-based compensation in the following amounts
  in respect of this consulting agreement:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Common shares issued </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;126,750 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>Common shares to be issued </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;125,849 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Stock &#150; based
      compensation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      &nbsp;- options vested </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;257,950 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD
      align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      - options not yet vested </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;62,802 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Supplemental Cash flow
      Information</U> </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%"  >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Investing and financing activities that do not have a
      direct impact on current cash flows are excluded from the statements of
      cash flows. </P></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%"  >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>During the year ended September 30, 2008: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>The Company terminated the services of its CEO and the
      agreed upon severance package included the issuance of 65,000 common
      shares at $5.24 per share totaling $340,600 and the issuance of a
      promissory note payable in the amount of $200,000 of which $128,500 was
      applied to unpaid consulting fees and the remaining $71,500 was charged as
      severance pay in the current year.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>The Company issued 10,000 shares at $4.50 per share for a
      total of $45,000 to settle an account payable.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD><P align=justify>The Company issued 50,000 common shares at $3.86 per
      share for a total of $193,000 and 25,000 common shares at $5.00 per share
      for a total of $125,000 for payments of consulting
      services.</P></TD>
  </TR>
</TABLE>
<p align="center">F-24<BR>
</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-26></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  (A Development Stage Company) <BR>
  Notes to the Financial Statements <BR>
  September 30, 2008 and 2007 <BR>
  (<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Supplemental Cash flow
      Information &#150; (cont&#146;d)</U> </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >During the year ended September
      30, 2007: </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>The Company issued 92,500 shares of common stock at $3.60
      per share to a significant shareholder for settlement of a loan payable of
      $333,000.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>The Company issued 222,222 shares of common stock at
      $3.60 per share for a total of $800,000 for research and development
      services.</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >There were no amounts paid in
      2008 and 2007 in respect of interest or income taxes. </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD align=left width="90%" ><U>Subsequent Event</U> </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >Subsequent to September 30, 2008: </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD><P align=justify>the Company issued 25,000 common shares to a director of
      the Company pursuant to a consulting agreement (Note 8(d)).</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">ii) </TD>
    <TD><P align=justify>the Company entered into private placement subscription
      agreements to issue units of the Company at a price of $2.25 per unit.
      Each unit consists of one common share and one share purchase warrant
      entitling the holder to purchase an additional share at a price of $4.00
      per share for a period of one year from the closing date of the offering.
      The total offering is intended to be $3,500,000. To date, the Company has
      raised $195,500 on this unit offering.</P></TD>
  </TR>
</TABLE>
<p align="center">F-25</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_32></A>
<P align=center>- 29 - </P>
<P align=justify><B>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL MATTERS</B></P>
<P align=justify>On January 21, 2008, Amisano Hanson. Chartered Accountants
resigned as our independent accountant. Amisano Hanson recently entered into an
agreement with BDO Dunwoody LLP, pursuant to which Amisano Hanson will merge its
operations into BDO Dunwoody and certain of the professional staff and partners
joined BDO Dunwoody either as employees or partners of BDO Dunwoody and will
continue to practice as members of BDO Dunwoody.</P>
<P align=justify>The report of Amisano Hanson regarding our financial statements
for the fiscal years ended December 31, 2006 and 2005 did not contain any
adverse opinion or disclaimer of opinion and was not qualified or modified as to
uncertainty, audit scope or accounting principles, except that such report on
our financial statements for the years ended December 31, 2006 and 2005
contained an explanatory paragraph in respect to uncertainty as to our ability
to continue as a going concern. During the years ended December 31, 2006 and
2005 and during the period from the end of the most recently completed fiscal
year through January 21, 2008, the date of resignation, there were no
disagreements with Amisano Hanson on any matter of accounting principles or
practices, financial statement disclosure or auditing scope or procedures, which
disagreements, if not resolved to the satisfaction of Amisano Hanson would have
caused it to make reference to such disagreements in its reports.</P>
<P align=justify>We provided Amisano Hanson with a copy of our current report on
Form 8-K prior to its filing with the Securities and Exchange Commission and
requested that Amisano Hanson furnish our company with a letter addressed to the
Securities and Exchange Commission stating whether it agrees with the above
statements and, if it does not agree, the respects in which it does not agree. A
copy of such letter, dated March 7, 2008, is attached as Exhibit 16.1 to our
current report on Form 8-K/A filed with the SEC on March 10, 2008.</P>
<P align=justify>Concurrent with the resignation of Amisano Hanson, we engaged
BDO Dunwoody, as our independent accountant. Prior to engaging BDO Dunwoody, we
did not consult with BDO Dunwoody regarding the application of accounting
principles to a specific completed or contemplated transaction or regarding the
type of audit opinion that might be rendered by BDO Dunwoody on our financial
statements, and BDO Dunwoody did not provide any written or oral advice that was
an important factor considered by our company in reaching a decision as to any
such accounting, auditing or financial reporting issue. The engagement of BDO
Dunwoody was approved by our board of directors. </P>
<P align=justify><B>ITEM 9A. CONTROLS AND PROCEDURES</B></P>
<P align=justify><I>Disclosure Controls and Procedures </I></P>
<P align=justify>As required by paragraph (b) of Rules 13a-15 and 15d-15 under
the Exchange Act, our management, with the participation of our principal
executive and principal financial officer, evaluated our company&#146;s disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the
Exchange Act) as of the end of the period covered by this Annual Report on Form
10-K. Disclosure controls and procedures are controls and other procedures that
are designed to ensure that information required to be disclosed in our
company's reports filed or submitted under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the
Securities and Exchange Commission's rules and forms. Disclosure controls and
procedures include controls and procedures designed to ensure that information
required to be disclosed in our company's reports filed under the Exchange Act
is accumulated and communicated to our principal executive officer and principal
financial officer, as appropriate, to allow timely decisions regarding required
disclosure.</P>
<P align=justify>Based on its evaluation, our management, with the participation
of our principal executive and principal financial officer concluded that as of
the end of the period covered by this Annual Report on Form 10-K, our disclosure
controls and procedures were not effective.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_33></A>
<P align=center>- 30 - </P>
<P align=justify><I>Management&#146;s Report on Internal Control over Financial
Reporting.</I></P>
<P align=justify>Management is responsible for establishing and maintaining
adequate internal control over our financial reporting, as such term is defined
in Exchange Act Rule 13a-15(f). Our management evaluated, under the supervision
and with the participation of our principal executive and principal financial
officer, the effectiveness of our internal control over financial reporting as
of September 30, 2008.</P>
<P align=justify>Based on its evaluation under the framework in Internal
Control&#151;Integrated Framework, issued by the Committee of Sponsoring
Organizations of the Treadway Commission, our management, with the participation
of our principal executive and principal financial officer concluded that our
internal control over financial reporting was not effective as of September 30,
2008, due to the existence of significant deficiencies constituting material
weaknesses, as described in greater detail below. A material weakness is a
control deficiency, or combination of control deficiencies, such that there is a
reasonable possibility that a material misstatement of the annual or interim
financial statements will not be prevented or detected on a timely basis.</P>
<P align=justify>This annual report does not include an attestation report of
our company&#146;s independent registered public accounting firm regarding internal
control over financial reporting. Management&#146;s report was not subject to
attestation by our company&#146;s independent registered public accounting firm
pursuant to temporary rules of the SEC that permit our company to provide only
management&#146;s report in this annual report.</P>
<P align=justify><U>Material Weaknesses Identified</U> </P>
<P align=justify>Based on our management&#146;s evaluation required by paragraph (d)
of Rule 13a-15 and of Rule 15d-15 of the Exchange Act, certain significant
deficiencies in internal control became evident to management that our
management believes represent material weaknesses, including: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(i) </TD>
    <TD>
      <P align=justify>Lack of independent members on our audit committee. Our
      principal executive and principal financial officer is the only member of
      our audit committee. We currently have three independent directors on our
      board, but have yet to elect a functioning audit committee. Our goal is to
      eventually have an audit committee comprised of independent
    directors.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(ii) </TD>
    <TD>
      <P align=justify>Insufficient segregation of duties in our finance and
      accounting functions due to limited personnel. During the year ended
      September 30, 2008, we had limited staff that performed nearly all aspects
      of our financial reporting process, including, but not limited to, access
      to the underlying accounting records and systems, the ability to post and
      record journal entries and responsibility for the preparation of the
      financial statements. This creates certain incompatible duties and a lack
      of review over the financial reporting process that would likely result in
      a failure to detect errors in spreadsheets, calculations, or assumptions
      used to compile the financial statements and related disclosures as filed
      with the SEC. These control deficiencies could result in a material
      misstatement to our interim or annual consolidated financial statements
      that would not be prevented or detected;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iii) </TD>
    <TD>
      <P align=justify>There is a lack of sufficient supervision and review by
      our management;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iv) </TD>
    <TD>
      <P align=justify>Insufficient corporate governance policies. Although we
      have a code of ethics which provides broad guidelines for corporate
      governance, our corporate governance activities and processes are not
      always formally documented. Specifically, decisions made by the board to
      be carried out by management should be documented and communicated on a
      timely basis to reduce the likelihood of any misunderstandings regarding
      key decisions affecting our operations and management; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(v) </TD>
    <TD>
      <P align=justify>Our company's accounting staff does not have sufficient
      technical accounting knowledge relating to accounting for income taxes and
      complex US GAAP matters. Management corrected any errors prior to the
      release of our company's September 30, 2008 financial
  statements.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_34></A>
<P align=center>- 31 - </P>
<P align=justify><U>Plan for Remediation of Material Weaknesses</U></P>
<P align=justify>We intend to take appropriate and reasonable steps to make the
necessary improvements to remediate these deficiencies. We intend to consider
the results of our remediation efforts and related testing as part of our
year-end 2009 assessment of the effectiveness of our internal control over
financial reporting.</P>
<P align=justify>We have implemented certain remediation measures and are in the
process of designing and implementing additional remediation measures for the
material weaknesses described in this annual report. Such remediation activities
include the following:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>We intend to appoint independent members to our audit
      committee in the 2009 fiscal year; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>We intend to update the documentation of our internal
      control processes, including formal risk assessment of our financial
      reporting processes.</P></TD></TR></TABLE>
<P align=justify><U>Limitations on Effectiveness of Controls</U></P>
<P align=justify>Our principal executive and principal financial officer does
not expect that our disclosure controls or our internal control over financial
reporting will prevent all errors and all fraud. A control system, no matter how
well conceived and operated, can provide only reasonable, not absolute,
assurance that the objectives of the control system are met. Further, the design
of a control system must reflect the fact that there are resource constraints,
and the benefits of controls must be considered relative to their costs. Because
of the inherent limitations in all control systems, no evaluation of controls
can provide absolute assurance that all control issues and instances of fraud,
if any, within our company have been detected. These inherent limitations
include the realities that judgments in decision-making can be faulty, and that
breakdowns can occur because of a simple error or mistake. Additional controls
can be circumvented by the individual acts of some persons, by collusion of two
or more people, or by management override of the controls. The design of any
system of controls also is based in part upon certain assumptions about the
likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions;
over time, controls may become inadequate because of changes in conditions, or
the degree of compliance with the policies or procedures may deteriorate.
Because of the inherent limitations in a cost-effective control system,
misstatements due to error or fraud may occur and not be detected.</P>
<P align=justify><I>Changes in Internal Control over Financial Reporting
</I></P>
<P align=justify>There were no changes in our internal control over financial
reporting during the fiscal year ended September 30, 2008 that have materially
affected, or are reasonably likely to materially affect our internal control
over financial reporting.</P>
<P align=justify><I>Certificates</I></P>
<P align=justify>Certificates with respect to disclosure controls and procedures
and internal control over financial reporting under Rules 13a-14(a) or 15d-14(a)
of the Exchange Act are attached to this annual report on Form 10-K.</P>
<P align=justify><B>ITEM 9B OTHER INFORMATION</B></P>
<P align=justify>None. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_35></A>
<P align=center>- 32 - </P>
<P align=center><B>PART III</B></P>
<P align=justify><B>ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE</B></P>
<P align=justify><B><I>Directors and Executive Officers, Promoters and Control
  Persons </I></B></P>
<P align=justify>As at September 30, 2008, our directors and executive officers,
their age, positions held, and duration of such, are as follows:</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=left style="BORDER-BOTTOM: #000000 1px solid">&nbsp; &nbsp; &nbsp;
        &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<B>Name</B> </TD>
      <TD width="40%" align=left style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<B>Position Held with our
        Company</B> </TD>
      <TD width="8%" align=center style="BORDER-BOTTOM: #000000 1px solid"
    ><B>Age</B> </TD>
      <TD
      width="27%" align=left style="BORDER-BOTTOM: #000000 1px solid"><B>Date First Elected or Appointed</B> </TD>
    </TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Panos Kontzalis
      <SUP>(1)</SUP> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="40%"
    >Former Chief Executive Officer and Director </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="8%"
    >63 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="27%">&nbsp;
      &nbsp; &nbsp;January 25, 2007 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Harvey Lalach </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="40%"
    >President, Chief Financial Officer and Director </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="8%"
    >42 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="27%">&nbsp;
      &nbsp; &nbsp;April 25, 2006 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Cameron Durrant
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="40%"
    >Director </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="8%"
    >47 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="27%">&nbsp;
      &nbsp; &nbsp;December 17, 2007 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Alison Ayers </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="40%"
    >Director </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="8%"
    >56 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="27%">&nbsp;
      &nbsp; &nbsp;May 20, 2008 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>David Tousley </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="40%"
    >Director </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="8%"
    >53 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="27%">&nbsp;
      &nbsp; &nbsp;June 3, 2008 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Alexander
      Vamvakides<SUP>(2)</SUP> </TD>
    <TD align=left width="40%" >Former Director </TD>
    <TD align=center width="8%" >69 </TD>
    <TD align=left width="27%">January 31, 2007 </TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><SUP>(1)</SUP> </TD>
    <TD>
      <P align=justify>Mr. Kontzalis resigned on May 20, 2008</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%"><SUP>(2)</SUP> </TD>
    <TD>
      <P align=justify>Mr. Vamvakides resigned on May 20,
2008</P></TD></TR></TABLE>
<P align=justify><B><I>Certain Significant Employees </I></B></P>
<P align=justify>As at September 30, 2008, our significant employees, their age,
positions held, and duration of such, are as follows:</P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="90%" border=1>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=center style="BORDER-BOTTOM: #000000 1px solid"><B>Name</B> </TD>
      <TD width="40%" align=left style="BORDER-BOTTOM: #000000 1px solid"
    ><B>Position Held with our Company</B> </TD>
      <TD width="8%" align=center style="BORDER-BOTTOM: #000000 1px solid"
    ><B>Age</B> </TD>
      <TD
      width="27%" align=left style="BORDER-BOTTOM: #000000 1px solid"><B>Date First Appointed</B> </TD>
    </TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Alexandre
      Vamvakides </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="40%"
    >Chief Scientific Officer </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="8%"
    >69 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      width="27%">January 27. 2007 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>George Kalkanis
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="40%"
    >VP Strategic Planning </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="8%"
    >42 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      width="27%">February 8, 2007 </TD></TR></TABLE></DIV>
<P align=justify><B><I>Business Experience </I></B></P>
<P align=justify>The following is a brief account of the education and business
experience of directors and executive officers during at least the past five
years, indicating their principal occupation during the period, and the name and
principal business of the organization by which they were employed. </P>
<P align=justify><U>Harvey Lalach, President, Chief Financial Officer and
Director since January 25, 2007</U> </P>
<P align=justify>For the past 22 years Mr. Lalach has been involved in various
aspects of the securities industry. From 1986 through to 1997 he was involved in
various roles in financial institutions starting at the Vancouver Stock Exchange
and later working in securities related roles for BMO Nesbitt Burns and TD Bank
and. For the past 10 years Mr. Lalach has focused on the operation and
administration of numerous start-up US and Canadian public companies serving as
both Director and Officer in various capacities. Most recently Mr. Lalach served
as President and CEO for Assure Energy, Inc. (OTCBB: ASUR) and Quarry Oil &amp;
Gas Corp. (TSXV: QUC). Throughout his career, Mr. Lalach has gained extensive
experience in the Management and Governance of listed public companies.</P>
<P align=justify><U>Cameron Durrant, Director since December 17, 2007</U> </P>
<P align=justify>Mr. Durrant is currently Worldwide Vice President, Virology
Global Strategic Marketing for Johnson + Johnson (NYSE: JNJ). Dr. Durrant was
president and CEO of Pediamed Pharmaceuticals, Inc. Dr. Durrant&#146;s background
also includes executive-level positions with Merck &amp; Co. (NYSE: MRK), Glaxo
Smith Kline PLL (NYSE GSK) and Pharmacia Healthcare Ltd. (now Pfizer Inc. (NYSE:
PFE)). Dr. Durrant was a regional winner and national finalist for Ernst &amp;
Young&#146;s Entrepreneur of the Year award in 2005. Dr. Durrant holds a MBA from
Henley Management College at Oxford and a MB and BCh (equivalent to American MD
degree) from the Welsh National School of Medicine in Cardiff, U.K. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_36></A>
<P align=center>- 33 - </P>
<P align=justify><U>Alison Ayers, Director since May 20, 2008</U> </P>
<P align=justify>Ms. Ayers is the current Worldwide Commercial Head for Oncology
for Pfizer Inc. (NYSE: PFE). She is a member of the leadership team that
develops Pfizer&#146;s oncology strategic plan and which manages the portfolio,
including asset prioritization, development planning, strategic and investment
decisions including licensing and acquisitions. </P>
<P align=justify>Previously, Ms. Ayers was Commercial Head, Infectious Disease,
Worldwide Marketing for Pfizer, responsible for strategic leadership for the
company's infectious disease portfolio. Under her leadership, Pfizer's
infectious disease portfolio exceeded $3 billion in sales in 2005, with two
compounds achieving sales growth of 20-30%. </P>
<P align=justify>Before joining Pfizer Ms. Ayers was Vice President of Portfolio
Management for Pharmacia Healthcare Ltd, where she developed and implemented
strategies to maximize earnings from the company's complex global $2.5 billion
diversified products portfolio, which is comprised of more than 600 mature, non-
promoted products. In her earlier role as Vice President, Commercial
Development, Oncology for Pharmacia, Ms. Ayers was responsible for providing
commercial leadership for the company's oncology pipeline, and held a pivotal
role in the acquisition of biotech company Sugen, which delivered Pfizer's
leading angiogenesis inhibitor, Sutent. Pharmacia was acquired by Pfizer in
2003. </P>
<P align=justify>Ms. Ayers' background also includes senior positions in
business and product planning for numerous bioscience and pharmaceutical
companies, including Merck &amp; Co. (NYSE: MRK), The Health Care Group, U.S.
Bioscience, Inc. (Amex: UBS), Bristol-Myers Squibb Co. (NYSE: BMY) and Lederle
Laboratories. She holds a Master of Science with distinction in biopharmacy and
a Diploma in Business Studies, both from the University of London, UK, as well
as a Bachelor of Science with honors in physiology and biochemistry from the
University of Southampton, UK. </P>
<P align=justify><U>David Tousley, Director since June 3, 2008</U> </P>
<P align=justify>Mr. Tousley has over 25 years of senior-level experience in
biotech, specialty pharmaceuticals and full-phase pharmaceutical companies. He
has held the position of President, COO and CFO at companies including
airPharma, PediaMed Pharmaceuticals, Inc., AVAX Technologies Inc. (AVXT.OB), and
Pasteur, Merieux, Connaught, (known today as Sanofi-Pasteur SA). During his
career, Mr. Tousley has led all aspects of operations, including pharmaceutical
development, in both the private and public company environment. His
accomplishments include the raising over $90 million in debt and equity
financings and he has led key business development activities, including joint
ventures, partnerships, acquisitions and divestitures in the U.S., Europe and
Australia. </P>
<P align=justify>Mr. Tousley currently serves as a director of ImmunoGenetix
Therapeutics, Inc, a biotech company that is developing advanced DNA
immunotherapies for HIV infection. He holds an MBA in accounting from Rutgers
Graduate School of Business and a B.A. in English from Rutgers College, both in
New Jersey. Mr. Tousley belongs to the New Jersey Society of Certified Public
Accountants and the American Institute of Certified Public Accountants. </P>
<P align=justify><U>Alexandre Vamvakides, Chief Scientific Officer since Chief
Scientific Officer</U></P>
<P align=justify>Dr. Vamvakides has spent 30 years in research focusing on the
therapeutic/pharmacological areas of nootropes, anti-neurodegenerative
(anti-Alzheimer), antiepileptic, antidepressive, and prototype molecules. During
his career, Dr. Vamvakides has been published over 80 times in highly respected
Medical/Scientific journals. In the past 30 years, Dr. Vamvakides has pioneered
his expertise at the Institut National de la Sante et de la Recherche Medicale
(INSERM) in Paris France, at the University of Athens (Greece), Ciba-Geigy
(Basel, Switzerland) and Sanofi (Montpellier, France), and many other research
laboratories throughout Europe for the discovery and development of new concepts
in the therapeutic areas of Central Nervous System, oncology and
anti-inflammatory diseases. Dr. Vamvakides holds a M.Sc. in Chemistry from
Bordeaux University, France, a M.Sc. in Pharmacology, a M.Sc. in Biochemistry
and a Ph.D. in Molecular Pharmacology all from the University of Paris Medical
School. </P>
<P align=justify><U>George Kalkanis, Vice-President, Strategic Planning since
February 8, 2007</U> </P>
<P align=justify>Mr. Kalkanis has over 15 years experience in the area of
Business Analysis. His expertise is in analyzing information from various
sources and developing intelligent models that provide assessments in order to
support managerial business decision making. In the Phamaceutical sector Dr.
Kalkanis has provided Busienss Forcasting </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_37></A>
<P align=center>- 34 - </P>
<P align=justify>and Marketing analysis solutions to Pharmaceutical Companies in
Greece, such as Novartis Inc. (NYSE: NVS) and Boehringer Ingelheim GmbH. Dr.
Kalkanis holds Masters and Doctorate Degrees from the University of Manchester
(UK) in the areas of Information engineering, Computation and Applied
Statisitcs. </P>
<P align=justify><I>Committees of the Board </I></P>
<P align=justify><U>Audit Committee</U> </P>
<P align=justify>We have an audit committee, comprised of one director, Harvey
Lalach, and an audit committee charter. A copy of our audit committee charter is
attached as an exhibit to this Annual Report. The Audit Committee represents the
Board of Directors in discharging its responsibility relating to the accounting,
reporting and financial practices of the Company and its subsidiaries, and has
general responsibility for oversight of internal controls, accounting and audit
activities and legal compliance of the Company and its subsidiaries. However,
the Audit Committee&#146;s function is one of oversight only and shall not relieve
the Company&#146;s management of its responsibilities for preparing financial
statements which accurately and fairly present the Company&#146;s financial results
and conditions or the responsibilities of the independent accountants relating
to the audit or review of financial statements. </P>
<P align=justify>Currently we have one member of our Board of Directors who is
considered as an &#147;audit committee financial expert&#148; as defined in Item
407(d)(5)(ii) of Regulation S-K, however he does not sit on our Audit Committee.
</P>
<P align=justify>We have three directors in total who qualify as &#147;independent&#148;
as the term is used in Item 7(d)(3)(iv) of Schedule 14A under the <I>Securities
Exchange Act of 1934, as amended</I>. </P>
<P align=justify><U>Nominating Committee</U> </P>
<P align=justify>We do not have a Nominating Committee, our entire board of
director performs the functions of a Nominating Committee and oversees the
process by which individuals may be nominated to our board of directors. </P>
<P align=justify>The current size of our board of directors does not facilitate
the establishment of a separate committee. We hope to establish a separate
Nominating Committee consisting of independent directors, if the number of our
directors is expanded. </P>
<P align=justify><U>Compensation Committee</U> </P>
<P align=justify>We do not have a compensation committee. </P>
<P align=justify><I>Family Relationships </I></P>
<P align=justify>There are no family relationships between any director or
executive officer. </P>
<P align=justify><I>Involvement in Certain Legal Proceedings </I></P>
<P align=justify>Our directors, executive officers, or control persons have not
been involved in any of the following events during the past five years: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>any bankruptcy petition filed by or against any business
      of which such person was a general partner or executive officer either at
      the time of the bankruptcy or within two years prior to that
  time;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>any conviction in a criminal proceeding or being subject
      to a pending criminal proceeding (excluding traffic violations and other
      minor offences);</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>being subject to any order, judgment, or decree, not
      subsequently reversed, suspended or vacated, of any court of competent
      jurisdiction, permanently or temporarily enjoining, barring, suspending or
      otherwise limiting his involvement in any type of business, securities or
      banking activities; or</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify>being found by a court of competent jurisdiction (in a
      civil action), the Commission or the Commodity Futures Trading Commission
      to have violated a federal or state securities or commodities law, and the
      judgment has not been reversed, suspended, or
vacated.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_38></A>
<P align=center>- 35 - </P>
<P align=justify><I>Code of Ethics </I></P>
<P align=justify>We have adopted a code of ethics in compliance with Item 406 of
Regulation S-K that applies to our principal executive officer, principal
financial officer, principal accounting officer or controller, or persons
performing similar functions. We undertake herewith to provide by mail to any
person without charge, upon request, a copy of such code of ethics if we receive
the request in writing by mail to: Anavex Life Sciences Corp. </P>
<P align=justify><I>Section 16(a) Beneficial Ownership Compliance </I></P>
<P align=justify>Section 16(a) of the Securities Exchange Act requires our
executive officers and directors, and persons who own more than 10% of our
common stock, to file reports regarding ownership of, and transactions in, our
securities with the Securities and Exchange Commission and to provide us with
copies of those filings. Based solely on our review of the copies of such forms
received by us, or written representations from certain reporting persons, we
believe that during fiscal year ended September 30, 2008, all filing
requirements applicable to its officers, directors and greater than ten percent
beneficial owners were complied with, with the exception of the following: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=center><BR><BR><B>Name</B> </TD>
    <TD align=center width="25%"><BR><BR><B>Number of Late Reports</B> </TD>
    <TD align=center width="25%"><B>Number of Transactions</B> <BR><B>Not
      Reported on a</B> <BR><B>Timely Basis</B> </TD>
    <TD align=center width="25%"><BR><B>Failure to File</B> <BR><B>Requested
      Forms</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Panos Kontzalis
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Alexandre
      Vamvakides </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Athanasios
      Skarpelos </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="25%">1<SUP>(1)</SUP> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">1
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>George Kalkanis
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Angela Vernadaki
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Cameron Durrant
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Alison Ayers </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Harvey Lalach </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>David Tousley </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="25%">Nil
    </TD></TR></TABLE></DIV>
<P align=justify><SUP>(1) </SUP>Mr. Skarpelos filed a late Form 4 </P>
<P align=justify><B>ITEM 11. EXECUTIVE COMPENSATION</B></P>
<P align=justify><B><I>Summary Compensation</I></B></P>
<P align=justify>The particulars of compensation paid to the following persons:
</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>our principal executive officer; </P>
  <LI>
  <P>each of our two most highly compensated executive officers who were serving
  as executive officers at the end of the year ended September 30, 2008 who had
  total compensation exceeding $100,000; and </P></LI></UL>
<P align=justify>individual was not serving as our executive officer at the end
of the most recently completed financial year, who we will collectively refer to
as the named executive officers, of our years ended September 30, 2008, 2007 and
2006, are set out in the following summary compensation table:</P>
<div>
  <table
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
bordercolor="#000000" cellspacing="0" cellpadding="3" width="100%" border="1">
    <tr valign="bottom" bgcolor="#EEEEEE">
      <td colspan="10" align="center" style="BORDER-BOTTOM: #000000 1px solid"
      >&nbsp;&nbsp;<b>SUMMARY COMPENSATION TABLE</b>&nbsp;&nbsp;&nbsp; </td>
    </tr>
    <tr valign="top" bgcolor="#EEEEEE">
      <td align="center" style="BORDER-BOTTOM: #000000 1px solid"
      ><br />
          <br />
          <br />
          <b>Name</b> <br />
          <b>and Principal</b> <br />
          <b>Position</b> </td>
      <td width="7%" align="center" style="BORDER-BOTTOM: #000000 1px solid"
    ><br />
          <br />
          <br />
          <br />
          <br />
          <b>Year</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <br />
          <b>Salary</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <br />
          <b>Bonus</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <b>Stock</b> <br />
          <b>Awards</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <b>Option </b><br />
          <b>Awards</b> <br />
          <b>($)</b> </td>
      <td width="9%" align="center"><b>Non-Equity</b> <br />
          <b>Incentive </b><br />
          <b>Plan</b> <br />
          <strong>Compensa-</strong> <br />
          <b>tion</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <strong>Nonqualified</strong> <br />
          <b>Deferred</b> <br />
          <strong>Compensation</strong> <br />
          <b>Earnings</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <b>All</b> <br />
          <b>Other</b> <br />
          <strong>Compensa-</strong> <br />
          <b>tion</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <br />
          <b>Total</b> <br />
          <b>($)</b> </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left"
      >Harvey Lalach<sup>(1)</sup> <br />
          <i>President, CFO and</i> <br />
          <i>Secretary</i> </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center" width="7%"
    >2008 <br />
        2007 <br />
        2006 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$111,500 <br />
        $56,000 <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$264,694 <br />
        Nil <br />
        Nil </td>
      <td align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$376,194 <br />
        $56,000 <br />
        Nil </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left"
      >Panos Kontzalis <sup>(2)</sup> <br />
        Former <i>CEO</i> <br /></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center" width="7%"
    >2008 <br />
        2007 <br />
        2006 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$127,500 <br />
        $136,000 <br />
        N/A </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$340,600 <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$71,500 <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$539,600 <br />
        $136,000 <br />
        N/A </td>
    </tr>
  </table>
</div>
<br />
<hr style="PAGE-BREAK-AFTER: always" align="center" width="100%" color="black"
noshade="noshade" size="5" />
<a name="page_39" id="page_39"></a>
<p align="center">- 36 - </p>
<div>
  <table
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
bordercolor="#000000" cellspacing="0" cellpadding="3" width="100%" border="1">
    <tr valign="bottom" bgcolor="#EEEEEE">
      <td colspan="10"
      align="center" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;&nbsp;<b>SUMMARY
        COMPENSATION TABLE</b>&nbsp;&nbsp;&nbsp; </td>
    </tr>
    <tr valign="top" bgcolor="#EEEEEE">
      <td align="center" style="BORDER-BOTTOM: #000000 1px solid"
      ><br />
          <br />
          <br />
          <b>Name</b> <br />
          <b>and Principal</b> <br />
          <b>Position</b> </td>
      <td width="8%" align="center" style="BORDER-BOTTOM: #000000 1px solid"
    ><br />
          <br />
          <br />
          <br />
          <br />
          <b>Year</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <br />
          <b>Salary</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <br />
          <b>Bonus</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <b>Stock</b> <br />
          <b>Awards</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <b>Option </b><br />
          <b>Awards</b> <br />
          <b>($)</b> </td>
      <td width="9%" align="center"><b>Non-Equity</b> <br />
          <b>Incentive </b><br />
          <b>Plan</b> <br />
          <strong>Compensa- </strong><br />
          <b>tion</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <strong>Nonqualified</strong> <br />
          <b>Deferred</b> <br />
          <strong>Compensation</strong> <br />
          <b>Earnings</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <b>All</b> <br />
          <b>Other</b> <br />
          <strong>Compensa-</strong> <br />
          <b>tion</b> <br />
          <b>($)</b> </td>
      <td
      width="9%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><br />
          <br />
          <br />
          <br />
          <b>Total</b> <br />
          <b>($)</b> </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left"
      >Alexandre Vamvakides<sup>(3)</sup> <br />
          <i>Chief Scientific Officer</i> <br /></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center" width="8%"
    >2008 <br />
        2007 <br />
        2006 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$113,382 <br />
        $48,000 <br />
        N/A </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        N/A </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        N/A </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        N/A </td>
      <td align="right" width="9%">Nil <br />
        Nil <br />
        N/A </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        N/A </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        N/A </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$113,382 <br />
        $48,000 <br />
        N/A </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left"
      >George Kalkanis<sup>(4)</sup> <br />
          <i>VP Strategic Planning</i> <br /></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center" width="8%"
    >2008 <br />
        2007 <br />
        2006 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$90,000 <br />
        $60,000 <br />
        N/A </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$90,000 <br />
        $60,000 <br />
        N/A </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left"
      >Angela Vernadaki<sup>(5)</sup> <br />
        Former <i>VP Business</i> <br />
        <i>Development</i> </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center" width="8%"
    >2008 <br />
        2007 <br />
        2006 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$28,280 <br />
        $41,600 <br />
        N/A </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">Nil <br />
        Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="9%">$28,280 <br />
        $41,600 <br />
        N/A </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" >Yang Wu<sup>(6)</sup> <br />
          <i>Former President and</i> <br />
          <i>CEO</i> </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center" width="8%"
    >2008 <br />
        2007 <br />
        2006 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" >Pei Ru Wu<sup>(7)</sup> <br />
          <i>Former COO</i> <br /></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center" width="8%"
    >2008 <br />
        2007 <br />
        2006 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="9%">N/A <br />
        N/A <br />
        Nil </td>
    </tr>
  </table>
</div>
<p align="justify"><sup>(1) </sup>Mr. Lalach was appointed President, CFO and
  Secretary on April 25, 2006. The fair value of the options granted to Harvey
  Lalach during the year was $378,675 of which $264,694 was expensed as
  stock-based compensation during the year. See Note 8 of the financial statements
  for the disclosure of the assumptions used in calculating the fair value of the
  options awarded. <br />
    <sup>(2) </sup>Dr. Kontzalis resigned as CEO on May 20,
  2008. <br />
    <sup>(3) </sup>Dr. Vamvakides was appointed Chief Scientific Officer
  on January 31, 2007. <br />
    <sup>(4) </sup>Mr. Kalkanis was appointed VP Strategic
  Planning on February 8, 2007. <br />
    <sup>(5) </sup>Ms. Vernadaki was appointed VP
  Business Development on February 8, 2007 and resigned the position on February
  29, 2008. <br />
    <sup>(6) </sup>Yang Wu resigned from his positions as CEO and
  President on April 25, 2006 and resigned as Director effective May 22, 2006. <br />
    <sup>(7) </sup>Pei Ru Wu resigned from his positions as COO and President on
  April 25, 2006 and resigned as Director effective May 22, 2006. </p>
<p align="justify"><b><i>Outstanding Equity Awards at Fiscal Year-End </i></b></p>
<p align="justify">The following table sets forth for each named executive officer
  certain information concerning the outstanding equity awards as of September 30
  2008.</p>
<div>
  <table
style="BORDER-COLOR: black; FONT-SIZE: 9pt; BORDER-COLLAPSE: collapse; "
bordercolor="#000000" cellspacing="0" cellpadding="3" width="100%" border="1">
    <tr valign="top" bgcolor="#EEEEEE">
      <td align="center" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</td>
      <td colspan="5" align="center" style="BORDER-BOTTOM: #000000 1px solid"><b>Option
        Awards</b> </td>
      <td colspan="4" align="center" style="BORDER-BOTTOM: #000000 1px solid"><b>Stock
        Awards</b> </td>
    </tr>
    <tr valign="top" bgcolor="#EEEEEE">
      <td
      align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <b>Name</b> </td>
      <td width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <b>Number
            of </b><br />
                    <b>Securities</b> <br />
                    <b>Underlying </b><br />
                    <b>Unexercised </b><br />
                    <b>Options</b> <br />
                    <b>Exercisable </b></td>
      <td
      width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <strong>Number
            of</strong> <br />
                    <b>Securities</b> <br />
                    <strong>Underlying</strong> <br />
                    <strong>Unexercised</strong> <br />
                    <b>Options</b> <br />
                    <strong>Unexercisable </strong></td>
      <td width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <b>Equity</b> <br />
          <b>Incentive</b> <br />
          <b>Plan</b> <br />
          <b>Awards:</b> <br />
          <strong>Number of</strong> <br />
          <b>Securities</b> <br />
          <strong>Underlying</strong> <br />
          <strong>Unexercised</strong> <br />
          <b>Unearned</b> <br />
          <strong>Options</strong> </td>
      <td
      width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <strong>Option</strong> <br />
          <b>Exercise</b> <br />
          <b>Price</b> </td>
      <td
      width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <b>Option</b> <br />
          <b>Expiration </b><br />
          <b>Date</b> </td>
      <td width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <b>Number</b> <br />
          <b>of Shares </b><br />
          <b>or Units</b> <br />
          <b>of Stock</b> <br />
          <b>that</b> <br />
          <strong>Have Not</strong> <br />
          <b>Vested</b> </td>
      <td width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <b>Market </b><br />
          <b>Value </b><br />
          <b>of</b> <br />
          <strong>Shares</strong> <strong>or </strong><br />
          <b>Units of</b> <br />
          <b>Stock</b> <br />
          <b>that</b> <br />
          <strong>Have Not</strong> <br />
          <b>Vested</b> </td>
      <td width="10%" align="center"><br />
          <br />
          <b>Equity</b> <br />
          <b>Incentive</b> <br />
          <b>Plan</b> <br />
          <strong>Awards :</strong> <br />
          <strong>Number of </strong><br />
          <b>Unearned</b> <br />
          <strong>Shares,</strong> <br />
          <b>Units
            or</b> <br />
                    <b>Other</b> <br />
                    <b>Rights that</b> <br />
                    <strong>Have Not</strong> <br />
                    <b>Vested</b> </td>
      <td
      width="10%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><b>Equity</b> <br />
          <b>Incentive</b> <br />
          <b>Plan</b> <br />
          <b>Awards :</b> <br />
          <b>Market
            or</b> <br />
                    <b>Payout</b> <br />
                    <strong>Value of</strong> <br />
                    <strong>Unearned </strong><br />
                    <b>Shares,</b> <br />
                    <strong>Units or </strong><br />
                    <b>Other</b> <br />
                    <strong>Rights that</strong> <br />
                    <strong>Have Not</strong> <br />
                    <b>Vested</b> </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Harvey Lalach </td>
      <td align="right" width="10%">75,000 </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">75,000 </td>
      <td align="right" width="10%">$5.00 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">June
        3, 2013 </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Panos Kontzalis </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">George Kalkanis </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">150,000 </td>
      <td align="right" width="10%">$3.00 </td>
      <td align="right" width="10%" >Feb 8, 2017 </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Angela </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="10%">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
        &nbsp;Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="10%">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="10%">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="10%">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">Nil </td>
    </tr>
  </table>
</div>
<br />
<hr style="PAGE-BREAK-AFTER: always" align="center" width="100%" color="black"
noshade="noshade" size="5" />
<a name="page_40" id="page_40"></a>
<p align="center">- 37 - </p>
<div>
  <table
style="BORDER-COLOR: black; FONT-SIZE: 9pt; BORDER-COLLAPSE: collapse; "
bordercolor="#000000" cellspacing="0" cellpadding="3" width="100%" border="1">
    <tr valign="top" bgcolor="#EEEEEE">
      <td align="center" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</td>
      <td colspan="5" align="center" style="BORDER-BOTTOM: #000000 1px solid"><b>Option
        Awards </b> </td>
      <td colspan="4" align="center" style="BORDER-BOTTOM: #000000 1px solid"><b>Stock
        Awards </b> </td>
    </tr>
    <tr valign="top" bgcolor="#EEEEEE">
      <td
      align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <b>Name </b></td>
      <td width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <b>Number
            of </b><br />
                    <b>Securities </b><br />
                    <b>Underlying </b><br />
                    <b>Unexercised </b><br />
                    <b>Options </b><br />
                    <b>Exercisable </b></td>
      <td
      width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <strong>Number
            of </strong><br />
                    <b>Securities </b><br />
                    <strong>Underlying </strong><br />
                    <strong>Unexercised </strong><br />
                    <b>Options </b><br />
                    <strong>Unexercisable </strong></td>
      <td width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <b>Equity </b><br />
          <b>Incentive </b><br />
          <b>Plan </b><br />
          <b>Awards: </b><br />
          <strong>Number of </strong><br />
          <b>Securities </b><br />
          <strong>Underlying </strong><br />
          <strong>Unexercised </strong><br />
          <b>Unearned </b><br />
          <strong>Options </strong></td>
      <td
      width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <strong>Option </strong><br />
          <strong>Exercise</strong> <br />
          <b>Price </b></td>
      <td
      width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <b>Option </b><br />
          <strong>Expiration </strong><br />
          <b>Date </b></td>
      <td width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <b>Number </b><br />
          <b>of Shares </b><br />
          <b>or Units </b><br />
          <b>of Stock </b><br />
          <b>that </b><br />
          <strong>Have Not </strong><br />
          <b>Vested </b></td>
      <td width="10%" align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <b>Market </b><br />
          <b>Value </b><br />
          <b>of </b><br />
          <strong>Shares </strong><strong>or </strong><br />
          <b>Units of </b><br />
          <b>Stock </b><br />
          <b>that </b><br />
          <strong>Have Not </strong><br />
          <b>Vested </b></td>
      <td width="10%" align="center"><br />
          <br />
          <b>Equity </b><br />
          <b>Incentive </b><br />
          <b>Plan </b><br />
          <strong>Awards : </strong><br />
          <strong>Number of </strong><br />
          <b>Unearned </b><br />
          <strong>Shares, </strong><br />
          <b>Units or </b><br />
          <b>Other </b><br />
          <b>Rights that </b><br />
          <strong>Have Not </strong><br />
          <b>Vested </b></td>
      <td
      width="10%" align="center" style="BORDER-BOTTOM: #000000 1px solid"><b>Equity </b><br />
          <b>Incentive </b><br />
          <b>Plan </b><br />
          <b>Awards : </b><br />
          <b>Market
            or </b><br />
                    <b>Payout </b><br />
                    <strong>Value of </strong><br />
                    <strong>Unearned</strong> <br />
                    <b>Shares, </b><br />
                    <strong>Units or </strong><br />
                    <b>Other </b><br />
                    <strong>Rights that </strong><br />
                    <strong>Have Not </strong><br />
                    <b>Vested </b></td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Vernadaki </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" width="10%">&nbsp;</td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" width="10%">&nbsp;</td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" width="10%">&nbsp;</td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" width="10%">&nbsp;</td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" width="10%">&nbsp;</td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" width="10%">&nbsp;</td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left"
    width="10%">&nbsp;</td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" width="10%">&nbsp;</td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left" width="10%">&nbsp;</td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Alison Ayers </td>
      <td align="right" width="10%">75,000 </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">75,000 </td>
      <td align="right" width="10%">$5.00 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">June
        3, 2013 </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Cameron <br />
        Durrant </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="10%">75,000 <br />
        100,000 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">Nil <br />
        Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="10%">75,000 <br />
        300,000 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">$5.00 <br />
        $5.25 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%"
    >June 3,2013 <br />
        May 20, 2011 </td>
      <td align="right" width="10%">Nil <br /></td>
      <td align="right" width="10%">Nil <br /></td>
      <td align="right" width="10%">Nil <br /></td>
      <td align="right" width="10%">Nil <br /></td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">David Tousley </td>
      <td align="right" width="10%">75,000 </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">75,000 </td>
      <td align="right" width="10%">$5.00 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="10%">June
        3, 2013 </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
      <td align="right" width="10%">Nil </td>
    </tr>
  </table>
</div>
<p align="justify"><i>Compensation of Directors </i></p>
<p align="justify">We reimburse our directors for expenses incurred in connection
  with attending board meetings. We have not paid any director's fees or other
  cash compensation for services rendered as a director since our inception to
  September 30, 2008. </p>
<p align="justify">On June 3, 2008, we approved a compensation package for company
  directors, under our 2007 Stock Option Plan, to issue 150,000 stock options to
  each director, exercisable into shares of common stock at an exercise price of
  US $5.00 per share until June 3, 2013. The options will vest in 50% increments
  with the first 50% vesting immediately and the second 50% vesting on June 3,
  2009. We issued a total of 450,000 options to three of our directors.</p>
<p align="justify">We have not adopted any other equity compensation plan other
  than our 2007 Stock Option Plan. The following issuances of common stock, stock
  options, or other equity securities were awarded to our directors during the
  year ended September 30, 2008: </p>
<div>
  <table
style="BORDER-COLOR: black; FONT-SIZE: 9pt; BORDER-COLLAPSE: collapse; "
bordercolor="#000000" cellspacing="0" cellpadding="3" width="100%" border="1">
    <tr valign="top">
      <td align="center"><br />
          <br />
          <br />
          <br />
          <br />
          <br />
          <b>Name </b></td>
      <td align="center" width="12%"><br />
          <br />
          <b>Fees </b><br />
          <b>Earned or </b><br />
          <b>Paid in </b><br />
          <b>Cash </b><br />
          <b>($) </b></td>
      <td align="center" width="12%"><br />
          <br />
          <br />
          <br />
          <b>Stock </b><br />
          <b>Awards </b><br />
          <b>($) </b></td>
      <td align="center" width="12%"><br />
          <br />
          <br />
          <br />
          <b>Option </b><br />
          <b>Awards </b><br />
          <b>($) </b></td>
      <td align="center" width="12%"><br />
          <br />
          <br />
          <b>Non-Equity </b><br />
          <b>Incentive Plan </b><br />
          <b>Compensation </b><br />
          <b>($) </b></td>
      <td align="center" width="12%"><b>Change in </b><br />
          <b>Pension Value </b><br />
          <b>and </b><br />
          <b>Nonqualified </b><br />
          <b>Deferred </b><br />
          <b>Compensation </b><br />
          <b>Earnings </b></td>
      <td align="center" width="12%"><br />
          <br />
          <br />
          <br />
          <b>All Other </b><br />
          <strong>Compensation </strong><br />
          <b>($) </b></td>
      <td align="center" width="12%"><br />
          <br />
          <br />
          <br />
          <br />
          <b>Total </b><br />
          <b>($) </b></td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center"><b>(a) </b></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center"
      width="12%"><b>(b) </b></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center"
      width="12%"><b>(c) </b></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center"
      width="12%"><b>(d) </b></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center"
      width="12%"><b>(e) </b></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center"
      width="12%"><b>(f) </b></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center"
      width="12%"><b>(g) </b></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="center"
      width="12%">&nbsp;<b>(h) </b></td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Harvey Lalach </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Panos Kontzalis </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$167,000 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$340,600 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$32,000 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$539,600 </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">George Kalkanis </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Angela Vernadaki </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$43,080 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$43,080 </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">Alison Ayers <sup>(1) </sup></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$264,694 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$264,694 </td>
    </tr>
    <tr valign="top">
      <td align="left">Cameron Durrant <sup>(2) </sup></td>
      <td align="right" width="12%">Nil </td>
      <td align="right" width="12%">Nil </td>
      <td align="right" width="12%">$256,954 </td>
      <td align="right" width="12%">Nil </td>
      <td align="right" width="12%">Nil </td>
      <td align="right" width="12%">Nil </td>
      <td align="right" width="12%">$256,954 </td>
    </tr>
    <tr valign="top">
      <td style="BORDER-BOTTOM: #000000 1px solid" align="left">David Tousley <sup>(3) </sup></td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$264,694 </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right" width="12%">Nil </td>
      <td style="BORDER-BOTTOM: #000000 1px solid" align="right"
      width="12%">$264,694 </td>
    </tr>
  </table>
</div>
<P style="MARGIN-LEFT: 5%" align=justify><SUP>(1) </SUP>Alison Ayers was granted
options having a fair value of $378,675 of which $264,694 was expensed as
stock-based compensation during the year. See Note 8 of the financial statements
for the disclosure of the assumptions used in calculating the fair value of the
options awarded. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_41></A>
<P align=center>- 38 - </P>
<P style="MARGIN-LEFT: 5%" align=justify><SUP>(2) </SUP>Cameron Durrant was
granted options having a fair value of $269,910 during the year ended September
30, 2008 of which $256,954 was expensed as stock-based compensation during the
year. See Note 8 of the financial statements for the disclosure of the
assumptions used in calculating the fair value of the options awarded.
<BR><SUP>(3)</SUP> David<SUP> </SUP>Tousley was granted options having a fair
value of $378,675 of which $264,694 was expensed as stock-based compensation
during the year. See Note 8 of the financial statements for the disclosure of
the assumptions used in calculating the fair value of the options awarded. </P>
<P align=justify>During the fiscal year ended September 30, 2008, there were no
standard or other arrangements pursuant to which any of our directors were
compensated for services provided in their capacity as directors. </P>
<P align=justify>We currently have no formal plan for compensating our directors
for their services in their capacity as directors, although we may elect to
issue additional stock options to such persons in the future. Directors are
entitled to reimbursement for reasonable travel and other out-of-pocket expenses
incurred in connection with attendance at meetings of our board of directors.
Our board of directors may award special remuneration to any director
undertaking any special services on our behalf other than services ordinarily
required of a director.</P>
<P align=justify><I>Long-Term Incentive Plans </I></P>
<P align=justify>There are no arrangements or plans in which we provide pension,
retirement or similar benefits for directors or executive officers, except that
our directors and executive officers may receive stock options at the discretion
of our board of directors. We do not have any material bonus or profit sharing
plans pursuant to which cash or non-cash compensation is or may be paid to our
directors or executive officers, except that stock options may be granted at the
discretion of our board of directors. </P>
<P align=justify>We have no plans or arrangements in respect of remuneration
received or that may be received by our executive officers to compensate such
officers in the event of termination of employment (as a result of resignation,
retirement, change of control) or a change of responsibilities following a
change of control, where the value of such compensation exceeds $60,000 per
executive officer. </P>
<P align=justify><B>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</B></P>
<P align=justify><B><I>Security ownership of certain beneficial owners
</I></B></P>
<P align=justify>In the following tables, we have determined the number and
percentage of shares beneficially owned in accordance with Rule 13d-3 of the
Exchange Act based on information provided to us by our controlling shareholder,
executive officers and directors, and this information does not necessarily
indicate beneficial ownership for any other purpose. In determining the number
of shares of our common stock beneficially owned by a person and the percentage
ownership of that person, we include any shares as to which the person has sole
or shared voting power or investment power, as well as any shares subject to
warrants or options held by that person that are currently exercisable or
exercisable within 60 days.</P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="90%" border=1>

  <TR vAlign=top>
    <TD align=center><BR><B>(1) Title of class</B> </TD>
    <TD align=center width="23%"><B>(2) Name and address of</B>
      <BR><B>beneficial owner</B> </TD>
    <TD align=center width="23%"><B>(3) Amount and nature of</B>
      <BR><B>beneficial ownership</B> </TD>
    <TD align=center width="10%" ><BR></TD>
    <TD align=center width="23%"><B>(4) Percent of</B> <BR><B>class
      </B><B><SUP>1</SUP></B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR><BR></TD>
    <TD align=left width="23%">Cede &amp; Co. <SUP>2</SUP> <BR>PO Box 20
      <BR>Bowling Green Station <BR>New York, NY 10004 </TD>
    <TD align=right width="23%">3,365,200 <BR><BR><BR></TD>
    <TD align=center width="10%" >Direct <BR><BR><BR></TD>
    <TD align=center width="23%">16.84% <BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR></TD>
    <TD align=left width="23%">Athanasios Skarpelos <BR>14 Rue Kleberg
      <BR>Geneva, Switzerland CH 1201 </TD>
    <TD align=right width="23%">7,475,000 <BR><BR></TD>
    <TD align=center width="10%" >Direct <BR><BR></TD>
    <TD align=center width="23%">37.45% <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR></TD>
    <TD align=left width="23%">Athanasios Skarpelos <BR>14 Rue Kleberg
      <BR>Geneva, Switzerland CH 1201 </TD>
    <TD align=right width="23%">92,500 <BR><BR></TD>
    <TD align=center width="10%" >Direct <BR><BR></TD>
    <TD align=center width="23%">0.46% <BR><BR></TD></TR></TABLE></DIV>
<P style="MARGIN-LEFT: 5%" align=justify><SUP>1</SUP> Percentage of ownership is
based on 19,982,420 common shares issued and outstanding as of January 8, 2009.
Except as otherwise indicated, we believe that the beneficial owners of the
common stock listed above, based on information furnished by such owners, have
sole investment and voting power with respect to such shares, subject to
community property laws where applicable. Beneficial ownership is determined in
accordance with the rules of the SEC and </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_42></A>
<P align=center>- 39 - </P>
<P style="MARGIN-LEFT: 5%" align=justify>generally includes voting or investment
power with respect to securities. Shares of common stock subject to options or
warrants currently exercisable, or exercisable within 60 days, are deemed
outstanding for purposes of computing the percentage ownership of the person
holding such option or warrants, but are not deemed outstanding for purposes of
computing the percentage ownership of any other person. </P>
<P style="MARGIN-LEFT: 5%" align=justify><SUP>2</SUP> Cede &amp; Co is the
nominee name for The Depository Trust Company, and we have no information on the
beneficial owners of our common stock. </P>
<P align=justify><B><I>Security ownership of management </I></B></P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="90%" border=1>

  <TR vAlign=top>
    <TD align=center><BR><B>(1) Title of class</B> </TD>
    <TD align=center width="30%" ><B>(2) Name and address of</B>
      <BR><B>beneficial owner</B> </TD>
    <TD align=center width="21%"><B>(3) Amount and nature of</B>
      <BR><B>beneficial ownership</B> </TD>
    <TD align=center width="10%"  ><BR></TD>
    <TD align=center width="21%"><B>(4) Percent of</B> <BR><B>class
      </B><B><SUP>1</SUP></B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR></TD>
    <TD align=left width="30%" ><B>Harvey Lalach</B> <BR>4837
      Canyon Ridge Crescent <BR>Kelowna, BC </TD>
    <TD align=right width="21%">675,000 <SUP>2</SUP> <BR><BR></TD>
    <TD align=center width="10%" >Direct <BR><BR></TD>
    <TD align=center width="21%">3.37% <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR></TD>
    <TD align=left width="30%" ><B>Alexandre Vamvakides</B>
      <BR>3, Cite De L&#146;alma <BR>Paris, France </TD>
    <TD align=right width="21%">Nil <BR><BR></TD>
    <TD align=center width="10%" ><BR><BR></TD>
    <TD align=center width="21%">Nil <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR></TD>
    <TD align=left width="30%" ><B>George Kalkanis</B> <BR>20
      Rfklodou Street <BR>Athens, Greece 10442 </TD>
    <TD align=right width="21%">1,060,000 <SUP>3</SUP> <BR><BR></TD>
    <TD align=center width="10%" >Direct <BR><BR></TD>
    <TD align=center width="21%">5.30% <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR></TD>
    <TD align=left width="30%" ><B>Cameron Durrant</B> <BR>#90
      Fairmount Road West <BR>Califon, NJ 07830-3330 </TD>
    <TD align=right width="21%">200,000 <SUP>4</SUP> <BR><BR></TD>
    <TD align=center width="10%" >Direct <BR><BR></TD>
    <TD align=center width="21%">1.00% <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR></TD>
    <TD align=left width="30%" ><B>Alison Ayers</B> <BR>27
      O'Connor Circle <BR>West Orange, NJ 07052 </TD>
    <TD align=right width="21%">75,000 <SUP>5</SUP> <BR><BR></TD>
    <TD align=center width="10%" >Direct <BR><BR></TD>
    <TD align=center width="21%">0.38% <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR></TD>
    <TD align=left width="30%" ><B>David Tousley</B> <BR>14610
      Pawnee Lane <BR>Leawood, KS 66224 </TD>
    <TD align=right width="21%">75,000 <SUP>6</SUP> <BR><BR></TD>
    <TD align=center width="10%" >Direct <BR><BR></TD>
    <TD align=center width="21%">0.38% <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="30%"
    ><B>TOTAL</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="21%"><B>2,085,000</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="10%"
    >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="21%">10.43% </TD>
  </TR></TABLE>
</DIV>
<P style="MARGIN-LEFT: 5%" align=justify><SUP>1</SUP> Percentage of ownership is
based on 19,982,420 common shares issued and outstanding as of January 8, 2009.
Except as otherwise indicated, we believe that the beneficial owners of the
common stock listed above, based on information furnished by such owners, have
sole investment and voting power with respect to such shares, subject to
community property laws where applicable. Beneficial ownership is determined in
accordance with the rules of the SEC and generally includes voting or investment
power with respect to securities. Shares of common stock subject to options or
warrants currently exercisable, or exercisable within 60 days, are deemed
outstanding for purposes of computing the percentage ownership of the person
holding such option or warrants, but are not deemed outstanding for purposes of
computing the percentage ownership of any other person. <BR><SUP>2
</SUP>Includes 600,000 shares of common stock and 75,000 stock options
exercisable within 60 days. <BR><SUP>3 </SUP>Includes 910,000 shares of common
stock and 150,000 stock options exercisable within 60 days. <BR><SUP>4
</SUP>Includes 50,000 shares of common stock and 150,000 stock options
exercisable within 60 days. <BR><SUP>5 </SUP>Includes 75,000 stock options
exercisable within 60 days. <BR><SUP>6 </SUP>Includes 75,000 stock options
exercisable within 60 days. </P>
<P align=justify><I>Changes in Control </I></P>
<P align=justify>We are unaware of any contract or other arrangement the
operation of which may at a subsequent date result in a change of control of our
company. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_43></A>
<P align=center>- 40 - </P>
<P align=justify><B>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE</B></P>
<P align=justify><B><I>Transactions with related persons </I></B></P>
<P align=justify>None of the following parties has, since our date of
incorporation, had any material interest, direct or indirect, in any transaction
with us or in any presently proposed transaction that has or will materially
affect us, other than as noted in this section:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(i) </TD>
    <TD>
      <P align=justify>Any of our directors or officers;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(ii) </TD>
    <TD>
      <P align=justify>Any person proposed as a nominee for election as a
      director;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iii) </TD>
    <TD>
      <P align=justify>Any person who beneficially owns, directly or indirectly,
      shares carrying more than 5% of the voting rights attached to our
      outstanding shares of common stock;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iv) </TD>
    <TD>
      <P align=justify>Any of our promoters; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(v) </TD>
    <TD>
      <P align=justify>Any member of the immediate family (including spouse,
      parents, children, siblings and in- laws) of any of the foregoing
      persons.</P></TD></TR></TABLE>
<P align=justify><I>Employment Contracts </I></P>
<P align=justify>Other than as described below, we are not party to any
employment contracts with our directors and officers: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">1. </TD>
    <TD colSpan=2>
      <P align=justify>We have a Consulting Agreement dated February 1, 2007
      with Harvey Lalach, our current President, CFO and Secretary to provide
      management services to our company for consideration of $7,000 per month.
      The contract has a two year term with can be extended for an additional
      two year term. During the year ended September 30, 2008, we agreed to
      increase the compensation of Mr. Lalach to $12,500 per month.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">2. </TD>
    <TD colSpan=2>
      <P align=justify>We have a Consulting Agreement with Cameron Durrant, our
      current Board of Directors Chairman to provide certain management and
      consulting services. Consideration for his services includes:</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>the issuance of 200,000 shares of common stock to be paid
      installments of 25,000 shares every quarter;</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>the issuance of 400,000 stock options exercisable at US
      $5.25 per share for a period of three years, subject to vesting
      provisions;</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>a payment of a finders fee for any financing our company
      receives in the amount of 4% on the first $100,000,000 and 2% on the
      balance.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The contract has a two year term dated May 20, 2008 and
      expiring May 20, 2010.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TR>
    <TD vAlign=top width="5%">3. </TD>
    <TD colSpan=2>
      <P align=justify>We have a Collaboration Agreement with our Chief
      Scientific Officer, Alexandre Vamvakides dated February 1, 2007 to provide
      the services of a Chief Scientific Officer and to acquire property for the
      development of a new drug compound including three patents and one patent
      application. Pursuant to the agreement, the Company agreed to the
      following:</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>invest a minimum of $200,000 every fiscal year into
      scientific research;</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>hire the Chief Scientific Officer as a consultant to
      carry out our company&#146;s Research and Development program at $6,000 per
      month;</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>pay to the director 6% of the net income earned from the
      exploitation of the patent and patent application;
and</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_44></A>
<P align=center>- 41 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>disburse a one-time payment to the director an amount of
      $72,000 before December 31, 2007 as consideration for the transfer of the
      patents and the patent application, which has been
paid.</P></TD></TR></TABLE>
<P style="MARGIN-LEFT: 5%" align=justify>The agreement is in force until
terminated by either Mr. Vamvakides or our company. During the year ended
September 30, 2008, we agreed to increase the compensation of Mr. Vamvakides to
7,000 Euros per month.</P>
<P align=justify><I>Pension, Retirement or Similar Benefit Plans </I></P>
<P align=justify>There are no arrangements or plans in which we provide pension,
retirement or similar benefits for directors or executive officers. We have no
material bonus or profit sharing plans pursuant to which cash or non-cash
compensation is or may be paid to our directors or executive officers, except
that stock options may be granted at the discretion of the Board of Directors or
a committee thereof.</P>
<P align=justify>We have no plans or arrangements in respect of remuneration
received or that may be received by our executive officers to compensate such
officers in the event of termination of employment (as a result of resignation,
retirement, change of control) or a change of responsibilities following a
change of control, where the value of such compensation exceeds $60,000 per
executive officer.<FONT color=#808080> </FONT></P>
<P align=justify><B>ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.</B></P>
<P align=justify><I>Audit Fees</I></P>
<P align=justify>The following table sets forth the fees billed to the Company
for professional services rendered by the Company's independent registered
public accounting firm, for the years ended September 30, 2008 and September 30,
2007: </P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>
    <TR vAlign=top>
    <TD align=left ><B>Fees</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="22%"><B>2008</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="22%"><B>2007</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=left >Amisano Hanson </TD>
      <TD width="1%" align=left >&nbsp;</TD>
      <TD width="22%" align=left>&nbsp; </TD>
      <TD width="2%" align=left >&nbsp;</TD>
      <TD width="1%" align=left >&nbsp;</TD>
      <TD width="22%" align=left>&nbsp; </TD>
      <TD width="2%" align=left >&nbsp;</TD>
    </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Audit fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;58,511 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;12,495 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Audit Related Fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Tax fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;All other fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=left >BDO Dunwoody LLP </TD>
      <TD width="1%" align=left >&nbsp;</TD>
      <TD width="22%" align=left>&nbsp; </TD>
      <TD width="2%" align=left >&nbsp;</TD>
      <TD width="1%" align=left >&nbsp;</TD>
      <TD width="22%" align=left>&nbsp; </TD>
      <TD width="2%" align=left >&nbsp;</TD>
    </TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Audit fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Audit Related Fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;Tax fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; &nbsp;All other fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="22%">&nbsp;Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left ><B>Total Fees</B> </TD>
    <TD align=left width="1%" ><B>$</B></TD>
    <TD align=right width="22%"><B>&nbsp;58,511</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" ><B>$</B></TD>
    <TD align=right width="22%"><B>&nbsp;13,495</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE></DIV>
<P align=justify><I>Audit Fees.</I> Consist of fees billed for professional
services rendered for the audits of our financial statements, reviews of our
interim consolidated financial statements included in quarterly reports,
services performed in connection with filings with the Securities and Exchange
Commission and related comfort letters and other services that are normally
provided by Amisano Hanson, Chartered Accountants for the fiscal years ended
September 30, 2008 and September 30, 2007 and BDO Dunwoody LLP for the fiscal
year ended September 30, 2008, in connection with statutory and regulatory
filings or engagements.</P>
<P align=justify><I>Tax Fees.</I> Consist of fees billed for professional
services for tax compliance, tax advice and tax planning. These services include
assistance regarding federal, state and local tax compliance and consultation in
connection with various transactions and acquisitions. </P>
<P align=justify><I>Policy on Pre-Approval by Audit Committee of Services Performed
  by Independent Auditors</I></P>
<P align=justify>We do not use Amisano Hanson or BDO, for financial information
system design and implementation. These services, which include designing or
implementing a system that aggregates source data underlying the financial
statements or generates information that is significant to our financial
statements, are provided internally or by other service providers. We do not
engage Amisano Hanson or BDO to provide compliance outsourcing services. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_45></A>
<P align=center>- 42 - </P>
<P align=justify>Effective May 6, 2003, the Securities and Exchange Commission
adopted rules that require that before Amisano Hanson is engaged by us to render
any auditing or permitted non-audit related service, the engagement be: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>approved by our audit committee (the functions of which are performed by
  our entire board of directors); or </P>
  <LI>
  <P>entered into pursuant to pre-approval policies and procedures established
  by the board of directors, provided the policies and procedures are detailed
  as to the particular service, the board of directors is informed of each
  service, and such policies and procedures do not include delegation of the
  board of directors' responsibilities to management. </P></LI></UL>
<P align=justify>Our entire board of directors pre-approves all services
provided by our independent auditors. All of the above services and fees were
reviewed and approved by our sole director either before or after the respective
services were rendered. </P>
<P align=justify>Our board of directors have considered the nature and amount of
fees billed by Amisano Hanson and BDO and believe that the provision of services
for activities unrelated to the audit is compatible with maintaining Amisano
Hanson and BDO&#146;s independence. </P>
<P align=center><B>PART IV</B></P>
<P align=justify><B>ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</B></P>
<P align=justify>Exhibits required by Item 601 of Regulation S-K:</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" ><BR><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>(3)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    >
      <P align=justify><B>(i) Articles of Incorporation; and (ii) Bylaws</B>
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Articles of Incorporation (attached as an exhibit to our
      Registration Statement on Form SB-2, filed on January 13, 2005).
</P></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>3.2 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    >
      <P align=justify>Bylaws (attached as an exhibit to our Registration
      Statement on Form SB-2, filed on January 13, 2005). </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.3 </TD>
    <TD align=left width="90%" >
      <P align=justify>Articles of Merger filed with the Secretary of State of
      Nevada on January 10, 2007 and which is effective January 25, 2007
      (attached as an exhibit to our Current Report on Form 8-K, filed on
      January 25, 2007). </P></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>(4)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    >
      <P align=justify><B>Instruments defining rights of security holders,
      including indentures</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Specimen Stock Certificate (attached as an exhibit to our
      Registration Statement on Form SB-2, filed on January 13, 2005).
</P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.2 </TD>
    <TD align=left width="90%" >
      <P align=justify>2007 Stock Option Plan (attached as an exhibit to our
      Current Report on Form 8-K, filed September 28, 2007). </P></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>(10)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    >
      <P align=justify><B>Material Contracts</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Agreement between Anavex Life Sciences Corp. and Dr.
      Alexandre Vamvakides, dated January 31, 2007 (attached as an exhibit to
      our Current Report on Form 8-K, filed February 7, 2007). </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.2 </TD>
    <TD align=left width="90%" >
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1002616
      (attached as an exhibit to our Current Report on Form 8-K, filed February
      7, 2007). </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.3 </TD>
    <TD align=left width="90%" >
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1004208
      (attached as an exhibit to our Current Report on Form 8-K, filed February
      7, 2007). </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.4 </TD>
    <TD align=left width="90%" >
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1004868
      (attached as an exhibit to our Current Report on Form 8-K, filed February
      7, 2007). </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.5 </TD>
    <TD align=left width="90%" >
      <P align=justify>Written description of Greek Patent Application Number
      20070100020 (attached as an exhibit to our Current Report on Form 8-K,
      filed February 7, 2007). </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.6 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Stock Option Agreement (attached as an exhibit to
      our Current Report on Form 8-K, filed February 22, 2007). </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.7 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services and Subscription Agreement dated
      September 11, 2007 between our company and Eurogenet Labs S.A. (attached
      as an exhibit to our Current Report on Form 8-K, filed September 27,
      2007). </P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_46></A>
<P align=center>- 43 - </P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=top>
      <TD align=left><B>Exhibit</B> <BR>
        <B>Number</B> </TD>
      <TD align=left width="90%" > <P align=justify><BR>
          <B>Description</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>10.8 </TD>
      <TD align=left width="90%" > <P align=justify>Consulting Agreement with
          Cameron Durrant dated May 20, 2008 (attached as an exhibit to our Form
          10-QSB, filed on August 18, 2008 </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>(14)</B> </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    > <P align=justify><B>Code of Ethics</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>14.1 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    > <P align=justify>Code of Conduct (attached as an exhibit to our Current
          Report on Form 8-K, filed September 28, 2007). </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>(16)</B> </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    > <P align=justify><B>Letter re Change in Certifying Accountant</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>16.1 </TD>
      <TD align=left width="90%" > <P align=justify>Letter from Amisano Hanson
          regarding change in certifying accountant. (attached as an exhibit to
          our Current Report on Form 8-K, filed March 4, 2008) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>(31)</B> </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    > <P align=justify><B>Rule 13a-14(a)/15d-14(a) Certifications</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><a href="exhibit31-1.htm">31.1*
        </a></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    > <P align=justify><a href="exhibit31-1.htm">Certification Pursuant to Section
          302 of the Sarbanes-Oxley Act of 2002 </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>(32)</B> </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="90%"
    > <P align=justify><B>Section 1350 Certifications</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left><a href="exhibit32-1.htm">32.1* </a></TD>
      <TD align=left width="90%" > <P align=justify><a href="exhibit32-1.htm">Certification
          Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906
          of the Sarbanes- Oxley Act of 2002 </a></P></TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>* Filed herewith. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_47></A>
<P align=center>- 44 - </P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized. </P>
<P align=justify><B>ANAVEX LIFE SCIENCES CORP. <BR></B>By:</P>
<P align=justify><I><U>/s/ Harvey Lalach</U></I><BR>Harvey Lalach
<BR>President, Chief Financial Officer, Secretary and Director<BR>(Principal
Executive Officer, Principal Financial Officer and Principal Accounting
Officer)</P>
<P align=justify>Dated: January 13, 2009 </P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
  1934, this report has been signed below by the following persons on behalf of
  the registrant and in the capacities and on the dates indicated.</P>
<P align=justify>&nbsp;</P>
<P align=justify><U><i>/s/ Harvey Lalach</i></U><BR>Harvey Lalach
<BR>President, Chief Financial Officer, Secretary and Director<BR>(Principal
Executive Officer, Principal Financial Officer and Principal Accounting
Officer)</P>
<P align=justify>Dated: January 13, 2009 </P>
<P align=justify>&nbsp;</P>
<P align=justify><u><i>/s/ Alison Ayers </i></u><BR>Alison Ayers <BR>Director</P>
<P align=justify>Dated: January 13, 2009 </P>
<P align=justify>&nbsp;</P>
<P align=justify><u><i>/s/ Cameron Durrant
</i></u><BR>Cameron Durrant
<BR>Director </P>
<P align=justify>Dated: January 13, 2009 </P>
<P align=justify>&nbsp;</P>
<P align=justify><u><i>/s/ Cameron Durrant
</i></u><BR>David Tousley <BR>Director</P>
<P align=justify>Dated: January 13, 2009 </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
